#BEGIN_DRUGCARD DB01942

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Formic acid is readily metabolized and eliminated by the body.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
64-18-6

# ChEBI_ID:
30751

# Chemical_Formula:
CH2O2

# Chemical_IUPAC_Name:
formic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. The principal use of formic acid is as a preservative and antibacterial agent in livestock feed. [Wikipedia]

# Dosage_Forms:
Not Available

# Drug_Category:
Antibacterial Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.54

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Formic Acid

# HET_ID:
FMT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/CH2O2/c2-1-3/h1H,(H,2,3)

# InChI_Key:
InChIKey=BDAGIHXWWSANSR-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00058

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1942

# Mechanism_Of_Action:
Not Available

# Melting_Point:
8.3 °C

# Molecular_Weight_Avg:
46.0254

# Molecular_Weight_Mono:
46.005479308

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1B93

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449705

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.47

# Predicted_LogS:
1.02

# Predicted_Water_Solubility:
4.77e+02 g/l

# Primary_Accession_No:
DB01942

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
284

# PubChem_Substance_ID:
46508355

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01461

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC=O

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Aminic acid
Formate
Formylic acid
Hydrogen carboxylic acid
Methanoic acid

# Synthesis_Reference:
Not Available

# Toxicity:
ORAL (LD<sub>50</sub>): Acute: 700 mg/kg [Mouse]. 1100 mg/kg [Rat]. 4000 mg/kg [Dog].

# Update_Date:
2013-02-08 16:20:38 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Formic_Acid

# pKa_Isoelectric_Point:
3.75 (at 25 °C)

# Drug_Target_10_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
CTBP1

# Drug_Target_10_GenBank_ID_Gene:
U37408

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
CTBP1

# Drug_Target_10_Gene_Sequence:
>1323 bp
ATGGGCAGCTCGCACTTGCTCAACAAGGGCCTGCCGCTTGGCGTCCGACCTCCGATCATG
AACGGGCCCCTGCACCCGCGGCCCCTGGTGGCATTGCTGGATGGCCGGGACTGCACAGTG
GAGATGCCCATCCTGAAGGACGTGGCCACTGTGGCCTTCTGCGACGCGCAGTCCACGCAG
GAGATCCATGAGAAGGTCCTGAACGAGGCTGTGGGGGCCCTGATGTACCACACCATCACT
CTCACCAGGGAGGACCTGGAGAAGTTCAAAGCCCTCCGCATCATCGTCCGGATTGGCAGT
GGTTTTGACAACATCGACATCAAGTCGGCCGGGGATTTAGGCATTGCCGTCTGCAACGTG
CCCGCGGCGTCTGTGGAGGAGACGGCCGACTCGACGCTGTGCCACATCCTGAACCTGTAC
CGGCGGGCCACCTGGCTGCACCAGGCGCTGCGGGAGGGCACACGAGTCCAGAGCGTCGAG
CAGATCCGCGAGGTGGCGTCCGGCGCTGCCAGGATCCGCGGGGAGACCTTGGGCATCATC
GGACTTGGTCGCGTGGGGCAGGCAGTGGCGCTGCGGGCCAAGGCCTTCGGCTTCAACGTG
CTCTTCTACGACCCTTACTTGTCGGATGGCGTGGAGCGGGCGCTGGGGCTGCAGCGTGTC
AGCACCCTGCAGGACCTGCTCTTCCACAGCGACTGCGTGACCCTGCACTGCGGCCTCAAC
GAGCACAACCACCACCTCATCAACGACTTCACCGTCAAGCAGATGAGACAAGGGGCCTTC
CTGGTGAACACAGCCCGGGGTGGCCTGGTGGATGAGAAGGCGCTGGCCCAGGCCCTGAAG
GAGGGCCGGATCCGCGGCGCGGCCCTGGATGTGCACGAGTCGGAACCCTTCAGCTTTAGC
CAGGGCCCTCTGAAGGATGCACCCAACCTCATCTGCACCCCCCATGCTGCATGGTACAGC
GAGCAGGCATCCATCGAGATGCGAGAGGAGGCGGCACGGGAGATCCGCAGAGCCATCACA
GGCCGGATCCCAGACAGCCTGAAGAACTGTGTCAACAAGGACCATCTGACAGCCGCCACC
CACTGGGCCAGCATGGACCCCGCCGTCGTGCACCCTGAGCTCAATGGGGCTGCCTATAGG
TACCCTCCGGGCGTGGTGGGCGTGGCCCCCACTGGCATCCCAGCTGCTGTGGAAGGTATC
GTCCCCAGCGCCATGTCCCTGTCCCACGGCCTGCCCCCTGTGGCCCACCCGCCCCACGCC
CCTTCTCCTGGCCAAACCGTCAAGCCCGAGGCGGATAGAGACCACGCCAGTGACCAGTTG
TAG

# Drug_Target_10_General_Function:
Involved in oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor

# Drug_Target_10_General_References:
14567915	Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH: Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell. 2003 Oct 17;115(2):177-86.
7479821	Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G: Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10467-71.
8440238	Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G: A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 1993 Feb;12(2):469-78.
9858600	Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP: C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol. 1999 Jan;19(1):777-87.

# Drug_Target_10_HGNC_ID:
HGNC:2494

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4496

# Drug_Target_10_Locus:
4p16

# Drug_Target_10_Molecular_Weight:
47536

# Drug_Target_10_Name:
C-terminal-binding protein 1

# Drug_Target_10_Number_of_Residues:
440

# Drug_Target_10_PDB_ID:
1HL3

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00389	2-Hacid_dh
PF02826	2-Hacid_dh_C

# Drug_Target_10_Protein_Sequence:
>C-terminal-binding protein 1
MGSSHLLNKGLPLGVRPPIMNGPLHPRPLVALLDGRDCTVEMPILKDVATVAFCDAQSTQ
EIHEKVLNEAVGALMYHTITLTREDLEKFKALRIIVRIGSGFDNIDIKSAGDLGIAVCNV
PAASVEETADSTLCHILNLYRRATWLHQALREGTRVQSVEQIREVASGAARIRGETLGII
GLGRVGQAVALRAKAFGFNVLFYDPYLSDGVERALGLQRVSTLQDLLFHSDCVTLHCGLN
EHNHHLINDFTVKQMRQGAFLVNTARGGLVDEKALAQALKEGRIRGAALDVHESEPFSFS
QGPLKDAPNLICTPHAAWYSEQASIEMREEAAREIRRAITGRIPDSLKNCVNKDHLTAAT
HWASMDPAVVHPELNGAAYRYPPGVVGVAPTGIPAAVEGIVPSAMSLSHGLPPVAHPPHA
PSPGQTVKPEADRDHASDQL

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Involved in controlling the equilibrium between tubular and stacked structures in the Golgi complex (By similarity). Co- repressor targeting diverse transcription regulators such as GLIS2. Has dehydrogenase activity

# Drug_Target_10_SwissProt_ID:
Q13363

# Drug_Target_10_SwissProt_Name:
CTBP1_HUMAN

# Drug_Target_10_Synonyms:
CtBP1
EC 1.1.1.-

# Drug_Target_10_Theoretical_pI:
6.76

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
AE000512

# Drug_Target_11_GenBank_ID_Protein:
4981702

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
pgl

# Drug_Target_11_Gene_Sequence:
>663 bp
TTATTTTCCCACAAACCAGACGGTTTTCTCTTTGCCTCTCACGAAGTAAGCGGGAAGTGG
TGTATCTTTTAAGATCTCCGTTAGTCTGTTTATCTTTTCTTTTCCCCTGATGAGAAAGAG
CACGTACAGTGATGTGTTCAGTGCACGAAACGTCAGGGTGACTCTGGGAACCTTAGGGTC
ACCGGAAGGATCTGTGAAAGTCACAAGGTTGTCTTTATTTCCCGTTTCCAAGTCGAATAT
GGACGCGACATGGCCATCGGGACCCATTCCAAGAATAGCGAGGTCGAACTGGTCAGTAGC
TGATCTTATTTCCCTCTCATATTTCTCGCAGGCTTTTTCAATAGGAAGAGAAGTGTCAAC
GTAGTGAACATTACCGGAAGGGATCTTTGCTCTGCTGAAAAGAACCTCGTTTATGTTCCT
GAAATTGCTTTGATCTGAGTCGAGGGGCACGTACCGCTCGTCGCTCAAAAAGAAGTGGAT
GCGATTCCATGGGAACTTCTGTTCTGCCAGTTTCTCATAAACGGGAAGTGGGGTTCTCCC
GCCGGCGAGAACGACGAAGATCTTATCCTTTTCCTCGAGAAGTTTTTCCATCTTTGTGCG
AATTTTCTCGACTACAAAATCAACGTACCCATCTTCGAGCAGGTATATCACAGTTTTCTC
CAT

# Drug_Target_11_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_11_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
3583

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
25325

# Drug_Target_11_Name:
6-phosphogluconolactonase

# Drug_Target_11_Number_of_Residues:
220

# Drug_Target_11_PDB_ID:
1VL1

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF01182	Glucosamine_iso

# Drug_Target_11_Protein_Sequence:
>6-phosphogluconolactonase
MEKTVIYLLEDGYVDFVVEKIRTKMEKLLEEKDKIFVVLAGGRTPLPVYEKLAEQKFPWN
RIHFFLSDERYVPLDSDQSNFRNINEVLFSRAKIPSGNVHYVDTSLPIEKACEKYEREIR
SATDQFDLAILGMGPDGHVASIFDLETGNKDNLVTFTDPSGDPKVPRVTLTFRALNTSLY
VLFLIRGKEKINRLTEILKDTPLPAYFVRGKEKTVWFVGK

# Drug_Target_11_Reaction:
6-phospho-D-glucono-1,5-lactone + H2O = 6-phospho-D-gluconate

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Hydrolysis of 6-phosphogluconolactone to 6- phosphogluconate

# Drug_Target_11_SwissProt_ID:
Q9X0N8

# Drug_Target_11_SwissProt_Name:
6PGL_THEMA

# Drug_Target_11_Synonyms:
6PGL
EC 3.1.1.31

# Drug_Target_11_Theoretical_pI:
6.81

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
BX842580

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
citE

# Drug_Target_12_Gene_Sequence:
>822 bp
TCATTCGGAGGTGGCTTCCCCGGCTCGCCGCAACATCGTTTCCGCGTGCGTGAGCACTGG
AGAGTCGACCATCTGGCCTTCGAACGCGAACGCCCCACGCTCGCTTCGCGACGCGGCCAA
AACCCGCCGAGCCCAGGCCAGCTTCTCGTGGCTGGGTCGATAGGCCTTGCGCACCACCGG
GATCTGACTCGGGTGAATGCACACGGTCACGTCAAAGCCCACCGCCGCGGCGTCTCTGGC
CTCTTCCTGCAAGCCCTCGACATCGAGGATATCCAGATGTACGGCATCGAGCGCGAGACG
GCCGAACGCGGACGCGGCGAGCAGGATGGTCGAGCGGACATGTCGGGCCACGTCACGATA
GGCACCGTCGGCCCGCCGGCTCGAGCTACCGCCAAGGGTGGCGATCAAGTCTTCGGCACC
CCACATCATTCCCACGGTGGGATCGGCCGCGGCGATTTCGGCGGCGCACACGGCACCGCG
CGCGGTCTCCACCAGCGCGATGACATCACGCGGCGCAAGCTCGATGACTTGGGCCGCCGA
TTCGGCCTTGGGCAGCATCACCGTGGTATAGGCGGTGCCTGCGAGGGCCTCCAGATCGCG
GGCCTGATCAGCAGTACCGCCCGCATTGATACGCACCACCGTGCGTTCCGGGTCCAGCGG
GGTGTCCCGCAACGCATTGCGCGCGGCAGGCTTCTGCGCCTCGGCCACGCCGTCCTCGAG
GTCGAGAATCACCACGTCGGCCGCGGCGGCAGCCTTCGCAAAGCGTTCCGGACGATCGGC
AGGGCAGAACAGCCACCCCGGACCGGCGGCACGCAGGTTCAT

# Drug_Target_12_General_Function:
Involved in citrate (pro-3S)-lyase activity

# Drug_Target_12_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4514

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
28886

# Drug_Target_12_Name:
Citrate lyase beta subunit-like protein

# Drug_Target_12_Number_of_Residues:
273

# Drug_Target_12_PDB_ID:
1U5H

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF03328	HpcH_HpaI

# Drug_Target_12_Protein_Sequence:
>Citrate lyase beta subunit-like protein
MNLRAAGPGWLFCPADRPERFAKAAAAADVVILDLEDGVAEAQKPAARNALRDTPLDPER
TVVRINAGGTADQARDLEALAGTAYTTVMLPKAESAAQVIELAPRDVIALVETARGAVCA
AEIAAADPTVGMMWGAEDLIATLGGSSSRRADGAYRDVARHVRSTILLAASAFGRLALDA
VHLDILDVEGLQEEARDAAAVGFDVTVCIHPSQIPVVRKAYRPSHEKLAWARRVLAASRS
ERGAFAFEGQMVDSPVLTHAETMLRRAGEATSE

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
May play a role in fatty acid biosynthesis (Potential)

# Drug_Target_12_SwissProt_ID:
O06162

# Drug_Target_12_SwissProt_Name:
CITEL_MYCTU

# Drug_Target_12_Synonyms:
EC 4.1.-.-

# Drug_Target_12_Theoretical_pI:
5.05

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Nucleus (By similarity). Cytoplasm (By similarity)

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
CASK

# Drug_Target_13_GenBank_ID_Gene:
AF032119

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
CASK

# Drug_Target_13_Gene_Sequence:
>2766 bp
ATGGCCGACGACGACGTGCTGTTCGAGGATGTGTACGAGCTGTGCGAGGTGATCGGAAAG
GGTCCCTTCAGTGTTGTACGACGATGTATCAACAGAGAAACTGGGCAACAATTTGCTGTA
AAAATTGTTGATGTAGCCAAGTTCACATCAAGTCCAGGGTTAAGTACAGAAGATCTAAAG
CGGGAAGCCAGTATCTGTCATATGCTGAAACATCCACACATTGTAGAGTTATTGGAGACA
TATAGCTCAGATGGAATGCTTTACATGGTTTTCGAATTTATGGATGGAGCAGATCTGTGT
TTTGAAATCGTAAAGCGAGCTGACGCTGGTTTTGTGTACAGTGAAGCTGTAGCCAGCCAT
TATATGAGACAGATACTGGAAGCTCTACGCTACTGCCATGATAATAACATAATTCACAGG
GATGTGAAGCCCCACTGTGTTCTCCTTGCCTCAAAAGAAAACTCGGCACCTGTTAAACTT
GGAGGCTTTGGGGTAGCTATTCAATTAGGGGAGTCTGGACTTGTAGCTGGAGGACGTGTT
GGAACACCTCATTTTATGGCACCAGAAGTGGTCAAAAGAGAGCCTTACGGAAAGCCTGTA
GACGTCTGGGGGTGCGGTGTGATCCTTTTTATCCTGCTCAGTGGTTGTTTGCCTTTTTAC
GGAACCAAGGAAAGATTGTTTGAAGGCATTATTAAAGGAAAATATAAGATGAATCCAAGG
CAGTGGAGCCATATCTCTGAAAGTGCCAAAGACCTAGTACGTCGCATGCTGATGCTGGAT
CCAGCTGAAAGGATCACTGTTTATGAAGCACTGAATCACCCATGGCTTAAGGAGCGGGAT
CGTTACGCCTACAAGATTCATCTTCCAGAAACAGTAGAGCAGCTGAGGAAATTCAATGCA
AGGAGGAAACTAAAGGGTGCAGTACTAGCCGCTGTGTCAAGTCACAAATTCAACTCATTC
TATGGGGATCCCCCTGAAGAGTTACCAGATTTCTCCGAAGACCCTACCTCCTCAGGGCTT
CTAGCAGCAGAAAGAGCAGTCTCACAGGTGCTGGACAGCCTGGAAGAGATTCATGCGCTT
ACAGACTGCAGTGAAAAGGACCTAGATTTTCTACACAGTGTTTTCCAGGATCAGCATCTT
CACACACTACTAGATCTGTATGACAAAATTAACACAAAGTCTTCACCACAAATCAGGAAT
CCTCCAAGCGATGCAGTACAGAGAGCCAAAGAGGTATTGGAAGAAATTTCATGTTACCCT
GAGAATAACGACGCAAAGGAACTAAAGCGTATTTTAACACAACCTCATTTCATGGCCTTA
CTTCAGACTCACGACGTAGTGGCACATGAAGTTTACAGTGATGAAGCATTGAGGGTCACA
CCTCCTCCCACCTCTCCCTATTTAAACGGCGATTCTCCAGAAAGTGCTAACGGAGGCATG
GATATGGAGAATGTGACCAGAGTTCGGCTGGTACAGTTTCAAAAGAACACAGATGAACCA
ATGGGAATCACTTTAAAAATGAATGAACTAAATCATTGTATTGTTGCAAGAATTATGCAT
GGGGGCATGATTCACAGGCAAGGTACACTTCATGTTGGTGATGAAATTCGAGAAATCAAT
GGCATCAGTGTGGCTAACCAAACAGTGGAACAACTGCAAAAAATGCTTAGGGAAATGCGG
GGGAGTATTACCTTCAAGATTGTGCCAAGTTACCGCACTCAGTCTTCGTCCTGTGAGAGA
GATTCCCCTTCCACTTCCAGACAGTCCCCAGCTAATGGTCATAGCAGCACTAACAATTCT
GTTTCGGACTTGCCATCAACTACCCAACCAAAAGGACGACAGATCTATGTAAGAGCACAA
TTTGAATATGATCCAGCCAAGGATGACCTCATCCCCTGTAAAGAAGCTGGCATTCGATTC
AGAGTTGGTGACATCATCCAGATTATTAGTAAGGATGATCATAATTGGTGGCAGGGTAAA
CTGGAAAACTCCAAAAATGGAACTGCAGGTCTCATTCCTTCTTCTGAACTTCAGGAATGG
CGAGTAGCTTGCATTGCCATGGAGAAGACCAAACAGGAGCAGCAGGCCAGCTGTACTTGG
TTTGGCAAGAAAAAGAAGCAGTACAAAGATAAATATTTGGCAAAGCACAATGCAGATCTT
GTCACATATGAAGAAGTAGTAAAACTGCCAGCATTCAAGAGGAAAACACTAGTCTTATTA
GGCGCACATGGTGTTGGGAGAAGACACATAAAAAACACTCTCATCACAAAGCACCCAGAC
CGGTTTGCGTACCCTATTCCACATACAACCAGACCTCCAAAGAGAGACGAAGAAAATGGA
AAGAATTATTACTTTGTATCTCATGACCAAATGATGCAAGACATCTCTAATAACGAGTAC
TTGGAGTACGGCAGCCACGAGGATGCGATGTATGGGACAAAACTGGAGACCATCCGGAAG
ATCCACGAGCAGGGGCTGATTGCAATACTGGACGTGGAGCCTCAGGCACTGAAGGTCCTG
AGAACTGCAGAGTTTGCTCCTTTTGTTGTTTTCATTGCTGCACCAACTATTACTCCAGGT
TTAAATGAGGATGAATCTCTTCAGCGTCTGCAGAAGGAGTCTGACATCTTACAGAGAACA
TATGCACACTACTTCGATCTCACAATTATCAACAATGAAATTGATGAGACAATCAGACAT
CTGGAGGAAGCTGTTGAGCTCGTGTGCACAGCCCCACAGTGGGTCCCTGTCTCCTGGGTC
TATTAG

# Drug_Target_13_General_Function:
Involved in protein binding

# Drug_Target_13_General_References:
11003712	Stevenson D, Laverty HG, Wenwieser S, Douglas M, Wilson JB: Mapping and expression analysis of the human CASK gene. Mamm Genome. 2000 Oct;11(10):934-7.
9546224	Daniels DL, Cohen AR, Anderson JM, Brunger AT: Crystal structure of the hCASK PDZ domain reveals the structural basis of class II PDZ domain target recognition. Nat Struct Biol. 1998 Apr;5(4):317-25.
9660868	Cohen AR, Woods DF, Marfatia SM, Walther Z, Chishti AH, Anderson JM: Human CASK/LIN-2 binds syndecan-2 and protein 4.1 and localizes to the basolateral membrane of epithelial cells. J Cell Biol. 1998 Jul 13;142(1):129-38.

# Drug_Target_13_HGNC_ID:
HGNC:1497

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4515

# Drug_Target_13_Locus:
Xp11.4

# Drug_Target_13_Molecular_Weight:
105124

# Drug_Target_13_Name:
Peripheral plasma membrane protein CASK

# Drug_Target_13_Number_of_Residues:
926

# Drug_Target_13_PDB_ID:
1KGD

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00069	Pkinase
PF00595	PDZ
PF00625	Guanylate_kin
PF02828	L27
PF07653	SH3_2

# Drug_Target_13_Protein_Sequence:
>Peripheral plasma membrane protein CASK
MADDDVLFEDVYELCEVIGKGPFSVVRRCINRETGQQFAVKIVDVAKFTSSPGLSTEDLK
REASICHMLKHPHIVELLETYSSDGMLYMVFEFMDGADLCFEIVKRADAGFVYSEAVASH
YMRQILEALRYCHDNNIIHRDVKPHCVLLASKENSAPVKLGGFGVAIQLGESGLVAGGRV
GTPHFMAPEVVKREPYGKPVDVWGCGVILFILLSGCLPFYGTKERLFEGIIKGKYKMNPR
QWSHISESAKDLVRRMLMLDPAERITVYEALNHPWLKERDRYAYKIHLPETVEQLRKFNA
RRKLKGAVLAAVSSHKFNSFYGDPPEELPDFSEDPTSSGLLAAERAVSQVLDSLEEIHAL
TDCSEKDLDFLHSVFQDQHLHTLLDLYDKINTKSSPQIRNPPSDAVQRAKEVLEEISCYP
ENNDAKELKRILTQPHFMALLQTHDVVAHEVYSDEALRVTPPPTSPYLNGDSPESANGDM
DMENVTRVRLVQFQKNTDEPMGITLKMNELNHCIVARIMHGGMIHRQGTLHVGDEIREIN
GISVANQTVEQLQKMLREMRGSITFKIVPSYRTQSSSCERDSPSTSRQSPANGHSSTNNS
VSDLPSTTQPKGRQIYVRAQFEYDPAKDDLIPCKEAGIRFRVGDIIQIISKDDHNWWQGK
LENSKNGTAGLIPSPELQEWRVACIAMEKTKQEQQASCTWFGKKKKQYKDKYLAKHNAVF
DQLDLVTYEEVVKLPAFKRKTLVLLGAHGVGRRHIKNTLITKHPDRFAYPIPHTTRPPKK
DEENGKNYYFVSHDQMMQDISNNEYLEYGSHEDAMYGTKLETIRKIHEQGLIAILDVEPQ
ALKVLRTAEFAPFVVFIAAPTITPGLNEDESLQRLQKESDILQRTYAHYFDLTIINNEID
ETIRHLEEAVELVCTAPQWVPVSWVY

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Multidomain scaffolding protein with a role in synaptic transmembrane protein anchoring and ion channel trafficking. Contributes to neural development and regulation of gene expression via interaction with the transcription factor TRB1. Binds to cell-surface proteins, including amyloid precursor protein, neurexins and syndecans. May mediate a link between the extracellular matrix and the actin cytoskeleton via its interaction with syndecan and with the actin/spectrin-binding protein 4.1

# Drug_Target_13_SwissProt_ID:
O14936

# Drug_Target_13_SwissProt_Name:
CSKP_HUMAN

# Drug_Target_13_Synonyms:
Calcium/calmodulin-dependent serine protein kinase
EC 2.7.11.1
Lin-2 homolog
hCASK

# Drug_Target_13_Theoretical_pI:
6.40

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
BX842576

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
gmk

# Drug_Target_14_Gene_Sequence:
>627 bp
GTGAGCGTCGGCGAGGGACCGGACACCAAGCCCACCGCGCGTGGCCAACCGGCGGCAGTG
GGACGTGTGGTGGTGCTGTCCGGTCCTTCCGCGGTCGGCAAATCCACGGTGGTTCGGTGT
CTGCGCGAGCGGATCCCGAATCTGCATTTCAGTGTCTCGGCCACGACGCGGGCGCCACGC
CCGGGCGAGGTCGACGGTGTCGACTACCACTTCATCGACCCCACCCGCTTTCAGCAGCTC
ATCGACCAGGGTGAGTTGCTGGAATGGGCAGAAATCCACGGCGGCCTGCACCGGTCGGGC
ACTTTGGCCCAGCCGGTGCGGGCGGCCGCGGCGACTGGTGTGCCGGTGCTTATCGAGGTT
GACCTGGCCGGGGCCAGGGCGATCAAGAAGACGATGCCCGAGGCTGTCACCGTGTTTCTG
GCGCCACCTAGCTGGCAGGATCTTCAGGCCAGACTGATTGGCCGCGGCACCGAAACAGCT
GACGTTATCCAACGCCGCCTGGACACCGCGCGGATCGAATTGGCAGCGCAGGGCGACTTT
GACAAGGTCGTGGTGAACAGGCGATTAGAGTCTGCGTGTGCGGAATTGGTATCCTTGCTG
GTGGGAACGGCACCGGGCTCCCCGTGA

# Drug_Target_14_General_Function:
Nucleotide transport and metabolism

# Drug_Target_14_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
4516

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
22096

# Drug_Target_14_Name:
Guanylate kinase

# Drug_Target_14_Number_of_Residues:
208

# Drug_Target_14_PDB_ID:
1S4Q

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00625	Guanylate_kin

# Drug_Target_14_Protein_Sequence:
>Guanylate kinase
MSVGEGPDTKPTARGQPAAVGRVVVLSGPSAVGKSTVVRCLRERIPNLHFSVSATTRAPR
PGEVDGVDYHFIDPTRFQQLIDQGELLEWAEIHGGLHRSGTLAQPVRAAAATGVPVLIEV
DLAGARAIKKTMPEAVTVFLAPPSWQDLQARLIGRGTETADVIQRRLDTARIELAAQGDF
DKVVVNRRLESACAELVSLLVGTAPGSP

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Essential for recycling GMP and indirectly, cGMP (By similarity)

# Drug_Target_14_SwissProt_ID:
P0A5I4

# Drug_Target_14_SwissProt_Name:
KGUA_MYCTU

# Drug_Target_14_Synonyms:
EC 2.7.4.8
GMP kinase

# Drug_Target_14_Theoretical_pI:
7.58

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
Not Available

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
AE000512

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
buk2

# Drug_Target_15_Gene_Sequence:
>1128 bp
GTGTTCAGAATCCTCACCATAAATCCCGGTTCTACATCCACAAAGCTGTCCATATTCGAA
GACGAAAGAATGGTGAAGATGCAAAATTTCAGTCATTCACCGGATGAACTCGGCAGATTC
CAGAAAATCCTGGATCAGCTTGAATTCAGGGAAAAGATAGCGAGACAGTTCGTCGAAGAA
ACTGGATACAGTCTGAGTTCTTTTTCCGCTTTTGTCAGCCGAGGAGGACTCCTCGATCCC
ATACCCGGGGGAGTGTATCTGGTGGACGGCCTAATGATAAAAACCCTGAAATCAGGAAAA
AACGGAGAACACGCTTCGAATCTGGGAGCGATCATAGCCCACAGATTCTCGTCTGAAACG
GGTGTTCCAGCCTACGTGGTGGATCCCGTCGTTGTCGATGAAATGGAAGATGTTGCACGT
GTCAGCGGACATCCAAACTATCAGAGAAAATCTATATTTCACGCTTTGAACCAGAAGACC
GTTGCAAAAGAAGTTGCCAGGATGATGAATAAAAGATACGAAGAGATGAACCTCGTTGTG
GCTCACATGGGTGGGGGCATATCAATCGCCGCACACAGAAAGGGAAGAGTGATCGACGTG
AACAACGCTCTGGACGGGGACGGACCGTTCACACCTGAAAGAAGCGGAACGCTACCTCTG
ACACAGCTTGTTGACCTTTGTTTCAGCGGGAAATTCACTTACGAAGAGATGAAGAAACGT
ATCGTGGGAAACGGTGGACTCGTGGCGTATCTTGGAACCAGCGATGCCAGAGAGGTGGTC
AGAAGAATCAAACAGGGTGATGAGTGGGCGAAGAGGGTTTACAGAGCGATGGCCTATCAG
ATAGCCAAGTGGATAGGTAAGATGGCAGCCGTTTTGAAAGGTGAGGTTGATTTCATAGTT
CTCACAGGTGGTCTGGCTCATGAAAAAGAGTTTCTGGTTCCATGGATCACCAAAAGGGTG
AGTTTCATAGCACCGGTACTTGTCTTTCCAGGAAGCAACGAGGAAAAAGCACTTGCCCTT
TCGGCACTGCGGGTGCTGAGAGGTGAAGAAAAGCCAAAAAATTATTCTGAAGAATCTCGA
AGGTGGAGAGAAAGGTATGATTCGTATCTTGATGGGATCTTACGGTAG

# Drug_Target_15_General_Function:
Involved in kinase activity

# Drug_Target_15_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
4517

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
42023

# Drug_Target_15_Name:
Probable butyrate kinase 2

# Drug_Target_15_Number_of_Residues:
375

# Drug_Target_15_PDB_ID:
1SAZ

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00871	Acetate_kinase

# Drug_Target_15_Protein_Sequence:
>Probable butyrate kinase 2
MFRILTINPGSTSTKLSIFEDERMVKMQNFSHSPDELGRFQKILDQLEFREKIARQFVEE
TGYSLSSFSAFVSRGGLLDPIPGGVYLVDGLMIKTLKSGKNGEHASNLGAIIAHRFSSET
GVPAYVVDPVVVDEMEDVARVSGHPNYQRKSIFHALNQKTVAKEVARMMNKRYEEMNLVV
AHMGGGISIAAHRKGRVIDVNNALDGDGPFTPERSGTLPLTQLVDLCFSGKFTYEEMKKR
IVGNGGLVAYLGTSDAREVVRRIKQGDEWAKRVYRAMAYQIAKWIGKMAAVLKGEVDFIV
LTGGLAHEKEFLVPWITKRVSFIAPVLVFPGSNEEKALALSALRVLRGEEKPKNYSEESR
RWRERYDSYLDGILR

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
ATP + butanoate = ADP + butanoyl phosphate

# Drug_Target_15_SwissProt_ID:
Q9X278

# Drug_Target_15_SwissProt_Name:
BUK2_THEMA

# Drug_Target_15_Synonyms:
BK 2
Branched-chain carboxylic acid kinase 2
EC 2.7.2.7

# Drug_Target_15_Theoretical_pI:
9.68

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Not Available

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
Not Available

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
A2LD1

# Drug_Target_16_Gene_Sequence:
Not Available

# Drug_Target_16_General_Function:
Not Available

# Drug_Target_16_General_References:
Not Available

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
7133

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
Not Available

# Drug_Target_16_Name:
AIG2-like domain-containing protein 1

# Drug_Target_16_Number_of_Residues:
0

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
Not Available

# Drug_Target_16_Protein_Sequence:
Not Available

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
Not Available

# Drug_Target_16_Specific_Function:
Not Available

# Drug_Target_16_SwissProt_ID:
Q9BVM4

# Drug_Target_16_SwissProt_Name:
A2LD1_HUMAN

# Drug_Target_16_Synonyms:
Not Available

# Drug_Target_16_Theoretical_pI:
Not Available

# Drug_Target_16_Transmembrane_Regions:
Not Available

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
Not Available

# Drug_Target_17_GenBank_ID_Protein:
Not Available

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
PVALB

# Drug_Target_17_Gene_Sequence:
Not Available

# Drug_Target_17_General_Function:
Not Available

# Drug_Target_17_General_References:
Not Available

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
6980

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
Not Available

# Drug_Target_17_Name:
Parvalbumin alpha

# Drug_Target_17_Number_of_Residues:
0

# Drug_Target_17_PDB_ID:
Not Available

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
Not Available

# Drug_Target_17_Protein_Sequence:
Not Available

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
Not Available

# Drug_Target_17_Specific_Function:
Not Available

# Drug_Target_17_SwissProt_ID:
P20472

# Drug_Target_17_SwissProt_Name:
PRVA_HUMAN

# Drug_Target_17_Synonyms:
Not Available

# Drug_Target_17_Theoretical_pI:
Not Available

# Drug_Target_17_Transmembrane_Regions:
Not Available

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
Not Available

# Drug_Target_18_GenBank_ID_Protein:
Not Available

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
ACYP2

# Drug_Target_18_Gene_Sequence:
Not Available

# Drug_Target_18_General_Function:
Not Available

# Drug_Target_18_General_References:
Not Available

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
7079

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
Not Available

# Drug_Target_18_Name:
Acylphosphatase-2

# Drug_Target_18_Number_of_Residues:
0

# Drug_Target_18_PDB_ID:
Not Available

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
Not Available

# Drug_Target_18_Protein_Sequence:
Not Available

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
Not Available

# Drug_Target_18_Specific_Function:
Not Available

# Drug_Target_18_SwissProt_ID:
P14621

# Drug_Target_18_SwissProt_Name:
ACYP2_HUMAN

# Drug_Target_18_Synonyms:
Not Available

# Drug_Target_18_Theoretical_pI:
Not Available

# Drug_Target_18_Transmembrane_Regions:
Not Available

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
Not Available

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
AE016877

# Drug_Target_19_GenBank_ID_Protein:
Not Available

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
BC_2969

# Drug_Target_19_Gene_Sequence:
>336 bp
TTACGACTGCTGATAAGCCGCTTTTGATGATTTCACATAATAAACTGCGTGATCCACATT
AATGATATGATCTGGTTTTGGTTTACCACGGCCCGCTCTATGTCCAGCTAAGTGTTCTTC
ACTTGTTTCCCAGTTTTTCCATGCTTCTTCAGATTCCCAGCGAATCATAACGACTACTTC
TTCGTCGCCGCGTCTTACTTTTTTCACAAGAACACTTAAGTCAATAAAGCCTTCAAATTT
TTCAATAATACCTTCTCCAGTAAAACGTTCTACAACTATATTTGATGTACCTTCTTTTAC
TGTAAATGTTTTCGTTTCGATAAACATATATCCCAC

# Drug_Target_19_General_Function:
Involved in oxidoreductase activity

# Drug_Target_19_General_References:
12721630	Ivanova N, Sorokin A, Anderson I, Galleron N, Candelon B, Kapatral V, Bhattacharyya A, Reznik G, Mikhailova N, Lapidus A, Chu L, Mazur M, Goltsman E, Larsen N, D'Souza M, Walunas T, Grechkin Y, Pusch G, Haselkorn R, Fonstein M, Ehrlich SD, Overbeek R, Kyrpides N: Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature. 2003 May 1;423(6935):87-91.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
4521

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
12778

# Drug_Target_19_Name:
Hypothetical protein

# Drug_Target_19_Number_of_Residues:
111

# Drug_Target_19_PDB_ID:
1TZ0

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF03992	ABM

# Drug_Target_19_Protein_Sequence:
>Hypothetical protein
MGYMFIETKTFTVKEGTSNIVVERFTGEGIIEKFEGFIDLSVLVKKVRRGDEEVVVMIRW
ESEEAWKNWETSEEHLAGHRAGRGKPKPDHIINVDHAVYYVKSSKAAYQQS

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Not Available

# Drug_Target_19_SwissProt_ID:
Q81C15

# Drug_Target_19_SwissProt_Name:
Q81C15_BACCR

# Drug_Target_19_Synonyms:
Not Available

# Drug_Target_19_Theoretical_pI:
6.52

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Microsome

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HMOX1

# Drug_Target_1_GenBank_ID_Gene:
X06985

# Drug_Target_1_GenBank_ID_Protein:
35173

# Drug_Target_1_GeneCard_ID:
HMOX1

# Drug_Target_1_Gene_Name:
HMOX1

# Drug_Target_1_Gene_Sequence:
>867 bp
ATGGAGCGTCCGCAACCCGACAGCATGCCCCAGGATTTGTCAGAGGCCCTGAAGGAGGCC
ACCAAGGAGGTGCACACCCAGGCAGAGAATGCTGAGTTCATGAGGAACTTTCAGAAGGGC
CAGGTGACCCGAGACGGCTTCAAGCTGGTGATGGCCTCCCTGTACCACATCTATGTGGCC
CTGGAGGAGGAGATTGAGCGCAACAAGGAGAGCCCAGTCTTCGCCCCTGTCTACTTCCCA
GAAGAGCTGCACCGCAAGGCTGCCCTGGAGCAGGACCTGGCCTTCTGGTACGGGCCCCGC
TGGCAGGAGGTCATCCCCTACACACCAGCCATGCAGCGCTATGTGAAGCGGCTCCACGAG
GTGGGGCGCACAGAGCCCGAGCTGCTGGTGGCCCACGCCTACACCCGCTACCTGGGTGAC
CTGTCTGGGGGCCAGGTGCTCAAAAAGATTGCCCAGAAAGCCCTGGACCTGCCCAGCTCT
GGCGAGGGCCTGGCCTTCTTCACCTTCCCCAACATTGCCAGTGCCACCAAGTTCAAGCAG
CTCTACCGCTCCCGCATGAACTCCCTGGAGATGACTCCCGCAGTCAGGCAGAGGGTGATA
GAAGAGGCCAAGACTGCGTTCCTGCTCAACATCCAGCTCTTTGAGGAGTTGCAGGAGCTG
CTGACCCATGACACCAAGGACCAGAGCCCCTCACGGGCACCAGGGCTTCGCCAGCGGGCC
AGCAACAAAGTGCAAGATTCTGCCCCCGTGGAGACTCCCAGAGGGAAGCCCCCACTCAAC
ACCCGCTCCCAGGCTCCGCTTCTCCGATGGGTCCTTACACTCAGCTTTCTGGTGGCGACA
GTTGCTGTAGGGCTTTATGCCATGTGA

# Drug_Target_1_General_Function:
Involved in heme oxygenase (decyclizing) activity

# Drug_Target_1_General_References:
10467099	Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL: Crystal structure of human heme oxygenase-1. Nat Struct Biol. 1999 Sep;6(9):860-7.
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
2537723	Shibahara S, Sato M, Muller RM, Yoshida T: Structural organization of the human heme oxygenase gene and the function of its promoter. Eur J Biochem. 1989 Feb 15;179(3):557-63.
2911585	Keyse SM, Tyrrell RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci U S A. 1989 Jan;86(1):99-103.
3345742	Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S: Human heme oxygenase cDNA and induction of its mRNA by hemin. Eur J Biochem. 1988 Feb 1;171(3):457-61.

# Drug_Target_1_HGNC_ID:
HGNC:5013

# Drug_Target_1_HPRD_ID:
00782

# Drug_Target_1_ID:
810

# Drug_Target_1_Locus:
22q12|22q13.1

# Drug_Target_1_Molecular_Weight:
32819

# Drug_Target_1_Name:
Heme oxygenase 1

# Drug_Target_1_Number_of_Residues:
288

# Drug_Target_1_PDB_ID:
1T5P

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01126	Heme_oxygenase

# Drug_Target_1_Protein_Sequence:
>Heme oxygenase 1
MERPQPDSMPQDLSEALKEATKEVHTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVA
LEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHE
VGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQ
LYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRAPGLRQRA
SNKVQDSAPVETPRGKPPLNTRSQAPLLRWVLTLSFLVATVAVGLYAM

# Drug_Target_1_Reaction:
heme + 3 AH2 + 3 O2 = biliverdin + Fe2+ + CO + 3 A + 3 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed

# Drug_Target_1_SwissProt_ID:
P09601

# Drug_Target_1_SwissProt_Name:
HMOX1_HUMAN

# Drug_Target_1_Synonyms:
EC 1.14.99.3
HO-1

# Drug_Target_1_Theoretical_pI:
8.68

# Drug_Target_1_Transmembrane_Regions:
265-287

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
Not Available

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
AF011922

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
astA

# Drug_Target_20_Gene_Sequence:
>1017 bp
ATGTTGGTGATGCGCCCCGCCCAAGCGGCCGACCTGCCACAGGTGCAGCGTCTGGCGGCG
GACAGCCCGGTAGGCGTCACGTCCTTGCCGGATGACGCCGAACGCCTGCGCGACAAGATC
CTCGCTTCCGAGGCCTCGTTCGCCGCGGAGGTGAGCTACAACGGCGAGGAAAGCTATTTC
TTCGTCCTCGAGGACAGCGCCAGCGGCGAACTGGTCGGCTGCTCGGCGATCGTCGCCTCG
GCCGGGTTCTCGGAACCGTTCTACAGCTTCCGCAACGAAACCTTCGTGCACGCCTCGCGC
TCGCTGTCGATCCACAACAAGATCCATGTCCTCTCGCTGTGCCACGACCTTACCGGCAAC
AGCCTGCTGACCAGTTTCTACGTACAGCGCGACCTGGTGCAGAGCGTCTACGCCGAACTC
AACTCGCGCGGTCGCCTGCTGTTCATGGCCAGCCATCCGGAGCGCTTCGCCGACGCGGTG
GTGGTGGAGATCGTCGGCTACAGCGACGAGCAGGGCGAATCGCCGTTCTGGAACGCGGTC
GGGCGCAACTTCTTCGACCTGAACTACATCGAGGCGGAAAAGCTCTCCGGGCTGAAGAGC
CGCACCTTCCTCGCCGAACTGATGCCGCACTATCCGATCTATGTGCCACTGTTGCCGGAT
GCCGCCCAGGAGTCCATGGGCCAGGTCCACCCGCGAGCGCAGATCACCTTCGATATCCTG
ATGCGCGAAGGCTTCGAGACCGACAACTACATCGACATCTTCGATGGCGGCCCGACCCTG
CACGCGCGTACCTCGGGGATTCGCTCGATCGCCCAGAGCCGGGTGGTTCCGGTGAAGATC
GGCGAGGCGCCGAAGAGCGGGCGTCCATACCTGGTCACCAACGGCCAGTTGCAGGACTTC
CGCGCGGTCGTGCTGGACCTGGACTGGGCGCCCGGCAAGCCGGTGGCCCTGAGTGTTGAA
GCCGCCGAGGCCCTGGGCGTCGGCGAAGGCGCCAGCGTGCGCCTGGTCGCGGTCTGA

# Drug_Target_20_General_Function:
Involved in binding

# Drug_Target_20_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
7523119	Tricot C, Vander Wauven C, Wattiez R, Falmagne P, Stalon V: Purification and properties of a succinyltransferase from Pseudomonas aeruginosa specific for both arginine and ornithine. Eur J Biochem. 1994 Sep 15;224(3):853-61.
9393691	Itoh Y: Cloning and characterization of the aru genes encoding enzymes of the catabolic arginine succinyltransferase pathway in Pseudomonas aeruginosa. J Bacteriol. 1997 Dec;179(23):7280-90.

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
4522

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
36931

# Drug_Target_20_Name:
Arginine N-succinyltransferase subunit alpha

# Drug_Target_20_Number_of_Residues:
338

# Drug_Target_20_PDB_ID:
1YLE

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF04958	AstA

# Drug_Target_20_Protein_Sequence:
>Arginine N-succinyltransferase subunit alpha
MLVMRPAQAADLPQVQRLAADSPVGVTSLPDDAERLRDKILASEASFAAEVSYNGEESYF
FVLEDSASGELVGCSAIVASAGFSEPFYSFRNETFVHASRSLSIHNKIHVLSLCHDLTGN
SLLTSFYVQRDLVQSVYAELNSRGRLLFMASHPERFADAVVVEIVGYSDEQGESPFWNAV
GRNFFDLNYIEAEKLSGLKSRTFLAELMPHYPIYVPLLPDAAQESMGQVHPRAQITFDIL
MREGFETDNYIDIFDGGPTLHARTSGIRSIAQSRVVPVKIGEAPKSGRPYLVTNGQLQDF
RAVVLDLDWAPGKPVALSVEAAEALGVGEGASVRLVAV

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Catalyzes the transfer of succinyl-CoA to arginine to produce 2-N-succinylarginine. Also acts on L-ornithine

# Drug_Target_20_SwissProt_ID:
P80357

# Drug_Target_20_SwissProt_Name:
ASTA_PSEAE

# Drug_Target_20_Synonyms:
AOST
ARUAI
AST
EC 2.3.1.109

# Drug_Target_20_Theoretical_pI:
4.66

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
Not Available

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
Not Available

# Drug_Target_21_GenBank_ID_Gene:
U02562

# Drug_Target_21_GenBank_ID_Protein:
Not Available

# Drug_Target_21_GeneCard_ID:
Not Available

# Drug_Target_21_Gene_Name:
yvyI

# Drug_Target_21_Gene_Sequence:
>951 bp
ATGACGCAATCACCGATTTTTCTAACGCCTGTGTTTAAAGAAAAAATCTGGGGCGGAACC
GCTTTACGAGATAGATTTGGATACAGTATTCCTTCAGAATCAACGGGGGAATGCTGGGCC
ATTTCCGCTCATCCAAAAGGACCGAGCACTGTTGCAAATGGCCCGTATAAAGGAAAGACA
TTGATCGAGCTTTGGGAAGAGCACCGTGAAGTATTCGGCGGCGTAGAGGGGGATCGGTTT
CCGCTTCTGACAAAGCTGCTGGATGTGAAGGAAGATACGTCAATTAAAGTTCACCCTGAT
GATTACTATGCCGGAGAAAACGAAGAGGGAGAACTCGGCAAGACGGAATGCTGGTACATT
ATCGACTGTAAGGAAAACGCAGAAATCATTTACGGGCATACGGCCCGCTCAAAAACCGAA
CTTGTCACAATGATCAACAGCGGTGACTGGGAGGGCCTGCTGCGAAGAATCAAAATTAAA
CCGGGTGATTTCTATTATGTGCCGAGCGGAACGCTGCACGCATTGTGCAAGGGGGCCCTT
GTTTTAGAGACTCAGCAAAATTCAGATGCCACATACCGGGTGTACGATTATGACCGTCTT
GATAGCAACGGAAGTCCGAGAGAGCTTCATTTTGCCAAAGCGGTCAATGCCGCCACGGTT
CCCCATGTGGACGGGTATATAGATGAATCGACAGAATCAAGAAAAGGAATAACCATTAAA
ACATTTGTCCAAGGGGAATATTTTTCGGTTTATAAATGGGACATCAATGGCGAAGCTGAA
ATGGCTCAGGATGAATCCTTTCTGATTTGCAGCGTGATAGAAGGAAGCGGTTTGCTCAAG
TATGAGGACAAAACATGTCCGCTCAAAAAAGGTGATCACTTTATTTTGCCGGCTCAAATG
CCCGATTTTACGATAAAAGGAACTTGTACCCTTATCGTGTCTCATATTTAA

# Drug_Target_21_General_Function:
Involved in mannose-6-phosphate isomerase activity

# Drug_Target_21_General_References:
7581999	Rashid MH, Mori M, Sekiguchi J: Glucosaminidase of Bacillus subtilis: cloning, regulation, primary structure and biochemical characterization. Microbiology. 1995 Oct;141 ( Pt 10):2391-404.
7934877	Margot P, Mauel C, Karamata D: The gene of the N-acetylglucosaminidase, a Bacillus subtilis 168 cell wall hydrolase not involved in vegetative cell autolysis. Mol Microbiol. 1994 May;12(4):535-45.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_21_HGNC_ID:
Not Available

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
4524

# Drug_Target_21_Locus:
Not Available

# Drug_Target_21_Molecular_Weight:
35428

# Drug_Target_21_Name:
Mannose-6-phosphate isomerase

# Drug_Target_21_Number_of_Residues:
316

# Drug_Target_21_PDB_ID:
1QWR

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF01238	PMI_typeI

# Drug_Target_21_Protein_Sequence:
>Mannose-6-phosphate isomerase
MTQSPIFLTPVFKEKIWGGTALRDRFGYSIPSESTGECWAISAHPKGPSTVANGPYKGKT
LIELWEEHREVFGGVEGDRFPLLTKLLDVKEDTSIKVHPDDYYAGENEEGELGKTECWYI
IDCKENAEIIYGHTARSKTELVTMINSGDWEGLLRRIKIKPGDFYYVPSGTLHALCKGAL
VLETQQNSDATYRVYDYDRLDSNGSPRELHFAKAVNAATVPHVDGYIDESTESRKGITIK
TFVQGEYFSVYKWDINGEAEMAQDESFLICSVIEGSGLLKYEDKTCPLKKGDHFILPAQM
PDFTIKGTCTLIVSHI

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
D-mannose 6-phosphate = D-fructose 6- phosphate

# Drug_Target_21_SwissProt_ID:
P39841

# Drug_Target_21_SwissProt_Name:
MANA3_BACSU

# Drug_Target_21_Synonyms:
EC 5.3.1.8
PMI
Phosphohexomutase
Phosphomannose isomerase

# Drug_Target_21_Theoretical_pI:
4.94

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Sarcolemma
peripheral membrane protein. In skeletal muscle, it is localized b
sarcolemmal membrane

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
NOS1

# Drug_Target_22_GenBank_ID_Gene:
U17327

# Drug_Target_22_GenBank_ID_Protein:
642526

# Drug_Target_22_GeneCard_ID:
NOS1

# Drug_Target_22_Gene_Name:
NOS1

# Drug_Target_22_Gene_Sequence:
>4305 bp
ATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC
TTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC
GTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC
GGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC
CTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT
GAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC
CGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG
GCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG
CATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC
AGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG
GAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC
AGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG
GACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA
GTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA
GAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC
AAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC
CTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC
ATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC
CCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA
GCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG
CTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT
GTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC
CACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC
AGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG
AACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC
CCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC
CGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG
ATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG
GACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC
GGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC
CGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC
TTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC
GCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC
GAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC
TGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG
CTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC
TGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATCGGCTTCAAGAAGCTAGCA
GAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG
ACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG
ATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC
CTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT
GAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG
GAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA
AAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC
AATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC
GGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG
GAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC
AAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT
TCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC
GAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC
CGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG
CGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC
TTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG
CCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC
ATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG
TACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA
GCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC
GAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT
ATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT
TCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT
TCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC
AACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC
CTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT
TTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC
CCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG
ACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG
CCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG
TACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT
GCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG
GACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT
GGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC
ATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA

# Drug_Target_22_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_22_General_References:
7515942	Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H: Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem. 1994 Jul;63(1):140-5.
7528745	Hall AV, Antoniou H, Wang Y, Cheung AH, Arbus AM, Olson SL, Lu WC, Kau CL, Marsden PA: Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J Biol Chem. 1994 Dec 30;269(52):33082-90.
7678401	Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 1993 Jan 25;316(2):175-80.
8879752	Park CS, Gianotti C, Park R, Krishna G: Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina. Cell Mol Neurobiol. 1996 Aug;16(4):499-515.
9111048	Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA: A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem. 1997 Apr 25;272(17):11392-401.

# Drug_Target_22_HGNC_ID:
HGNC:7872

# Drug_Target_22_HPRD_ID:
01226

# Drug_Target_22_ID:
76

# Drug_Target_22_Locus:
12q24.2-q24.31

# Drug_Target_22_Molecular_Weight:
160972

# Drug_Target_22_Name:
Nitric-oxide synthase, brain

# Drug_Target_22_Number_of_Residues:
1434

# Drug_Target_22_PDB_ID:
1TLL

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00595	PDZ
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_22_Protein_Sequence:
>Nitric-oxide synthase, brain
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS

# Drug_Target_22_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter

# Drug_Target_22_SwissProt_ID:
P29475

# Drug_Target_22_SwissProt_Name:
NOS1_HUMAN

# Drug_Target_22_Synonyms:
Constitutive NOS
EC 1.14.13.39
N-NOS
NC-NOS
NOS type I
Neuronal NOS
bNOS
nNOS

# Drug_Target_22_Theoretical_pI:
7.44

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Not Available

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
Not Available

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
Not Available

# Drug_Target_23_GenBank_ID_Gene:
AE000512

# Drug_Target_23_GenBank_ID_Protein:
Not Available

# Drug_Target_23_GeneCard_ID:
Not Available

# Drug_Target_23_Gene_Name:
TM_1223

# Drug_Target_23_Gene_Sequence:
>1674 bp
TTACTTTGCTTCAATACCAAAGAGCGTCTTGATTCCTGTGAGCTGCCACCAGCCGTTCCA
GCCTATCGGGACAGCGTACGGATTCTTCTCCGTTGGCCAGTTGGTCCACACAGCTTCAGA
AGCCTGGAACCATGCACCGTTGTACCACAGAGGAATGAACGGCAGATCCTTGAGCAGTAT
CTCTGACAGCTTGGCTACTACTTCTTTAATTTTAGCATCATCATTGCTTCTGTTGAGTTC
GTCGAGAAGAGTCTCAACTTCAGGATTGGCGTACTTTCCAAAGTTTCCGGAGTAGGAGTA
CTCGGATTCTACTGCATCCGGATAGAACACACCGTTGAAATAGGACCAGATGGTAGCGGA
AACACCGGTTGTAAAGTTGTTGAGTATGAGATCGAACTTTCCACCGTAGAGGTCGTCTGC
GTATTTGGAGTAGTCGGGGTATTTAGGTTCGACGTTGATTCCGACTTTCACGAGATCTTC
TGCAATGGACTGGATAGAAACCATCCAGTCGGTCCATCCGTACGGACACTCAATCGTGAG
CTTGAACGGCTTTCCGTTCGGATCTTCTCTGAATCCATCCTTGTTCACATCTTTGAATCC
AAGCTCGTCGAGGATCTTCTTTGCCATCTCCGGATCGTACTTGAATCCGTACTTATCGAC
GACTTCTTTCGGATAGTACTTCATGTAACCGGGAAGCGGCAGGATTCCAGCGGGATTGGC
AGCCGTCACCATGTTCTCGTAAGCTCTGGTAACGATCTTCTCGGGATTGATAGCGTAAGC
CATTGCTCTTCTGAACTCAGGTATGCTGAGAGGATACTTATTCACGTTGATGTAGATTCC
TGCGGTGTTGGCCGGGAGCATGTAAGGAGCGTTTTCATACCAGGTGACGATTCCGTATGC
TTTCTTCAAAACCGGAACACCCGGCAGGAAGAAGTTGCTCCAGTCGAGTTCTCCTTTCAT
GAGCATTCCTACTGCGACATTGTTGCTGAGCACTCTCAGTTCCACGATCCTTTCAGGTTT
GGGATCGTAACCGAGTTCTCTGATGCCCCACCAGTTCCCGTTCTTCTTGAATACACATCT
GTCGTCTGCCCAGCTTTCAACGTAGTACGGACCGGATCCAACTGGATTTTCATTGGCCGC
CTGAAGAACTTCTTCCTCTGTTTTGTTTTCCCAGATGTGTTTTGGTACGATCGGTGTGTT
GATGAGCATCTGTTTCCATTCCTGGTACCTCGGGTCGGAGAAGACGAACTTCAGCGTTCG
TTCATCGACCCTTTCGATCCTGCCGAGCCAGTTCCACACAGGACTGTAGCTGATACCAGT
GTACTTCTTGGCGATTTCAAAGGTGAAAACCACGTCGTCTGCCGTGAGAGGAACTCCGTC
CTGCCATCTGAGACCCTTTCTGAGCGTGAGTACGTATTCGTTGTTGCTGACCCATTCTCC
TTTTTCTGCAAGCCACGGCTCGAACTTGTCGTTCAGAGGATCGTAGAGGAACAGAGGTTC
ATAGACAAGACCGATGGTTCCCGCAACCGCGTTCCATGGTGTGAACGGGTTCCAGTTGGA
TGGAGGAGACCACAGCGCTCCACCCCAGTAGAGCGTTTTGTTTCTCTCAAAAGTCTGTCC
GAAAACCGAAACCAGTGCCAGGACCAGAACGAGAACGACTAAAAACCTTTTCAT

# Drug_Target_23_General_Function:
Involved in transporter activity

# Drug_Target_23_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_23_HGNC_ID:
Not Available

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
4526

# Drug_Target_23_Locus:
Not Available

# Drug_Target_23_Molecular_Weight:
64079

# Drug_Target_23_Name:
Oligopeptide ABC transporter, periplasmic oligopeptide-binding protein

# Drug_Target_23_Number_of_Residues:
557

# Drug_Target_23_PDB_ID:
1VR5

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00496	SBP_bac_5

# Drug_Target_23_Protein_Sequence:
>Oligopeptide ABC transporter, periplasmic oligopeptide-binding protein
MKRFLVVLVLVLALVSVFGQTFERNKTLYWGGALWSPPSNWNPFTPWNAVAGTIGLVYEP
LFLYDPLNDKFEPWLAEKGEWVSNNEYVLTLRKGLRWQDGVPLTADDVVFTFEIAKKYTG
ISYSPVWNWLGRIERVDERTLKFVFSDPRYQEWKQMLINTPIVPKHIWENKTEEEVLQAA
NENPVGSGPYYVESWADDRCVFKKNGNWWGIRELGYDPKPERIVELRVLSNNVAVGMLMK
GELDWSNFFLPGVPVLKKAYGIVTWYENAPYMLPANTAGIYINVNKYPLSIPEFRRAMAY
AINPEKIVTRAYENMVTAANPAGILPLPGYMKYYPKEVVDKYGFKYDPEMAKKILDELGF
KDVNKDGFREDPNGKPFKLTIECPYGWTDWMVSIQSIAEDLVKVGINVEPKYPDYSKYAD
DLYGGKFDLILNNFTTGVSATIWSYFNGVFYPDAVESEYSYSGNFGKYANPEVETLLDEL
NRSNDDAKIKEVVAKLSEILLKDLPFIPLWYNGAWFQASEAVWTNWPTEKNPYAVPIGWN
GWWQLTGIKTLFGIEAK

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Not Available

# Drug_Target_23_SwissProt_ID:
Q9X0V0

# Drug_Target_23_SwissProt_Name:
Q9X0V0_THEMA

# Drug_Target_23_Synonyms:
Not Available

# Drug_Target_23_Theoretical_pI:
4.80

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Cytoplasmic

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
Not Available

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
U00096

# Drug_Target_24_GenBank_ID_Protein:
Not Available

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
ycdX

# Drug_Target_24_Gene_Sequence:
>738 bp
ATGTATCCCGTCGACCTTCATATGCATACCGTTGCCAGCACACATGCATATAGCACATTA
AGTGATTACATTGCCCAGGCCAAACAAAAGGGCATTAAACTTTTTGCGATCACCGATCAT
GGCCCGGATATGGAAGATGCGCCGCATCACTGGCACTTCATTAACATGCGTATCTGGCCG
CGAGTGGTTGATGGGGTAGGGATCCTGCGCGGCATCGAAGCTAACATTAAAAATGTTGAT
GGTGAAATTGACTGCAGCGGTAAAATGTTTGACTCGCTGGATCTAATTATTGCCGGTTTT
CATGAGCCGGTTTTTGCGCCACATGACAAAGCGACCAATACACAAGCGATGATCGCCACT
ATCGCCAGCGGCAATGTGCATATAATAAGCCATCCCGGAAATCCCAAATATGAAATAGAT
GTGAAAGCCGTTGCTGAAGCAGCCGCGAAACATCAGGTGGCGCTGGAAATCAATAATTCC
TCATTTTTACACTCACGTAAGGGCAGTGAAGACAACTGTCGTGAGGTAGCCGCAGCGGTA
CGTGATGCTGGAGGTTGGGTGGCATTAGGCTCGGATTCTCACACCGCGTTTACCATGGGG
GAATTTGAAGAGTGTCTTAAAATCCTCGACGCGGTAGATTTTCCGCCAGAGCGCATTTTG
AATGTTTCTCCGCGCCGCTTACTGAACTTCCTTGAATCTCGCGGTATGGCACCGATTGCG
GAATTTGCAGACCTTTAA

# Drug_Target_24_General_Function:
Involved in DNA binding

# Drug_Target_24_General_References:
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
4527

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
26891

# Drug_Target_24_Name:
Putative hydrolase ycdX

# Drug_Target_24_Number_of_Residues:
245

# Drug_Target_24_PDB_ID:
1PB0

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF02811	PHP

# Drug_Target_24_Protein_Sequence:
>Putative hydrolase ycdX
MYPVDLHMHTVASTHAYSTLSDYIAQAKQKGIKLFAITDHGPDMEDAPHHWHFINMRIWP
RVVDGVGILRGIEANIKNVDGEIDCSGKMFDSLDLIIAGFHEPVFAPHDKATNTQAMIAT
IASGNVHIISHPGNPKYEIDVKAVAEAAAKHQVALEINNSSFLHSRKGSEDNCREVAAAV
RDAGGWVALGSDSHTAFTMGEFEECLKILDAVDFPPERILNVSPRRLLNFLESRGMAPIA
EFADL

# Drug_Target_24_Reaction:
Not Available

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Not Available

# Drug_Target_24_SwissProt_ID:
P75914

# Drug_Target_24_SwissProt_Name:
YCDX_ECOLI

# Drug_Target_24_Synonyms:
EC 3.1.-.-

# Drug_Target_24_Theoretical_pI:
5.83

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Cytoplasmic

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
Not Available

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
Not Available

# Drug_Target_25_GenBank_ID_Gene:
AE004091

# Drug_Target_25_GenBank_ID_Protein:
Not Available

# Drug_Target_25_GeneCard_ID:
Not Available

# Drug_Target_25_Gene_Name:
phzD1

# Drug_Target_25_Gene_Sequence:
>624 bp
ATGAGCGGCATTCCCGAAATCACCGCCTATCCCTTGCCGACCGCCCAGCAACTGCCGGCC
AACCTGGCGCGCTGGAGCCTGGAGCCGCGGCGCGCGGTGCTGCTGGTGCACGACATGCAG
CGCTACTTCCTACGCCCGCTGCCCGAGAGCCTGCGCGCCGGACTGGTGGCCAACGCCGCG
CGGCTGCGCCGCTGGTGCGTCGAGCAGGGCGTGCAGATCGCCTACACCGCCCAGCCGGGC
AGCATGACCGAGGAGCAGCGCGGTCTGCTCAAGGACTTCTGGGGGCCGGGCATGCGCGCC
AGTCCGGCCGACCGCGAGGTGGTCGAGGAGCTGGCGCCGGGGCCGGACGACTGGCTGCTG
ACCAAGTGGCGCTACAGCGCCTTCTTCCACTCCGACCTGCTCCAGCGGATGCGCGCCGCC
GGCCGCGACCAGTTGGTGCTGTGCGGCGTATACGCCCACGTCGGGGTGCTGATCTCCACG
GTCGACGCCTACTCCAACGACATCCAGCCGTTCCTGGTGGCCGACGCCATCGCCGACTTC
AGCGAGGCGCACCACCGCATGGCCCTGGAATACGCCGCCAGCCGCTGCGCGATGGTGGTC
ACCACCGACGAGGTGCTGGAATGA

# Drug_Target_25_General_Function:
Involved in catalytic activity

# Drug_Target_25_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
11591691	Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS: Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from Pseudomonas aeruginosa PAO1. J Bacteriol. 2001 Nov;183(21):6454-65.

# Drug_Target_25_HGNC_ID:
Not Available

# Drug_Target_25_HPRD_ID:
Not Available

# Drug_Target_25_ID:
4528

# Drug_Target_25_Locus:
Not Available

# Drug_Target_25_Molecular_Weight:
23196

# Drug_Target_25_Name:
Phenazine biosynthesis protein PhzD

# Drug_Target_25_Number_of_Residues:
207

# Drug_Target_25_PDB_ID:
1NF9

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00857	Isochorismatase

# Drug_Target_25_Protein_Sequence:
>Phenazine biosynthesis protein PhzD
MSGIPEITAYPLPTAQQLPANLARWSLEPRRAVLLVHDMQRYFLRPLPESLRAGLVANAA
RLRRWCVEQGVQIAYTAQPGSMTEEQRGLLKDFWGPGMRASPADREVVEELAPGPDDWLL
TKWRYSAFFHSDLLQRMRAAGRDQLVLCGVYAHVGVLISTVDAYSNDIQPFLVADAIADF
SEAHHRMALEYAASRCAMVVTTDEVLE

# Drug_Target_25_Reaction:
Not Available

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Not Available

# Drug_Target_25_SwissProt_ID:
Q7DC80

# Drug_Target_25_SwissProt_Name:
Q7DC80_PSEAE

# Drug_Target_25_Synonyms:
PhzD

# Drug_Target_25_Theoretical_pI:
5.63

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Cytoplasm

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
Not Available

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
Not Available

# Drug_Target_26_GenBank_ID_Gene:
AJ223978

# Drug_Target_26_GenBank_ID_Protein:
Not Available

# Drug_Target_26_GeneCard_ID:
Not Available

# Drug_Target_26_Gene_Name:
oxdC

# Drug_Target_26_Gene_Sequence:
>1158 bp
TTATTTACTGCATTTCTTTTTCACTACTGGGTGCTTTTCTTTTGAAAGCACATCAGTAAA
GTCTTTGCCCAAGTCAAGGTGCGCTTGAACAAATGTTTCAGGAAGCATGGCAAGCCATTG
GTTTAAAGATACATCAGCATAATGGTCGTCTTTGAAGATTTCTAAAAAGACAAGCGGTTC
ATCCCCGATGTTTTCAACGTAATGACCCATTGCAAATGGTACATATCCGACATCACCGGC
TTGGTAATTAAACGTTCTGGCATGGCCGTCAGATGCAAAAACGGTCATTCTAGCTTTACC
GGAGATGTAGTATTGCCATTCGTGGGTATTCGGGTGCCAGTGCAGTTCTCTCATGGCGCC
GGGTTCTACTGTTACGAGCGCTGATGCGATGGTTTTAGACACTTTGAAGTTTGTCGAATC
TGCAATGTATACTTTTCCTCCCTCAGATTCGATCGGCTCTTGTTCAAGAAGGCGGTAAGT
AAATGGATAAGGCACTTCGCCATTCGGCCCTTCCACAATATCATCTTTTAAACTGCCAGG
AAGTTGGTTTTCAAATATATATTTTTCTTTGCCAGGCAAATTGGAAATCTCTTCTTTTGT
CACGCCGAAGTTCGCAGCAATGACTTCTTTTGGAGTGTGGGCCAGCCAATCTGTCAGCTG
GAACGTGCTGTTTTCAGAGAATGATCCATCGTCAAACACGAGCAGGAACTCAGCTCCCTC
CTCCAGCGCTTGGATGGAGTGCGGCAGGCCTGACGGGAAGTACCAAAGGTCTCCTTCACC
TACATCGTCAATAAAGCTGCGCCCTTTTTCATCTACAATTGTGACTCTTGCACTTCCGTA
AATCATATAAGCCCATTCAGCTTCTTTATGCCAGTGAAGCTCGCGAATCGCGCCTGGCTT
CAGCCGCATATTTACGGATGCAAGGTTTTCTGAAATCGGCAATTCACGTACTGTCACTTC
CCGGGCATATCCGCCTTTTTCTAATCGGTTATGAGTATCAGAGAATGAAAACTTCATATT
GCTGACGGTGCCATGATCGGTTTCAGGCGGAACGAGCATATCAGGGTTTTGCCGGTCTCT
TTCAATATTGCGCGGGATTTTTACCGTTGCTCCTTTGTCTCCTCTAATTGGCTGCGGAAT
GTCATTTTGTTTTTTCAT

# Drug_Target_26_General_Function:
Involved in nutrient reservoir activity

# Drug_Target_26_General_References:
10960116	Tanner A, Bornemann S: Bacillus subtilis YvrK is an acid-induced oxalate decarboxylase. J Bacteriol. 2000 Sep;182(18):5271-3.
11546787	Tanner A, Bowater L, Fairhurst SA, Bornemann S: Oxalate decarboxylase requires manganese and dioxygen for activity. Overexpression and characterization of Bacillus subtilis YvrK and YoaN. J Biol Chem. 2001 Nov 23;276(47):43627-34. Epub 2001 Aug 23.
12056897	Anand R, Dorrestein PC, Kinsland C, Begley TP, Ealick SE: Structure of oxalate decarboxylase from Bacillus subtilis at 1.75 A resolution. Biochemistry. 2002 Jun 18;41(24):7659-69.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9639930	Wipat A, Brignell SC, Guy BJ, Rose M, Emmerson PT, Harwood CR: The yvsA-yvqA (293 degrees-289 degrees) region of the Bacillus subtilis chromosome containing genes involved in metal ion uptake and a putative sigma factor. Microbiology. 1998 Jun;144 ( Pt 6):1593-600.

# Drug_Target_26_HGNC_ID:
Not Available

# Drug_Target_26_HPRD_ID:
Not Available

# Drug_Target_26_ID:
4529

# Drug_Target_26_Locus:
Not Available

# Drug_Target_26_Molecular_Weight:
43566

# Drug_Target_26_Name:
Oxalate decarboxylase oxdC

# Drug_Target_26_Number_of_Residues:
385

# Drug_Target_26_PDB_ID:
1UW8

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00190	Cupin_1

# Drug_Target_26_Protein_Sequence:
>Oxalate decarboxylase oxdC
MKKQNDIPQPIRGDKGATVKIPRNIERDRQNPDMLVPPETDHGTVSNMKFSFSDTHNRLE
KGGYAREVTVRELPISENLASVNMRLKPGAIRELHWHKEAEWAYMIYGSARVTIVDEKGR
SFIDDVGEGDLWYFPSGLPHSIQALEEGAEFLLVFDDGSFSENSTFQLTDWLAHTPKEVI
AANFGVTKEEISNLPGKEKYIFENQLPGSLKDDIVEGPNGEVPYPFTYRLLEQEPIESEG
GKVYIADSTNFKVSKTIASALVTVEPGAMRELHWHPNTHEWQYYISGKARMTVFASDGHA
RTFNYQAGDVGYVPFAMGHYVENIGDEPLVFLEIFKDDHYADVSLNQWLAMLPETFVQAH
LDLGKDFTDVLSKEKHPVVKKKCSK

# Drug_Target_26_Reaction:
Not Available

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Converts oxalate to formate and CO(2) in an O(2)- dependent reaction. Can also catalyze minor side reactions:oxalate oxidation to produce H(2)O(2), and oxalate-dependent, H(2)O(2)-independent dye oxidations

# Drug_Target_26_SwissProt_ID:
O34714

# Drug_Target_26_SwissProt_Name:
OXDC_BACSU

# Drug_Target_26_Synonyms:
EC 4.1.1.2

# Drug_Target_26_Theoretical_pI:
5.11

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Not Available

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
Not Available

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
M19536

# Drug_Target_27_GenBank_ID_Protein:
Not Available

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
actIII

# Drug_Target_27_Gene_Sequence:
>786 bp
ATGGCCACGCAGGACTCCGAAGTCGCACTGGTGACGGGTGCGACCAGCGGAATCGGGCTG
GAGATCGCCCGCAGGCTCGGTAAGGAGGGGTTGCGCGTGTTCGTCTGCGCGCGCGGCGAA
GAAGGACTGCGGACGACGCTGAAGGAGTTGCGGGAGGCGGGCGTGGAGGCGGACGGGCGG
ACCTGCGACGTCCGCTCGGTCCCGGAGATCGAGGCTCTCGTGGCGGCGGTGGTCGAGCGT
TACGGTCCGGTCGACGTGCTGGTGAACAACGCGGGCCGGCCCGGCGGCGGCGCCACGGCC
GAACTCGCCGACGAACTCTGGCTCGATGTCGTGGAGACCAACCTCACCGGCGTGTTCCGG
GTGACCAAACAGGTCCTCAAGGCGGGCGGCATGCTCGAACGGGGCACGGGCCGAATCGTC
AACATCGCCTCGACCGGCGGAAAGCAGGGTGTGGTGCACGCCGCGCCCTACTCCGCCTCG
AAGCACGGCGTGGTCGGCTTCACCAAGGCGCTCGGTCTCGAACTGGCGAGGACCGGCATC
ACGGTGAACGCCGTCTGCCCCGGATTCGTCGAGACGCCGATGGCCGCGTCCGTGCGCGAG
CACTACTCGGACATCTGGGAGGTGTCGACCGAGGAGGCCTTCGACCGGATCACCGCGCGC
GTGCCGATCGGCCGGTACGTGCAGCCGTCCGAGGTGGCGGAGATGGTGGCGTACCTGATC
GGGCCCGGTGCGGCCGCGGTCACCGCGCAGGCGCTGAACGTCTGCGGCGGGCTGGGGAAC
TACTGA

# Drug_Target_27_General_Function:
Involved in oxidoreductase activity

# Drug_Target_27_General_References:
12000953	Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature. 2002 May 9;417(6885):141-7.
2469622	Hallam SE, Malpartida F, Hopwood DA: Nucleotide sequence, transcription and deduced function of a gene involved in polyketide antibiotic synthesis in Streptomyces coelicolor. Gene. 1988 Dec 30;74(2):305-20.

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
4531

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
27265

# Drug_Target_27_Name:
Putative ketoacyl reductase

# Drug_Target_27_Number_of_Residues:
261

# Drug_Target_27_PDB_ID:
1X7H

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_27_Protein_Sequence:
>Putative ketoacyl reductase
MATQDSEVALVTGATSGIGLEIARRLGKEGLRVFVCARGEEGLRTTLKELREAGVEADGR
TCDVRSVPEIEALVAAVVERYGPVDVLVNNAGRPGGGATAELADELWLDVVETNLTGVFR
VTKQVLKAGGMLERGTGRIVNIASTGGKQGVVHAAPYSASKHGVVGFTKALGLELARTGI
TVNAVCPGFVETPMAASVREHYSDIWEVSTEEAFDRITARVPIGRYVQPSEVAEMVAYLI
GPGAAAVTAQALNVCGGLGNY

# Drug_Target_27_Reaction:
Not Available

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Not Available

# Drug_Target_27_SwissProt_ID:
P16544

# Drug_Target_27_SwissProt_Name:
ACT3_STRCO

# Drug_Target_27_Synonyms:
EC 1.3.1.-

# Drug_Target_27_Theoretical_pI:
5.02

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Not Available

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
GPHN

# Drug_Target_28_GenBank_ID_Gene:
AF272663

# Drug_Target_28_GenBank_ID_Protein:
Not Available

# Drug_Target_28_GeneCard_ID:
Not Available

# Drug_Target_28_Gene_Name:
GPHN

# Drug_Target_28_Gene_Sequence:
>2211 bp
ATGGCGACCGAGGGAATGATCCTTACTAACCACGACCATCAAATCCGTGTCGGAGTCCTT
ACAGTGAGTGATAGTTGCTTCAGGAATCTTGCAGAAGACCGCAGTGGGATAAATCTCAAA
GATCTCGTACAAGATCCTTCTTTGTTGGGTGGGACTATATCAGCATACAAGATAGTACCA
GATGAAATAGAAGAAATCAAGGAAACCCTGATAGATTGGTGTGATGAAAAGGAACTTAAT
TTGATATTAACAACTGGAGGAACAGGATTTGCACCACGAGATGTCACTCCAGAGGCCACA
AAAGAAGTAATAGAACGGGAAGCACCAGGGATGGCCCTGGCAATGCTGATGGGATCACTT
AATGTTACACCTCTGGGCATGCTCTCTAGGCCTGTATGTGGAATCAGAGGGAAAACGCTC
ATAATTAACCTGCCAGGTAGCAAGAAAGGATCTCAGGAATGCTTTCAATTCATACTGCCA
GCTCTACCTCATGCCATTGACCTTTTACGTGATGCCATTGTAAAAGTAAAGGAGGTGCAT
GATGAACTTGAAGATTTGCCTTCCCCACCTCCCCCTCTTTCCCCTCCTCCTACTACCAGC
CCCCATAAACAGACAGAAGACAAAGGAGTTCAATGTGAGGAAGAGGAAGAAGAGAAGAAA
GACAGTGGTGTTGCTTCAACAGAAGATAGTTCCTCATCACATATAACTGCAGCAGCCATT
GCTGCCAAGATTCCAGACTCCATCATTTCTCGTGGTGTTCAGGTGCTCCCACGAGACACA
GCCTCCCTCAGCACTACTCCTTCAGAATCGCCTCGTGCTCAGGCTACATCTCGCCTCTCT
ACAGCTTCCTGCCCAACACCAAAAGTCCAGTCCAGGTGCAGCAGCAAGGAGAACATTCTC
AGAGCCAGTCACAGTGCTGTCGATATCACCAAGGTGGCTAGAAGACATCGCATGTCTCCT
TTTCCTCTGACATCTATGGACAAAGCCTTTATCACAGTCCTGGAGATGACTCCGGTGCTT
GGGACAGAAATCATCAATTACCGAGATGGAATGGGGCGAGTCCTTGCTCAAGATGTATAT
GCAAAAGACAATTTACCCCCCTTCCCAGCATCAGTAAAAGATGGCTATGCTGTCCGAGCT
GCTGATGGCCCAGGAGATCGTTTCATCATTGGGGAATCCCAAGCTGGTGAACAGCCAACT
CAGACAGTAATGCCAGGACAAGTCATGCGGGTTACAACAGGTGCTCCAATACCCTGCGGT
GCTGATGCAGTAGTACAAGTGGAAGATACCGAACTTATCAGGGAATCAGATGATGGCACT
GAAGAACTTGAAGTGCGAATTCTGGTGCAAGCTCGGCCAGGCCAAGATATCAGACCCATC
GGCCATGACATTAAAAGAGGGGAATGTGTTTTGGCCAAAGGAACCCACATGGGCCCCTCA
GAGATTGGTCTTCTGGCAACTGTAGGTGTCACAGAGGTTGAAGTTAATAAGTTTCCAGTG
GTTGCAGTCATGTCAACAGGGAATGAGCTGCTAAATCCTGAAGATGACCTCTTACCAGGG
AAGATTCGAGACAGCAATCGTTCAACTCTTCTAGCAACAATTCAGGAACATGGTTACCCC
ACGATCAACTTGGGTATTGTAGGAGACAACCCAGATGACTTACTCAATGCCTTGAATGAG
GGTATCAGTCGTGCTGATGTCATCATCACATCAGGGGGTGTATCCATGGGGGAAAAGGAC
TATCTCAAGCAGGTGCTGGACATTGATCTTCATGCTCAGATCCATTTTGGCAGGGTTTTT
ATGAAACCAGGCTTGCCAACAACATTTGCAACTTTGGATATTGATGGTGTAAGAAAAATA
ATCTTTGCACTACCTGGGAATCCTGTATCGGCTGTGGTCACCTGCAATCTCTTTGTTGTG
CCTGCACTGAGGAAAATGCAGGGCATCTTGGATCCTCGGCCAACCATCATCAAAGCAAGG
TTATCATGTGATGTAAAACTTGATCCTCGTCCAGAATACCATCGGTGTATACTAACTTGG
CATCACCAAGAACCACTACCTTGGGCACAGAGTACAGGTAATCAAATGAGCAGCCGTCTG
ATGAGCATGCGCAGTGCCAATGGATTGTTGATGCTACCTCCAAAGACAGAACAGTACGTG
GAGCTCCACAAAGGCGAGGTGGTGGATGTCATGGTCATTGGACGGCTATGA

# Drug_Target_28_General_Function:
Coenzyme transport and metabolism

# Drug_Target_28_General_References:
10718198	Nagase T, Kikuno R, Ishikawa KI, Hirosawa M, Ohara O: Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2000 Feb 28;7(1):65-73.
11418245	David-Watine B: The human gephyrin (GPHN) gene: structure, chromosome localization and expression in non-neuronal cells. Gene. 2001 Jun 27;271(2):239-45.
11554796	Schwarz G, Schrader N, Mendel RR, Hecht HJ, Schindelin H: Crystal structures of human gephyrin and plant Cnx1 G domains: comparative analysis and functional implications. J Mol Biol. 2001 Sep 14;312(2):405-18.

# Drug_Target_28_HGNC_ID:
HGNC:15465

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
4532

# Drug_Target_28_Locus:
14q23.3

# Drug_Target_28_Molecular_Weight:
79749

# Drug_Target_28_Name:
Gephyrin

# Drug_Target_28_Number_of_Residues:
736

# Drug_Target_28_PDB_ID:
1T3E

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00994	MoCF_biosynth
PF03453	MoeA_N
PF03454	MoeA_C

# Drug_Target_28_Protein_Sequence:
>Gephyrin
MATEGMILTNHDHQIRVGVLTVSDSCFRNLAEDRSGINLKDLVQDPSLLGGTISAYKIVP
DEIEEIKETLIDWCDEKELNLILTTGGTGFAPRDVTPEATKEVIEREAPGMALAMLMGSL
NVTPLGMLSRPVCGIRGKTLIINLPGSKKGSQECFQFILPALPHAIDLLRDAIVKVKEVH
DELEDLPSPPPPLSPPPTTSPHKQTEDKGVQCEEEEEEKKDSGVASTEDSSSSHITAAAI
AAKIPDSIISRGVQVLPRDTASLSTTPSESPRAQATSRLSTASCPTPKVQSRCSSKENIL
RASHSAVDITKVARRHRMSPFPLTSMDKAFITVLEMTPVLGTEIINYRDGMGRVLAQDVY
AKDNLPPFPASVKDGYAVRAADGPGDRFIIGESQAGEQPTQTVMPGQVMRVTTGAPIPCG
ADAVVQVEDTELIRESDDGTEELEVRILVQARPGQDIRPIGHDIKRGECVLAKGTHMGPS
EIGLLATVGVTEVEVNKFPVVAVMSTGNELLNPEDDLLPGKIRDSNRSTLLATIQEHGYP
TINLGIVGDNPDDLLNALNEGISRADVIITSGGVSMGEKDYLKQVLDIDLHAQIHFGRVF
MKPGLPTTFATLDIDGVRKIIFALPGNPVSAVVTCNLFVVPALRKMQGILDPRPTIIKAR
LSCDVKLDPRPEYHRCILTWHHQEPLPWAQSTGNQMSSRLMSMRSANGLLMLPPKTEQYV
ELHKGEVVDVMVIGRL

# Drug_Target_28_Reaction:
Not Available

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Microtubule-associated protein involved in membrane protein-cytoskeleton interactions. It is thought to anchor the inhibitory glycine receptor (GLYR) to subsynaptic microtubules (By similarity). Involved in molybdenum cofactor biosynthesis. Required for molybdenum transfer to molybdopterin. In a first step, copper-molybdopterin is adenylated. Subsequently, molybdate is inserted into adenylated molybdopterin and AMP is released (By similarity)

# Drug_Target_28_SwissProt_ID:
Q9NQX3

# Drug_Target_28_SwissProt_Name:
GEPH_HUMAN

# Drug_Target_28_Synonyms:
Not Available

# Drug_Target_28_Theoretical_pI:
5.09

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Not Available

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
Not Available

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
Not Available

# Drug_Target_29_GenBank_ID_Gene:
AE016877

# Drug_Target_29_GenBank_ID_Protein:
Not Available

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
BC_1747

# Drug_Target_29_Gene_Sequence:
>453 bp
TTATTTATTACCGAGTTCTTCTGCTAAACCGATTAAAATTCCTTCGACTCCACGAATGTA
GCAGAGACGATACGAGTTCTCGTACTGAACTACTTCGCCAACGAGCTCTGCACCATGCTT
AGTGAGTCTCGATACCATTTCGTCAATATCCTCGACAGTGAACATGACGCGTAGATAACC
GAGGGCGTTTACAGGAGCTGTTCGGTGATCTGCTATAGTAGGAGGGGTGAGAAATCGCGA
AAGTTCAATTCGGCTGTGGCCATCTGGAGTGACCATCATAGCAATCTCTACGCACTGAGA
ACCGAGTCCAGTTACGCGACCAGCCCATTCACCTTCGACATTTGCTCGACCTTCGAGATT
CAAGCCAATCTCCTCAAAGAAAGAGATTGCGTTATCAAGGGATTCTACAACGATGCTGAC
ATTGTCCATTCGTAGTAATTTGTTTTTTGCCAT

# Drug_Target_29_General_Function:
Amino acid transport and metabolism

# Drug_Target_29_General_References:
12721630	Ivanova N, Sorokin A, Anderson I, Galleron N, Candelon B, Kapatral V, Bhattacharyya A, Reznik G, Mikhailova N, Lapidus A, Chu L, Mazur M, Goltsman E, Larsen N, D'Souza M, Walunas T, Grechkin Y, Pusch G, Haselkorn R, Fonstein M, Ehrlich SD, Overbeek R, Kyrpides N: Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature. 2003 May 1;423(6935):87-91.

# Drug_Target_29_HGNC_ID:
Not Available

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
4533

# Drug_Target_29_Locus:
Not Available

# Drug_Target_29_Molecular_Weight:
16582

# Drug_Target_29_Name:
Glyoxalase family protein

# Drug_Target_29_Number_of_Residues:
150

# Drug_Target_29_PDB_ID:
1SS4

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00903	Glyoxalase

# Drug_Target_29_Protein_Sequence:
>Glyoxalase family protein
MAKNKLLRMDNVSIVVESLDNAISFFEEIGLNLEGRANVEGEWAGRVTGLGSQCVEIAMM
VTPDGHSRIELSRFLTPPTIADHRTAPVNALGYLRVMFTVEDIDEMVSRLTKHGAELVGE
VVQYENSYRLCYIRGVEGILIGLAEELGNK

# Drug_Target_29_Reaction:
Not Available

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Not Available

# Drug_Target_29_SwissProt_ID:
Q81F54

# Drug_Target_29_SwissProt_Name:
Q81F54_BACCR

# Drug_Target_29_Synonyms:
Not Available

# Drug_Target_29_Theoretical_pI:
4.59

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
RNASE1

# Drug_Target_2_GenBank_ID_Gene:
D26129

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
RNASE1

# Drug_Target_2_Gene_Sequence:
>471 bp
ATGGCTCTGGAGAAGTCTCTTGTCCGGCTCCTTCTGCTTGTCCTGATACTGCTGGTGCTG
GGCTGGGTCCAGCCTTCCCTGGGCAAGGAATCCCGGGCCAAGAAATTCCAGCGGCAGCAT
ATGGACTCAGACAGTTCCCCCAGCAGCAGCTCCACCTACTGTAACCAAATGATGAGGCGC
CGGAATATGACACAGGGGCGGTGCAAACCAGTGAACACCTTTGTGCACGAGCCCCTGGTA
GATGTCCAGAATGTCTGTTTCCAGGAAAAGGTCACCTGCAAGAACGGGCAGGGCAACTGC
TACAAGAGCAACTCCAGCATGCACATCACAGACTGCCGCCTGACAAACGGCTCCAGGTAC
CCCAACTGTGCATACCGGACCAGCCCGAAGGAGAGACACATCATTGTGGCCTGTGAAGGG
AGCCCATATGTGCCAGTCCACTTTGATGCTTCTGTGGAGGACTCTACCTAA

# Drug_Target_2_General_Function:
Involved in nucleic acid binding

# Drug_Target_2_General_References:
1741299	Haugg M, Schein CH: The DNA sequences of the human and hamster secretory ribonucleases determined with the polymerase chain reaction (PCR). Nucleic Acids Res. 1992 Feb 11;20(3):612.
2049798	Sakakibara R, Hashida K, Tominaga N, Sakai K, Ishiguro M, Imamura S, Ohmatsu F, Sato E: A putative mouse oocyte maturation inhibitory protein from urine of pregnant women: N-terminal sequence homology with human nonsecretory ribonuclease. Chem Pharm Bull (Tokyo). 1991 Jan;39(1):146-9.
2383019	Mizuta K, Awazu S, Yasuda T, Kishi K: Purification and characterization of three ribonucleases from human kidney: comparison with urine ribonucleases. Arch Biochem Biophys. 1990 Aug 15;281(1):144-51.
3202829	Beintema JJ, Blank A, Schieven GL, Dekker CA, Sorrentino S, Libonati M: Differences in glycosylation pattern of human secretory ribonucleases. Biochem J. 1988 Oct 15;255(2):501-5.
6201087	Beintema JJ, Wietzes P, Weickmann JL, Glitz DG: The amino acid sequence of human pancreatic ribonuclease. Anal Biochem. 1984 Jan;136(1):48-64.
7649283	Russo N, de Nigris M, Ciardiello A, Di Donato A, D'Alessio G: Expression in mammalian cells, purification and characterization of recombinant human pancreatic ribonuclease. FEBS Lett. 1995 Aug 7;369(2-3):352.
8049276	Seno M, Futami J, Kosaka M, Seno S, Yamada H: Nucleotide sequence encoding human pancreatic ribonuclease. Biochim Biophys Acta. 1994 Aug 2;1218(3):466-8.
8588814	Kochetov AV, Lukasheva VV, Filipenko ML, Mertvetsov NP, Rivkin MI: [Primary structure of the coding part of the gene for human pancreatic ribonuclease and its chromosomal location] Bioorg Khim. 1995 Sep;21(9):691-4.

# Drug_Target_2_HGNC_ID:
HGNC:10044

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5682

# Drug_Target_2_Locus:
14q11.2

# Drug_Target_2_Molecular_Weight:
17644

# Drug_Target_2_Name:
Ribonuclease pancreatic

# Drug_Target_2_Number_of_Residues:
156

# Drug_Target_2_PDB_ID:
1E21

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_2_Protein_Sequence:
>Ribonuclease pancreatic
MALEKSLVRLLLLVLILLVLGWVQPSLGKESRAKKFQRQHMDSDSSPSSSSTYCNQMMRR
RNMTQGRCKPVNTFVHEPLVDVQNVCFQEKVTCKNGQGNCYKSNSSMHITDCRLTNGSRY
PNCAYRTSPKERHIIVACEGSPYVPVHFDASVEDST

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-28

# Drug_Target_2_Specific_Function:
Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single stranded and double stranded RNA

# Drug_Target_2_SwissProt_ID:
P07998

# Drug_Target_2_SwissProt_Name:
RNAS1_HUMAN

# Drug_Target_2_Synonyms:
EC 3.1.27.5
HP-RNase
RIB-1
RNase 1
RNase A
RNase UpI-1
Ribonuclease pancreatic precursor

# Drug_Target_2_Theoretical_pI:
8.94

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Not Available

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
Not Available

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
PSCD2

# Drug_Target_30_GenBank_ID_Gene:
X99753

# Drug_Target_30_GenBank_ID_Protein:
Not Available

# Drug_Target_30_GeneCard_ID:
Not Available

# Drug_Target_30_Gene_Name:
CYTH2

# Drug_Target_30_Gene_Sequence:
>1200 bp
ATGGAGGACGGCGTTTATGAACCCCCAGACCTGACTCCGGAGGAGCGGATGGAGCTGGAG
AACATCCGGCGGCGGAAGCAGGAGCTGCTGGTGGAGATTCAGCGCCTGCGGGAGGAGCTC
AGTGAAGCCATGAGCGAGGTGGAGGGGCTGGAGGCCAATGAGGGCAGTAAGACCTTGCAA
CGGAACCGGAAGATGGCAATGGGCAGGAAGAAGTTCAACATGGACCCCAAGAAGGGGATC
CAGTTCTTGGTGGAGAATGAACTGCTGCAGAACACACCCGAGGAGATCGCCCGCTTCCTG
TACAAGGGCGAGGGGCTGAACAAGACAGCCATCGGGGACTACCTGGGGGAGAGGGAAGAA
CTGAACCTGGCAGTGCTCCATGCTTTTGTGGATCTGCATGAGTTCACCGACCTCAATCTG
GTGCAGGCCCTCAGGCAGTTTCTATGGAGCTTTCGCCTACCCGGAGAGGCCCAGAAAATT
GACCGGATGATGGAGGCCTTCGCCCAGCGATACTGCCTGTGCAACCCTGGGGTTTTCCAG
TCCACAGACACGTGCTATGTGCTGTCCTTCGCCGTCATCATGCTCAACACCAGTCTCCAC
AATCCCAATGTCCGGGACAAGCCGGGCCTGGAGCGCTTTGTGGCCATGAACCGGGGCATC
AACGAGGGCGGGGACCTGCCTGAGGAGCTGCTCAGGAACCTGTACGACAGCATCCGAAAT
GAGCCCTTCAAGATTCCTGAGGATGACGGGAATGACCTGACCCACACCTTCTTCAACCCG
GACCGGGAGGGCTGGCTCCTGAAGCTGGGGGGCCGGGTGAAAACGTGGAAGCGGCGCTGG
TTTATCCTCACAGACAACTGCCTCTACTACTTTGAGTACACCACGGACAAGGAGCCCCGA
GGAATCATCCCCCTGGAGAATCTGAGCATCCGAGAGGTGGACGACCCCCGGAAACCGAAC
TGCTTTGAACTTTACATCCCCAACAACAAGGGGCAGCTCATCAAAGCCTGCAAAACTGAG
GCGGACGGCCGAGTGGTGGAGGGAAACCACATGGTGTACCGGATCTCGGCCCCCACGCAG
GAGGAGAAGGACGAGTGGATCAAGTCCATCCAGGCGGCTGTGAGTGTGGACCCCTTCTAT
GAGATGCTGGCAGCGAGAAAGAAGCGGATTTCAGTCAAGAAGAAGCAGGAGCAGCCCTGA

# Drug_Target_30_General_Function:
Involved in ARF guanyl-nucleotide exchange factor activity

# Drug_Target_30_General_References:
8945478	Chardin P, Paris S, Antonny B, Robineau S, Beraud-Dufour S, Jackson CL, Chabre M: A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains. Nature. 1996 Dec 5;384(6608):481-4.
9417041	Frank S, Upender S, Hansen SH, Casanova JE: ARNO is a guanine nucleotide exchange factor for ADP-ribosylation factor 6. J Biol Chem. 1998 Jan 2;273(1):23-7.
9476900	Mossessova E, Gulbis JM, Goldberg J: Structure of the guanine nucleotide exchange factor Sec7 domain of human arno and analysis of the interaction with ARF GTPase. Cell. 1998 Feb 6;92(3):415-23.
9510256	Cherfils J, Menetrey J, Mathieu M, Le Bras G, Robineau S, Beraud-Dufour S, Antonny B, Chardin P: Structure of the Sec7 domain of the Arf exchange factor ARNO. Nature. 1998 Mar 5;392(6671):101-5.

# Drug_Target_30_HGNC_ID:
HGNC:9502

# Drug_Target_30_HPRD_ID:
Not Available

# Drug_Target_30_ID:
4534

# Drug_Target_30_Locus:
19q13.3

# Drug_Target_30_Molecular_Weight:
46547

# Drug_Target_30_Name:
Cytohesin-2

# Drug_Target_30_Number_of_Residues:
400

# Drug_Target_30_PDB_ID:
1R8Q

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF00169	PH
PF01369	Sec7

# Drug_Target_30_Protein_Sequence:
>Cytohesin-2
MEDGVYEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEVEGLEANEGSKTLQ
RNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIGDYLGEREE
LNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPGVFQ
STDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRN
EPFKIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEP
RGIIPLENLSIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPT
QEEKDEWIKSIQAAVSVDPFYEMLAARKKRISVKKKQEQP

# Drug_Target_30_Reaction:
Not Available

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Promotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Promotes the activation of ARF through replacement of GDP with GTP

# Drug_Target_30_SwissProt_ID:
Q99418

# Drug_Target_30_SwissProt_Name:
CYH2_HUMAN

# Drug_Target_30_Synonyms:
ARF exchange factor
ARF nucleotide-binding site opener
PH, SEC7 and coiled-coil domain-containing protein 2
Protein ARNO

# Drug_Target_30_Theoretical_pI:
5.21

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Not Available

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
Not Available

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
Not Available

# Drug_Target_31_GenBank_ID_Gene:
X69435

# Drug_Target_31_GenBank_ID_Protein:
Not Available

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
gcdA

# Drug_Target_31_Gene_Sequence:
>1764 bp
ATGGGTTTCTACTCTATGCCTAGATATTTCCAAAATATGCCTCAGGTGGGCAAACCCCTG
AAAAAGGCGGATGCCGCCAATGAAGAACAGCTGAAAAAGATCGAAGAAGAGATCCATCAG
CTGATCAAAGAGGCTCAGGAAGCCGGCAAGGCAGATGCTGATGTAAACAAGAGAGGGGAA
CTGACCGCTCTCCAGAGAATTGAAAAACTGGTGGAACCGGGCTCCTGGAGACCCCTGAAC
ACCCTGTTCAACCCTCAGGGCAACAAGAACGGCTCCGTGGCCATCGTCAAGGGCCTGGGC
CGTGTAAACGGCAAATGGTGCGTGGTCGTGGCTTCCGACAACAAGAAGCTGGCCGGTGCC
TGGGTGCCAGGCCAGGCTGAATGCCTGCTGCGGGCTTCCGATACCGCCAAGACCCTGCAC
GTGCCTCTGGTGTATGTGCTGAACTGCTCCGGCGTTAAGTTCGACGAACAGGAAAAGGTA
TACCCCAACCGTCGTGGCGGCGGTACGCCTTTCTTCCGGAACGCTGAACTGAACCAGCTG
GGCATTCCCGTCATCGTTGGCATCTACGGCACCAACCCTGCCGGCGGCGGCTATCATTCC
ATCAGCCCCACGGTGATCATTGCCCATGAAAAAGCCAACATGGCTGTGGGCGGCGCCGGC
ATTATGGGCGGCATGAACCCCAAAGGTCATGTGGACCTGGAATATGCCAACGAAATCGCC
GACATGGTGGACCGTACCGGCAAGACCGAACCTCCGGGAGCTGTCGACATCCACTACACC
GAAACCGGTTTCATGCGTGAAGTCTATGCTTCCGAAGAAGGCGTTCTGGAAGGGATCAAG
AAGTATGTAGGCATGCTGCCGAAATACGATCCTGAATTCTTCCGGGTGGACGATCCGAAA
GCACCGGCATTCCCGGCTGACGACCTGTACAGCATGGTTCCTCTGAACGACAAACGGGCT
TATGACATCTACAATGTAATTGCCCGCCTGTTCGACAACAGCGAACTCCATGAATACAAA
AAAGGCTACGGCCCTGAAATGGTCACCGGTCTGGCCAAAGTCAACGGCCTGCTGGTGGGC
GTTGTGGCCAACGTCCAGGGTCTCCTGATGAACTACCCTGAATACAAGGCTGCAGGCTCC
GTAGGGATCGGCGGCAAACTGTACCGCCAGGGTCTGGTGAAAATGAATGAATTCGTCACC
CTGTGCGCCAGAGACCGTCTGCCCATCGTCTGGATCCAGGATACCACCGGGATCGATGTG
GGCAACGATGCGGAAAAGGCTGAACTGCTGGGTCTGGGCCAGTCCCTGATCTACTCCATC
CAGACTTCCCACATCCCTCAATTCGAAATTACCCTGAGAAAAGGCACGGCTGCTGCCCAC
TACGTACTGGGCGGGCCTCAGGGCAATGACACCAACGCCTTCTCCATCGGTACCGCTGCT
ACGGAAATCGCCGTTATGAACGGTGAAACCGCTGCCACCGCCATGTACTCCCGGAGACTG
GCCAAAGACCGGAAAGCCGGCAAGGATCTGCAGCCGACCATCGACAAGATGAACAACCTG
ATCCAGGCTTTCTACACCAAATCTCGTCCGAAAGTCTGTGCTGAACTGGGTCTGGTGGAT
GAAATCGTGGACATGAACAAGATCCGCGGGTATGTGGAAGCCTTCACGGAAGCTGCTTAT
CAGAATCCGGAAAGCATCTGCCCGTTCCATCAGATGATTCTGCCTCGTGCCATCAGAGAG
TTTGAGACTTTCGTAAAGAAATAA

# Drug_Target_31_General_Function:
Involved in ligase activity

# Drug_Target_31_General_References:
7607244	Muller U, Buckel W: Activation of (R)-2-hydroxyglutaryl-CoA dehydratase from Acidaminococcus fermentans. Eur J Biochem. 1995 Jun 1;230(2):698-704.
8365476	Bendrat K, Muller U, Klees AG, Buckel W: Identification of the gene encoding the activator of (R)-2-hydroxyglutaryl-CoA dehydratase from Acidaminococcus fermentans by gene expression in Escherichia coli. FEBS Lett. 1993 Aug 30;329(3):329-31.
8382157	Bendrat K, Buckel W: Cloning, sequencing and expression of the gene encoding the carboxytransferase subunit of the biotin-dependent Na+ pump glutaconyl-CoA decarboxylase from Acidaminococcus fermentans in Escherichia coli. Eur J Biochem. 1993 Feb 1;211(3):697-702.

# Drug_Target_31_HGNC_ID:
Not Available

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
4535

# Drug_Target_31_Locus:
Not Available

# Drug_Target_31_Molecular_Weight:
64347

# Drug_Target_31_Name:
Glutaconyl-CoA decarboxylase subunit alpha

# Drug_Target_31_Number_of_Residues:
587

# Drug_Target_31_PDB_ID:
1PIX

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF01039	Carboxyl_trans

# Drug_Target_31_Protein_Sequence:
>Glutaconyl-CoA decarboxylase subunit alpha
MGFYSMPRYFQNMPQVGKPLKKADAANEEQLKKIEEEIHQLIKEAQEAGKADADVNKRGE
LTALQRIEKLVEPGSWRPLNTLFNPQGNKNGSVAIVKGLGRVNGKWCVVVASDNKKLAGA
WVPGQAECLLRASDTAKTLHVPLVYVLNCSGVKFDEQEKVYPNRRGGGTPFFRNAELNQL
GIPVIVGIYGTNPAGGGYHSISPTVIIAHEKANMAVGGAGIMGGMNPKGHVDLEYANEIA
DMVDRTGKTEPPGAVDIHYTETGFMREVYASEEGVLEGIKKYVGMLPKYDPEFFRVDDPK
APAFPADDLYSMVPLNDKRAYDIYNVIARLFDNSELHEYKKGYGPEMVTGLAKVNGLLVG
VVANVQGLLMNYPEYKAAGSVGIGGKLYRQGLVKMNEFVTLCARDRLPIVWIQDTTGIDV
GNDAEKAELLGLGQSLIYSIQTSHIPQFEITLRKGTAAAHYVLGGPQGNDTNAFSIGTAA
TEIAVMNGETAATAMYSRRLAKDRKAGKDLQPTIDKMNNLIQAFYTKSRPKVCAELGLVD
EIVDMNKIRGYVEAFTEAAYQNPESICPFHQMILPRAIREFETFVKK

# Drug_Target_31_Reaction:
Not Available

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Decarboxylase subunit of the primary sodium pump glutaconyl-CoA decarboxylase (GCD)

# Drug_Target_31_SwissProt_ID:
Q06700

# Drug_Target_31_SwissProt_Name:
GCDA_ACIFV

# Drug_Target_31_Synonyms:
Carboxyltransferase
EC 4.1.1.70

# Drug_Target_31_Theoretical_pI:
7.05

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Cytoplasmic

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
Not Available

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
Not Available

# Drug_Target_32_GenBank_ID_Gene:
AE000512

# Drug_Target_32_GenBank_ID_Protein:
Not Available

# Drug_Target_32_GeneCard_ID:
Not Available

# Drug_Target_32_Gene_Name:
TM_0065

# Drug_Target_32_Gene_Sequence:
>741 bp
TTGAATACCCTCAAAAAAGCCTTCGAAATACTGGATTTCATCGTAAAGAATCCTGGCGAT
GTAAGCGTTTCTGAAATAGCCGAAAAGTTCAATATGAGCGTTTCAAACGCATACAAATAC
ATGGTTGTTCTCGAAGAGAAAGGGTTTGTTCTCAGAAAAAAAGACAAGAGATACGTACCG
GGGTACAAATTGATAGAGTACGGTTCATTCGTTCTGAGGCGCTTCAACATTAGGGATATA
GCTCACGACCATCTCGTGGATATCATGAAAAGAACGGGGGAAACAGTACACCTGATTTTG
AAAGATGGCTTCGAGGGAGTTTACATAGACAAGGTGGAGGGTGAGCAGAGCATTCCTATG
GTCTCAAGACTTGGTATGAAAGTCGACCTTTACTCCACAGCCTCTGGTAAATCCATTCTC
GCCTTCGTTCCCGAAAAAGAATTGAAGGAATACCTGAAAATTGTGGAACTAAAACCAAAA
ACCCCAAACACCATCACGAATCCCAGAGTACTGAAGAGAGAGCTTGAAAAAATTAGAAAG
CGAGGATACGCCGTAGACAACGAAGAAAACGAAATAGGTATCATGTGTGTGGGAGTTCCT
ATATTTGATCACAACGGATATCCGGTGGCTGGAGTGAGTATTTCCGGGGTTGCACGAAAG
TTCACAGAGGAAAAAATAGAAGAATACTCCGATGTACTCAAAGAAAAGGCAGAAGAAATA
TCCAGAAAACTTGGATATTGA

# Drug_Target_32_General_Function:
Involved in DNA binding

# Drug_Target_32_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
11877432	Zhang RG, Kim Y, Skarina T, Beasley S, Laskowski R, Arrowsmith C, Edwards A, Joachimiak A, Savchenko A: Crystal structure of Thermotoga maritima 0065, a member of the IclR transcriptional factor family. J Biol Chem. 2002 May 24;277(21):19183-90. Epub 2002 Mar 4.

# Drug_Target_32_HGNC_ID:
Not Available

# Drug_Target_32_HPRD_ID:
Not Available

# Drug_Target_32_ID:
4536

# Drug_Target_32_Locus:
Not Available

# Drug_Target_32_Molecular_Weight:
28119

# Drug_Target_32_Name:
Transcriptional regulator, IclR family

# Drug_Target_32_Number_of_Residues:
246

# Drug_Target_32_PDB_ID:
1MKM

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF01614	IclR
PF08279	HTH_11

# Drug_Target_32_Protein_Sequence:
>Transcriptional regulator, IclR family
MNTLKKAFEILDFIVKNPGDVSVSEIAEKFNMSVSNAYKYMVVLEEKGFVLRKKDKRYVP
GYKLIEYGSFVLRRFNIRDIAHDHLVDIMKRTGETVHLILKDGFEGVYIDKVEGEQSIPM
VSRLGMKVDLYSTASGKSILAFVPEKELKEYLKIVELKPKTPNTITNPRVLKRELEKIRK
RGYAVDNEENEIGIMCVGVPIFDHNGYPVAGVSISGVARKFTEEKIEEYSDVLKEKAEEI
SRKLGY

# Drug_Target_32_Reaction:
Not Available

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Not Available

# Drug_Target_32_SwissProt_ID:
Q9WXS0

# Drug_Target_32_SwissProt_Name:
Q9WXS0_THEMA

# Drug_Target_32_Synonyms:
Not Available

# Drug_Target_32_Theoretical_pI:
9.05

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Not Available

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
Not Available

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
Not Available

# Drug_Target_33_GenBank_ID_Gene:
AE004265

# Drug_Target_33_GenBank_ID_Protein:
Not Available

# Drug_Target_33_GeneCard_ID:
Not Available

# Drug_Target_33_Gene_Name:
VC_1899

# Drug_Target_33_Gene_Sequence:
>1152 bp
ATGGCTATTCACGTAGGGATTATCGATCAGGACCCGGTTCGCTTAGTGACACCGCTGCTC
GATCATCGAACCGTTAGCCGCCACATTATTTTTATTGGCGACCATACCCAAACGGTAATT
TATCAACGCCTTAGCGACGTTTTAAACAAGCGTAATATCTCAACAGACTTCTTTGAAATT
CCCGCCGGCTCAAACACCTCTGCCATCAAAAGTGCGATTCGAGAACTTGCCGAAACACTT
AAAGCGCGTGGTGAAGAGGTCAAATTCAACGCCAGTTGTGGGTTACGCCACCGCTTGCTG
TCGGCTTACGAAGTGTTTCGCAGCTACCACTGGCCAATTTTTGTCGTAGAACCCAATAGT
GACTGCTTATGCTGGCTGTATCCCGAAGGCAATAACGATACTCAAGTTCAAGACCGCATC
ACCATTGCCGACTATCTCACCATTTTTGGTGCGCGTGGCGAATTCAATGAGCATCAACTC
TCTCCACAATTAGATCAGCAGTTGTATCAGCTTGGCGAACGCTGGGCGAGTAATGCATTG
GAATTAGGCCCAGGCCTCGCCACCCTCAATTACCTCGCCACCACTTGCCGAAAAGAGCAG
AAGCTGGATGTGGAATTATCTGACAAACAGCAAGGCTATCGCGAATTAAACTTGCTACTC
AGCGATCTGGTTGAGGCCAAGATTGCCAGTTATGAAAACGGCATTCTCACGTTCATAAAC
GAAGAGGCTCGTCGCTTTGCCAATGGTGAGTGGTTAGAAACCCTAGTTCACAGCACTGTA
AAACAGATCCAAGATGACATGCCAACCATTCAAGATCGCTCGCTGAACGTGCAAGTCTAT
CGCCAGCTTGGAGAGAGAGAAGTGCGTAACGAGTTGGATGTGGCGACCGTGGTGAACAAC
AAACTGCACATTATTGAGTGTAAAACCAAAGGGATGCGTGATGACGGTGACGATACCTTG
TACAAACTCGAATCTCTGCGTGACCTTCTCGGCGGTCTACAGGCTCGAGCTATGTTGGTC
AGCTTCCGCCCTCTACGCCATAACGATATTACGCGTGCCGAAGATTTGGGGCTGGCTTTG
ATTGGTCCAGATGAATTGAAAGATTTGAAAACCCATTTAACCCAATGGTTCAAAGCCGCA
GGGGGAAATTAA

# Drug_Target_33_General_Function:
Not Available

# Drug_Target_33_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.
12562793	Herz K, Vimont S, Padan E, Berche P: Roles of NhaA, NhaB, and NhaD Na+/H+ antiporters in survival of Vibrio cholerae in a saline environment. J Bacteriol. 2003 Feb;185(4):1236-44.

# Drug_Target_33_HGNC_ID:
Not Available

# Drug_Target_33_HPRD_ID:
Not Available

# Drug_Target_33_ID:
4538

# Drug_Target_33_Locus:
Not Available

# Drug_Target_33_Molecular_Weight:
43587

# Drug_Target_33_Name:
Hypothetical protein VC1899

# Drug_Target_33_Number_of_Residues:
383

# Drug_Target_33_PDB_ID:
1XMX

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
Not Available

# Drug_Target_33_Protein_Sequence:
>Hypothetical protein VC1899
MAIHVGIIDQDPVRLVTPLLDHRTVSRHIIFIGDHTQTVIYQRLSDVLNKRNISTDFFEI
PAGSNTSAIKSAIRELAETLKARGEEVKFNASCGLRHRLLSAYEVFRSYHWPIFVVEPNS
DCLCWLYPEGNNDTQVQDRITIADYLTIFGARGEFNEHQLSPQLDQQLYQLGERWASNAL
ELGPGLATLNYLATTCRKEQKLDVELSDKQQGYRELNLLLSDLVEAKIASYENGILTFIN
EEARRFANGEWLETLVHSTVKQIQDDMPTIQDRSLNVQVYRQLGEREVRNELDVATVVNN
KLHIIECKTKGMRDDGDDTLYKLESLRDLLGGLQARAMLVSFRPLRHNDITRAEDLGLAL
IGPDELKDLKTHLTQWFKAAGGN

# Drug_Target_33_Reaction:
Not Available

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
Q9KQU9

# Drug_Target_33_SwissProt_Name:
Q9KQU9_VIBCH

# Drug_Target_33_Synonyms:
Not Available

# Drug_Target_33_Theoretical_pI:
5.46

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
Not Available

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
U67458

# Drug_Target_34_GenBank_ID_Protein:
Not Available

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
katA

# Drug_Target_34_Gene_Sequence:
>1518 bp
ATGGTTAATAAAGATGTGAAACAAACCACTGCTTTTGGCGCTCCCGTTTGGGATGATAAC
AATGTGATTACGGCTGGTCCTAGAGGTCCTGTTTTATTACAAAGCACTTGGTTTTTGGAA
AAGTTAGCAGCGTTTGACAGAGAAAGGATCCCTGAAAGGGTAGTGCATGCTAAAGGAAGC
GGGGCTTATGGCACTTTCACCGTGACTAAAGACATCACTAAATACACTAAAGCGAAGATT
TTTTTTAAAGTGGGCAAAAAAACCGAATGCTTTTTCAGGTTTTTTACTGTGGCTGGTGAA
AGAGGCAGTGCGGATGCAGTGAGAGACCCTAGAGGTTTTGCGATGAAGTATTACACTGAA
GAAGGTAACTGGGATTTAGTAGGGAACAACACGCCTGTTTTCTTTATCCGTGATGCGATC
AAATTCCCTGATTTCATCCACACCCAAAAAAGAGACCCTCAAACCAATTTGCCTAACCAC
GACATGGTATGGGATTTTTGGAGTAATGTTCCTGAAAGCTTGTATCAAGTAACATGGGTT
ATGAGCGATAGAGGGATCCCTAAATCTTTCCGCCACATGGATGGTTTTGGCAGCCACACT
TTCAGTCTTATCAACGCTAAGGGCGAACGCTTTTGGGTGAAATTCCACTTTCACACCATG
CAAGGCGTTAAGCACTTGACTAACGAAGAAGCCGCAGAAGTCAGAAAATATGATCCTGAT
TCCAATCAAAGGGATTTATTCAATGCGATCGCTAGAGGGGATTTCCCAAAATGGAAATTA
AGCATTCAAGTGATGCCAGAAGAAGATGCTAAGAAGTATCGATTCCATCCGTTTGATGTT
ACTAAAATTTGGTATCTCCAAGATTATCCGTTGATGGAAGTGGGCATTGTAGAGTTGAAT
AAAAATCCTGAAAACTATTTTGCAGAAGTGGAGCAAGTGGCATTCACTCCGGCTAATGTC
GTTCCTGGAATTGGCTATAGCCCTGATAGGATGTTACAAGGACGCTTGTTCTCTTATGGG
GACACACACCGCTACCGCTTAGGGGTTAATTATCCTCAAATACCGGTTAATAAACCAAGA
TGCCCGTTCCACTCTTCTAGCAGAGATGGTTACATGCAAAACGGATACTACGGCTCTTTA
CAAAACTATACGCCTAGCTCATTGCCAGGTTATAAAGAAGATAAGAGCGCGAGAGATCCT
AAGTTCAACTTAGCTCATATTGAGAAAGAGTTTGAAGTGTGGAATTGGGATTACAGGGCT
GATGATAGCGATTACTACACCCAACCAGGTGATTACTACCGCTCATTGCCAGCTGATGAA
AAAGAAAGGTTGCATGACACTATTGGAGAGTCTTTGGCTCATGTTACCCATAAGGAAATT
GTGGATAAACAATTGGAGCATTTCAAGAAAGCTGATCCCAAATACGCTGAGGGAGTTAAA
AAAGCTCTTGAAAAACACCAAAAGATGATGAAAGACATGCATGGAAAAGACATGCACCAC
ACAAAAAAGAAAAAGTAA

# Drug_Target_34_General_Function:
Involved in catalase activity

# Drug_Target_34_General_References:
8955320	Odenbreit S, Wieland B, Haas R: Cloning and genetic characterization of Helicobacter pylori catalase and construction of a catalase-deficient mutant strain. J Bacteriol. 1996 Dec;178(23):6960-7.
9252185	Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47.
9546115	Manos J, Kolesnikow T, Hazell SL: An investigation of the molecular basis of the spontaneous occurrence of a catalase-negative phenotype in Helicobacter pylori. Helicobacter. 1998 Mar;3(1):28-38.

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
4539

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
58630

# Drug_Target_34_Name:
Catalase

# Drug_Target_34_Number_of_Residues:
505

# Drug_Target_34_PDB_ID:
1QWM

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF00199	Catalase

# Drug_Target_34_Protein_Sequence:
>Catalase
MVNKDVKQTTAFGAPVWDDNNVITAGPRGPVLLQSTWFLEKLAAFDRERIPERVVHAKGS
GAYGTFTVTKDITKYTKAKIFSKVGKKTECFFRFSTVAGERGSADAVRDPRGFAMKYYTE
EGNWDLVGNNTPVFFIRDAIKFPDFIHTQKRDPQTNLPNHDMVWDFWSNVPESLYQVTWV
MSDRGIPKSFRHMDGFGSHTFSLINAKGERFWVKFHFHTMQGVKHLTNEEAAEVRKYDPD
SNQRDLFNAIARGDFPKWKLSIQVMPEEDAKKYRFHPFDVTKIWYLQDYPLMEVGIVELN
KNPENYFAEVEQAAFSPANVVPGIGYSPDRMLQGRLFSYGDTHRYRLGVNYPQIPVNKPR
CPFHSSSRDGYMQNGYYGSLQNYTPSSLPGYKEDKSARDPKFNLAHIEKEFEVWNWDYRA
DDSDYYTQPGDYYRSLPADEKERLHDTIGESLAHVTHKEIVDKQLEHFKKADPKYAEGVK
KALEKHQKMMKDMHGKDMHHTKKKK

# Drug_Target_34_Reaction:
Not Available

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide

# Drug_Target_34_SwissProt_ID:
P77872

# Drug_Target_34_SwissProt_Name:
CATA_HELPY

# Drug_Target_34_Synonyms:
EC 1.11.1.6

# Drug_Target_34_Theoretical_pI:
9.04

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Not Available

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
Not Available

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
Not Available

# Drug_Target_35_GenBank_ID_Gene:
AE000512

# Drug_Target_35_GenBank_ID_Protein:
Not Available

# Drug_Target_35_GeneCard_ID:
Not Available

# Drug_Target_35_Gene_Name:
TM_1070

# Drug_Target_35_Gene_Sequence:
>345 bp
ATGAACGGTGCCAGAAAATGGTTCTTTCCAGATGGTTACATTCCAAACGGCAAAAGAGGA
TATCTTGTTTCTCATGAATCTCTGTGTATCATGAATACGGGTGATGAAACAGCAAAAATA
AGGATCACGTTCCTCTTCGAAGACTCTAAACCAGTTGTTCATGAAGTAGAAATTTCACCA
ATGAAGAGTTTGCATCTGAGACTGGACAAACTTGGTATACCAAAATGTAAGCCTTACAGC
ATAATGGCGGAAAGCAACGTACCTGTTGTCATGCAGCTTTCACGTCTCGACGTTGGAAAA
AACCACTACACTCTTATGACAACCATCGGTTACTGGGAGGAGTGA

# Drug_Target_35_General_Function:
Not Available

# Drug_Target_35_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_35_HGNC_ID:
Not Available

# Drug_Target_35_HPRD_ID:
Not Available

# Drug_Target_35_ID:
4540

# Drug_Target_35_Locus:
Not Available

# Drug_Target_35_Molecular_Weight:
13061

# Drug_Target_35_Name:
Hypothetical protein

# Drug_Target_35_Number_of_Residues:
114

# Drug_Target_35_PDB_ID:
1NC7

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF07100	DUF1362

# Drug_Target_35_Protein_Sequence:
>Hypothetical protein
MNGARKWFFPDGYIPNGKRGYLVSHESLCIMNTGDETAKIRITFLFEDSKPVVHEVEISP
MKSLHLRLDKLGIPKCKPYSIMAESNVPVVMQLSRLDVGKNHYTLMTTIGYWEE

# Drug_Target_35_Reaction:
Not Available

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Not Available

# Drug_Target_35_SwissProt_ID:
Q9X0F9

# Drug_Target_35_SwissProt_Name:
Q9X0F9_THEMA

# Drug_Target_35_Synonyms:
Not Available

# Drug_Target_35_Theoretical_pI:
8.22

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Not Available

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
AF426836

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
GST

# Drug_Target_36_Gene_Sequence:
>642 bp
ATGAAGCTTGGAGATAATATAGTGTTATATTATTTTGATGCAAGGGGTAAAGCTGAATTG
ATAAGATTAATTTTTGCCTACCTTGGAATAGAATATACAGATAAAAGATTTGGAGTAAAC
GGTGATGCTTTTGTTGAATTTAAAAATTTTAAAAAAGAAAAGGATACTCCTTTTGAGCAA
GTACCCATATTACAAATTGGAGATTTGATATTAGCTCAAAGCCAAGCTATAGTTCGTTAT
TTATCAAAAAAATATAATATATGTGGTGAAAGTGAATTGAATGAATTTTATGCAGATATG
ATATTTTGTGGTGTTCAGGATATTCATTATAAATTTAATAATACCAATTTATTTAAACAA
AATGAAACAACTTTTTTAAATGAGGATTTACCAAAATGGTCAGGTTATTTTGAGAAACTT
TTAAAAAAAAATCATACAAATAATAATAATGATAAATATTATTTTGTAGGTAATAATTTA
ACATATGCTGACCTAGCTGTTTTTAATTTATATGATGATATTGAAACAAAATATCCAAGT
AGCTTGAAAAATTTCCCTTTATTAAAAGCTCATAATGAATTTATAAGTAACTTGCCTAAT
ATCAAAAATTATATAACTAATAGAAAAGAAAGTGTATACTAA

# Drug_Target_36_General_Function:
Not Available

# Drug_Target_36_General_References:
12108547	Harwaldt P, Rahlfs S, Becker K: Glutathione S-transferase of the malarial parasite Plasmodium falciparum: characterization of a potential drug target. Biol Chem. 2002 May;383(5):821-30.
12387854	Liebau E, Bergmann B, Campbell AM, Teesdale-Spittle P, Brophy PM, Luersen K, Walter RD: The glutathione S-transferase from Plasmodium falciparum. Mol Biochem Parasitol. 2002 Sep-Oct;124(1-2):85-90.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
4541

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
24789

# Drug_Target_36_Name:
Glutathione S-transferase

# Drug_Target_36_Number_of_Residues:
211

# Drug_Target_36_PDB_ID:
1Q4J

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00043	GST_C
PF02798	GST_N

# Drug_Target_36_Protein_Sequence:
>Glutathione S-transferase
MGDNIVLYYFDARGKAELIRLIFAYLGIEYTDKRFGVNGDAFVEFKNFKKEKDTPFEQVP
ILQIGDLILAQSQAIVRYLSKKYNICGESELNEFYADMIFCGVQDIHYKFNNTNLFKQNE
TTFLNEDLPKWSGYFEKLLKKNHTNNNNDKYYFVGNNLTYADLAVFNLYDDIETKYPSSL
KNFPLLKAHNEFISNLPNIKNYITNRKESVY

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May also function as a storage protein or ligandin for parasitotoxic ferriprotoporphyrin IX (hemin)

# Drug_Target_36_SwissProt_ID:
Q8MU52

# Drug_Target_36_SwissProt_Name:
GST_PLAFA

# Drug_Target_36_Synonyms:
EC 2.5.1.18
PfGST

# Drug_Target_36_Theoretical_pI:
6.28

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
Not Available

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
L07486

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
HGPRTase

# Drug_Target_37_Gene_Sequence:
>666 bp
ATGCCACGGGAGTACGAGTTTGCAGAGAAGATTCTTTTCACAGAAGAGGAGATCCGCACC
CGCATTATGGAGGTTGCCAAGCGCATTGCGGATGACTACAAGGGAAAGGGTCTGCGCCCT
TATGTCAACCCTCTTGTGCTCATATCTGTGCTGAAGGGAAGCTTTATGTTTACTGCTGAC
TTGTGCCGTGCACTGAGTGATTTCAACGTGCCGGTGCGAATGGAGTTCATTTGCGTCTCA
TCATATGGCGAAGGAGTCACGAGCTCCGGTCAGGTGCGCATGTTGCTTGACACGCGTCAC
AGCATTGAGGGGCACCATGTGTTGATTGTGGAGGACATTGTTGACACCGCCCTTACGCTG
AATTACTTGTACCACATGTATTTTACACGCAGGCCAGCGAGCTTAAAAACAGTTGTGTTG
CTTGACAAGCGTGAGGGGCGACGCGTGCCCTTTTCTGCGGACTACGTTGTGGCGAATATA
CCCAACGCCTTTGTGATTGGCTACGGTCTTGATTACGACGACACCTACCGTGAGTTACGC
GATATTGTTGTTCTTCGTCCGGAGGTGTATGCGGAGAGGGAGGCGGCGCGGCAGAAGAAG
CAGCGGGCCATTGGTAGCGCTGACACCGACAGAGACGCCAAGAGGGAGTTTCATAGCAAG
TACTGA

# Drug_Target_37_General_Function:
Involved in hypoxanthine phosphoribosyltransferase activity

# Drug_Target_37_General_References:
7969265	Allen TE, Ullman B: Molecular characterization and overexpression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma cruzi. Mol Biochem Parasitol. 1994 Jun;65(2):233-45.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
4269

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
25530

# Drug_Target_37_Name:
Hypoxanthine-guanine phosphoribosyltransferase, putative

# Drug_Target_37_Number_of_Residues:
221

# Drug_Target_37_PDB_ID:
1P19

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00156	Pribosyltran

# Drug_Target_37_Protein_Sequence:
>Hypoxanthine-guanine phosphoribosyltransferase, putative
MPREYEFAEKILFTEEEIRTRIMEVAKRIADDYKGKGLRPYVNPLVLISVLKGSFMFTAD
LCRALSDFNVPVRMEFICVSSYGEGVTSSGQVRMLLDTRHSIEGHHVLIVEDIVDTALTL
NYLYHMYFTRRPASLKTVVLLDKREGRRVPFSADYVVANIPNAFVIGYGLDYDDTYRELR
DIVVLRPEVYAEREAARQKKQRAIGSADTDRDAKREFHSKY

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
GMP + diphosphate = guanine + 5-phospho-alpha- D-ribose 1-diphosphate

# Drug_Target_37_SwissProt_ID:
Q27796

# Drug_Target_37_SwissProt_Name:
Q27796_TRYCR

# Drug_Target_37_Synonyms:
EC 2.4.2.8

# Drug_Target_37_Theoretical_pI:
7.61

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Cytoplasmic

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
AB006424

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
glsA1

# Drug_Target_38_Gene_Sequence:
>984 bp
TTAAAAAATGCTGAGCTCCCATTCCTGCGCCATATGCTTCAGCAGCATACCGCCAGTGAG
GCTGTTGCCGTATTCATCAATGGCAGGCCCGTAAATGCCGATGCCGCATCCGGATTGAAA
AGGCTGTTCTCTTCTGGCGCTTGGAGGCACCAGCGCCATGATGCCGCCGGAGACGCCGCT
TTTGGCCGGCACGCCGACAAACGCCGCATATTTGCCTGAAGCGTTGTACATGCCGCACGT
CAGCATTAATGCCTTGGCCAATTTTGCCACATCTTTTGGAATCACCTGCTCGTGTCGAAT
CGGATGATACCCGTCATGAGCAAGGATCAGGCCGATCAACGCAATATCTTCTGTAGTGCT
CTCCATAGCGCATTGCTTCAAGTACACCTCAAGTGTTTCTTCTACTTCAGCTTCTAAAAA
GTTTGTTTCTTTTAAATAGTAGGCCAGCGCTCTGTTGCGGTGGGCGGTTTCCCATTCAGA
ACGGAATACTTCTTCATGAATTCTTGGCCGTTTTCCTATCAAAGTTTCCATCACCGAGTA
AAGAAACTCGAGCTTTTCGTATGCAGATTCTCCGGGAAGGATCGAAGCGATGGTGAGGGC
ACCCGCGTTGATCATGGGATTGAAGGGCTTTCCCGGCTTGTTGATTTCGAGCCGAATGAT
TGAATTAAAGGCGTCACCTGTCGGCTCGACATCTACGCGGTCAAGCACATAGGGAATGCC
GCGGCTCATGCAGGCGGCAATAAAGCTAATCACTTTTGAAATGCTTTGCATGGTAAAAGA
GACGTTCCAGTCGCCGGCGTGTATCATCGTTCCATCAGGCTCCAATACACAGATGCCGAG
CTGTGAATCATTGACTTTTCCTAAAGCGGGGATATAGTTTGCGCTTTGTCCATTGGCGGC
AAAAGGGCGATAGTATTCAACCCAATCATGAAGCTGTAACGCCGGGTTTATGTCTTTCTG
GTGCTCTTTTATCAATTCTTTCAT

# Drug_Target_38_General_Function:
Involved in glutaminase activity

# Drug_Target_38_General_References:
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
4542

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
36187

# Drug_Target_38_Name:
Glutaminase 1

# Drug_Target_38_Number_of_Residues:
327

# Drug_Target_38_PDB_ID:
1MKI

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF04960	Glutaminase

# Drug_Target_38_Protein_Sequence:
>Glutaminase 1
MKELIKEHQKDINPALQLHDWVEYYRPFAANGQSANYIPALGKVNDSQLGICVLEPDGTM
IHAGDWNVSFTMQSISKVISFIAACMSRGIPYVLDRVDVEPTGDAFNSIIRLEINKPGKP
FNPMINAGALTIASILPGESAYEKLEFLYSVMETLIGKRPRIHEEVFRSEWETAHRNRAL
AYYLKETNFLEAEVEETLEVYLKQCAMESTTEDIALIGLILAHDGYHPIRHEQVIPKDVA
KLAKALMLTCGMYNASGKYAAFVGVPAKSGVSGGIMALVPPSARREQPFQSGCGIGIYGP
AIDEYGNSLTGGMLLKHMAQEWELSIF

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
L-glutamine + H(2)O = L-glutamate + NH(3)

# Drug_Target_38_SwissProt_ID:
O31465

# Drug_Target_38_SwissProt_Name:
GLSA1_BACSU

# Drug_Target_38_Synonyms:
EC 3.5.1.2

# Drug_Target_38_Theoretical_pI:
5.40

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Cytoplasmic

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
Not Available

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
Not Available

# Drug_Target_39_GenBank_ID_Gene:
U82664

# Drug_Target_39_GenBank_ID_Protein:
Not Available

# Drug_Target_39_GeneCard_ID:
Not Available

# Drug_Target_39_Gene_Name:
glsA1

# Drug_Target_39_Gene_Sequence:
>933 bp
ATGTTAGATGCAAACAAATTACAGCAGGCAGTGGATCAGGCTTACACCCAATTTCACTCA
CTTAACGGCGGACAAAATGCCGATTACATTCCCTTTCTGGCGAATGTACCAGGTCAACTG
GCGGCAGTGGCTATCGTGACCTGCGATGGCAACGTCTATAGTGCGGGTGACAGTGATTAC
CGCTTTGCACTGGAATCCATCTCGAAAGTCTGTACGTTAGCCCTTGCGTTAGAAGATGTC
GGCCCGCAGGCGGTACAGGACAAAATTGGCGCTGACCCGACCGGATTGCCCTTTAACTCA
GTTATCGCCTTAGAGTTGCATGGCGGCAAACCGCTTTCGCCACTGGTAAATGCTGGCGCT
ATTGCCACCACCAGCCTGATTAACGCTGAAAATGTTGAACAACGCTGGCAGCGAATTTTA
CATATCCAACAGCAACTGGCTGGCGAGCAGGTAGCGCTCTCTGACGAAGTCAACCAGTCG
GAACAAACAACCAACTTCCATAACCGGGCCATAGCCTGGCTGCTGTACTCCGCCGGATAT
CTCTATTGTGATGCAATGGAAGCCTGTGACGTGTATACCCGTCAGTGCTCCACGCTCCTC
AATACTATTGAACTGGCAACGCTTGGCGCGACGCTGGCGGCAGGTGGTGTGAATCCGTTG
ACGCATAAACGCGTTCTTCAGGCCGACAACGTGCCGTACATTCTGGCCGAAATGATGATG
GAAGGGCTGTATGGTCGCTCCGGTGACTGGGCGTATCGTGTTGGTTTACCGGGCAAAAGC
GGTGTAGGTGGCGGTATTCTGGCGGTCGTCCCTGGAGTGATGGGAATTGCCGCGTTCTCA
CCACCGCTGGACGAAGATGGCAACAGTGTTCGCGGTCAAAAAATGGTGGCATCGGTCGCT
AAGCAACTCGGCTATAACGTGTTTAAGGGCTGA

# Drug_Target_39_General_Function:
Involved in glutaminase activity

# Drug_Target_39_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_39_HGNC_ID:
Not Available

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
4544

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
32904

# Drug_Target_39_Name:
Glutaminase 1

# Drug_Target_39_Number_of_Residues:
310

# Drug_Target_39_PDB_ID:
1U60

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF04960	Glutaminase

# Drug_Target_39_Protein_Sequence:
>Glutaminase 1
MLDANKLQQAVDQAYTQFHSLNGGQNADYIPFLANVPGQLAAVAIVTCDGNVYSAGDSDY
RFALESISKVCTLALALEDVGPQAVQDKIGADPTGLPFNSVIALELHGGKPLSPLVNAGA
IATTSLINAENVEQRWQRILHIQQQLAGEQVALSDEVNQSEQTTNFHNRAIAWLLYSAGY
LYCDAMEACDVYTRQCSTLLNTIELATLGATLAAGGVNPLTHKRVLQADNVPYILAEMMM
EGLYGRSGDWAYRVGLPGKSGVGGGILAVVPGVMGIAAFSPPLDEDGNSVRGQKMVASVA
KQLGYNVFKG

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
L-glutamine + H(2)O = L-glutamate + NH(3)

# Drug_Target_39_SwissProt_ID:
P77454

# Drug_Target_39_SwissProt_Name:
GLSA1_ECOLI

# Drug_Target_39_Synonyms:
EC 3.5.1.2

# Drug_Target_39_Theoretical_pI:
4.58

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cell membrane
peripheral membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X02826

# Drug_Target_3_GenBank_ID_Protein:
42609

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
pyrD

# Drug_Target_3_Gene_Sequence:
>1011 bp
ATGTACTACCCCTTCGTTCGTAAAGCCCTTTTCCAGCTCGATCCAGAGCGCGCTCATGAG
TTTACTTTTCAGCAATTACGCCGTATTACAGGAACGCCGTTTGAAGCACTGGTGCGGCAG
AAAGTGCCTGCGAAACCTGTTAACTGCATGGGCCTGACGTTTAAAAATCCGCTTGGTCTG
GCAGCCGGTCTTGATAAAGACGGGGAGTGCATTGACGCGTTAGGCGCGATGGGATTTGGA
TCGATCGAGATCGGTACCGTCACGCCACGTCCACAGCCAGGTAATGACAAGCCGCGTCTC
TTTCGTCTGGTAGATGCCGAAGGTTTGATCAACCGTATGGGCTTTAATAATCTTGGCGTT
GATAACCTCGTAGAGAACGTAAAAAAGGCCCATTATGACGGCGTCCTGGGTATTAACATC
GGCAAAAATAAAGATACGCCAGTGGAGCAGGGCAAAGATGACTATCTGATTTGTATGGAA
AAAATCTATGCCTATGCGGGATATATCGCCATCAATATTTCATCGCCGAATACCCCAGGA
TTACGCACGCTGCAATATGGTGAAGCGCTGGATGATCTCTTAACCGCGATTAAAAATAAG
CAAAATGATTTGCAAGCGATGCACCATAAATATGTGCCGATCGCAGTGAAGATCGCGCCG
GATCTTTCTGAAGAAGAATTGATCCAGGTTGCCGATAGTTTAGTTCGCCATAATATTGAT
GGCGTTATTGCAACCAATACCACACTCGATCGTTCTCTTGTTCAGGGAATGAAAAATTGC
GATCAAACCGGTGGCTTAAGTGGTCGTCCGCTTCAGTTAAAAAGCACCGAAATTATTCGC
CGCTTGTCACTGGAATTAAACGGTCGCTTACCGATCATCGGTGTTGGCGGCATCGACTCG
GTTATCGCTGCGCGTGAAAAGATTGCTGCGGGTGCCTCACTGGTGCAAATTTATTCTGGT
TTTATTTTTAAAGGTCCGCCGCTGATTAAAGAAATCGTTACCCATATCTAA

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
12220493	Norager S, Jensen KF, Bjornberg O, Larsen S: E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure. 2002 Sep;10(9):1211-23.
2992959	Larsen JN, Jensen KF: Nucleotide sequence of the pyrD gene of Escherichia coli and characterization of the flavoprotein dihydroorotate dehydrogenase. Eur J Biochem. 1985 Aug 15;151(1):59-65.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2775

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
36775

# Drug_Target_3_Name:
Dihydroorotate dehydrogenase

# Drug_Target_3_Number_of_Residues:
336

# Drug_Target_3_PDB_ID:
1F76

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_3_Protein_Sequence:
>Dihydroorotate dehydrogenase
MYYPFVRKALFQLDPERAHEFTFQQLRRITGTPFEALVRQKVPAKPVNCMGLTFKNPLGL
AAGLDKDGECIDALGAMGFGSIEIGTVTPRPQPGNDKPRLFRLVDAEGLINRMGFNNLGV
DNLVENVKKAHYDGVLGINIGKNKDTPVEQGKDDYLICMEKIYAYAGYIAINISSPNTPG
LRTLQYGEALDDLLTAIKNKQNDLQAMHHKYVPIAVKIAPDLSEEELIQVADSLVRHNID
GVIATNTTLDRSLVQGMKNCDQTGGLSGRPLQLKSTEIIRRLSLELNGRLPIIGVGGIDS
VIAAREKIAAGASLVQIYSGFIFKGPPLIKEIVTHI

# Drug_Target_3_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
(S)-dihydroorotate + O(2) = orotate + H(2)O(2)

# Drug_Target_3_SwissProt_ID:
P0A7E1

# Drug_Target_3_SwissProt_Name:
PYRD_ECOLI

# Drug_Target_3_Synonyms:
DHOD
DHODase
DHOdehase
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_3_Theoretical_pI:
7.97

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
Not Available

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
X70420

# Drug_Target_40_GenBank_ID_Protein:
Not Available

# Drug_Target_40_GeneCard_ID:
Not Available

# Drug_Target_40_Gene_Name:
moaE

# Drug_Target_40_Gene_Sequence:
>453 bp
ATGGCAGAAACCAAAATTGTTGTTGGTCCGCAGCCGTTCAGCGTAGGAGAAGAGTACCCG
TGGCTGGCGGAGCGTGACGAAGACGGTGCGGTAGTCACCTTTACTGGTAAGGTGCGCAAC
CATAACCTGGGCGACAGCGTCAACGCATTAACCCTCGAACACTATCCGGGGATGACTGAA
AAAGCACTGGCAGAAATTGTTGATGAAGCGCGTAACCGCTGGCCGCTGGGGCGCGTCACT
GTGATTCACCGCATCGGGGAATTATGGCCGGGCGATGAAATCGTTTTTGTCGGTGTCACC
AGTGCGCATCGCAGCAGTGCGTTTGAAGCCGGGCAGTTTATTATGGATTATCTCAAAACC
CGCGCACCGTTCTGGAAGCGCGAAGCCACGCCGGAAGGCGACCGCTGGGTTGAAGCTCGG
GAGAGCGATCAGCAGGCGGCAAAACGCTGGTAG

# Drug_Target_40_General_Function:
Coenzyme transport and metabolism

# Drug_Target_40_General_References:
11135669	Rudolph MJ, Wuebbens MM, Rajagopalan KV, Schindelin H: Crystal structure of molybdopterin synthase and its evolutionary relationship to ubiquitin activation. Nat Struct Biol. 2001 Jan;8(1):42-6.
8361352	Rivers SL, McNairn E, Blasco F, Giordano G, Boxer DH: Molecular genetic analysis of the moa operon of Escherichia coli K-12 required for molybdenum cofactor biosynthesis. Mol Microbiol. 1993 Jun;8(6):1071-81.
8514782	Pitterle DM, Rajagopalan KV: The biosynthesis of molybdopterin in Escherichia coli. Purification and characterization of the converting factor. J Biol Chem. 1993 Jun 25;268(18):13499-505.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_40_HGNC_ID:
Not Available

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
4545

# Drug_Target_40_Locus:
Not Available

# Drug_Target_40_Molecular_Weight:
16981

# Drug_Target_40_Name:
Molybdopterin-converting factor subunit 2

# Drug_Target_40_Number_of_Residues:
150

# Drug_Target_40_PDB_ID:
1NVI

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF02391	MoaE

# Drug_Target_40_Protein_Sequence:
>Molybdopterin-converting factor subunit 2
MAETKIVVGPQPFSVGEEYPWLAERDEDGAVVTFTGKVRNHNLGDSVNALTLEHYPGMTE
KALAEIVDEARNRWPLGRVTVIHRIGELWPGDEIVFVGVTSAHRSSAFEAGQFIMDYLKT
RAPFWKREATPEGDRWVEARESDQQAAKRW

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
Converts molybdopterin precursor Z into molybdopterin. This requires the incorporation of two sulfur atoms into precursor Z to generate a dithiolene group

# Drug_Target_40_SwissProt_ID:
P30749

# Drug_Target_40_SwissProt_Name:
MOAE_ECOLI

# Drug_Target_40_Synonyms:
MPT synthase subunit 2
Molybdenum cofactor biosynthesis protein E
Molybdopterin synthase subunit 2
Molybdopterin-converting factor large subunit

# Drug_Target_40_Theoretical_pI:
5.06

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
AE000512

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
TM_1131

# Drug_Target_41_Gene_Sequence:
>1242 bp
TCACAGAAGGTGTTTTTCCTTGCCGTACTCGAGGACAACTTCCCTGAGCCTTTTGATCCC
TTCAACGATCTTTTCATCCGGCGGCAGACAGAAGGAAAGCCTCATAGAGGGACTCGGCTC
GTCGTACACTTTGAAAACCCTTCCAGGAACGTAAAACACCTTCTTTCTCTTTGCGTACTC
GAACATCTCCCAGGTGTCGAAACCCTCAGGAAGGGTGAGCCAGATGAAGAGACCGCCTTC
CGATTTCACCCATTTCACGCCTGGTATGTCGGAGAAGTACTCTTCGAGAGCGTTGAGCAT
CACCGTTCTCTTTCTTCTGTAGAGTTCGATGGTGGGTTTCAACTGCTCGAGAAGATCGTA
CCTCTCCAAATAACGGGCAGCGAGACGATGAGTGATAGCGGGACTGCACAGATCCGCTGA
CTGCTTCGCCTGAACGATCTTTCTGATGAACTCCTTGCTTCCCGCCACCATTCCTATTCT
GAGACCCGGAGCGAGGACTTTGCTGAACGTGTTGAGAAGAACCACTCTTTCTGGTCCACC
TATCTTGAAGATGGGATCCACAGTTTCTCCTTCGTACCTCAAAGCACCGTAGGGATCGTC
TTCCACTATGAAGAGGTCGTACTTCTCTGCGATCTCGACGAGCGCTTTTCTCTTTTCCAG
AGAAGTTGTGACTCCCGCTGGGTTGTGGAAATTTGAAACAACGTAGATGAACTTCACCTG
TTTTATCTTTCCGTTTTTGTCGAATTCAGAAAGCTTTCTTTCCAGAACGTTGAGATCCAT
TCCGTCGTCTTCGAGCGGGACCACAACGAAGTTCGCAAGATACTGCCTGAACGCGTTTAT
GGCTCCGAGGTACGCGGGATCATCGAGAACGCAGTAACTCTCATCGTCGAGGAAGAGCTT
TCCAATGAGATCCAGCGCCTGCTGGGATCCAACGGTGAATATCAGATTGTCTTCGTCGAG
TCCTGTGATGCCGTACATCCTCTCCAGAAGCTTCAAAATTTGCTGTTTAAGAACGGGATC
TCCTTCTGTTGTGGAGTACTGAAGAGTGTAATGGTACTCTTTTTCTATGATTTCCTTTGC
GATTTCTGCGAGTTCTTTTCTCGGGAAAGTCTCAGGATCGGGTACTCCCCCTCCGAAAGA
AATGGCGTCTTTGTCCGCGGCAAATTTGAGAATTTCCCTGATGATGGAGGATTTCATGTT
TTGGCCTATCTTTGAGATCTTGCCTTCTAGATTCACGACCAC

# Drug_Target_41_General_Function:
Involved in transferase activity, transferring nitrogenous groups

# Drug_Target_41_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
4546

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
47136

# Drug_Target_41_Name:
Aminotransferase, putative

# Drug_Target_41_Number_of_Residues:
413

# Drug_Target_41_PDB_ID:
1VP4

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_41_Protein_Sequence:
>Aminotransferase, putative
MVVNLEGKISKIGQNMKSSIIREILKFAADKDAISFGGGVPDPETFPRKELAEIAKEIIE
KEYHYTLQYSTTEGDPVLKQQILKLLERMYGITGLDEDNLIFTVGSQQALDLIGKLFLDD
ESYCVLDDPAYLGAINAFRQYLANFVVVPLEDDGMDLNVLERKLSEFDKNGKIKQVKFIY
VVSNFHNPAGVTTSLEKRKALVEIAEKYDLFIVEDDPYGALRYEGETVDPIFKIGGPERV
VLLNTFSKVLAPGLRIGMVAGSKEFIRKIVQAKQSADLCSPAITHRLAARYLERYDLLEQ
LKPTIELYRRKRTVMLNALEEYFSDIPGVKWVKSEGGLFIWLTLPEGFDTWEMFEYAKRK
KVFYVPGRVFKVYDEPSPSMRLSFCLPPDEKIVEGIKRLREVVLEYGKEKHLL

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Not Available

# Drug_Target_41_SwissProt_ID:
Q9X0L5

# Drug_Target_41_SwissProt_Name:
Q9X0L5_THEMA

# Drug_Target_41_Synonyms:
Not Available

# Drug_Target_41_Theoretical_pI:
5.45

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Not Available

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
Not Available

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
Not Available

# Drug_Target_42_GenBank_ID_Gene:
AF047427

# Drug_Target_42_GenBank_ID_Protein:
Not Available

# Drug_Target_42_GeneCard_ID:
Not Available

# Drug_Target_42_Gene_Name:
fbpA

# Drug_Target_42_Gene_Sequence:
>1029 bp
ATGAAAAAAACACTTTCTGCACTTGCTATTGCTGCAGCCACTTTTACATCAACTTCAACG
CTTGCTGCAAATGAAGTGAATGTTTATTCTTACCGCCAGCCTTACTTAATTGAGCCAATG
CTAAAAAACTTTGAAAAAGATACTGGCATTAAAGTAAACATCATCTTCGCTGATAAAGGG
TTGGTTGATCGTGTAAAACAAGAAGGTGAATTAAGTCCTGCTGATGTGCTTTTAACAGTA
GATATTTCACGCGTAATGGAAATTGTTAACGCTGATCTTGCACAAAAAATTGACTCTAAA
GTGTTAGAAAAAAATATTCCTGCACAATTCCGTGACTCTAACGACCAATGGTTTGGTTTA
ACCACACGTGCTCGTGTTATCTACACGTCAAAAGATCGTGTAGGTAAATTACCAGCAGGC
TTTGACTACCTAGATTTAGCTAAACCAGAGTATAAAGGTAAAGTCTGCGTGCGTTCAGGC
AAAAACTCTTACAATGTCTCACTATTCGCGGCGATGATCGAACATTACGGCATTGAAAAA
ACCAAAGCATTCTTAGAAGGCTTAAAAGCGAACTTAGCACGAAAACCACAAGGTGGTGAC
CGTGATCAAGTAAAAGCAATTAAAGAAGGCATCTGTGATTACTCTATCGGTAACAGCTAC
TACTACGGCAAAATGTTAGATGATGAGAAACAAAAATCGTGGGCTGAAGCAGCGATTATT
AATTTCCCGAGTGGTGAACACGGCACGCACAAAAACATCAGCGGCGTAGTTATTGCAAAA
CACTCACCAAATAAAGCAAACGCGGTGAAATTAATTGAATACCTAAGTGGCGAAAAAGCA
CAAGGTTTATATGCTGAACTTAACCACGAATATCCAGTAAAAGAAGGCATCGAGCCATCA
GCAATCGTAAAAGGTTGGGGTACGTTCAAATCAGATACCATCAAACTTGAAGATATCGCA
AAAAATTACGAAGCCGCATTAAAATTAGTTGATGAAGTGAAATTTGACGATTTCTCTGAG
AAAAAATAA

# Drug_Target_42_General_Function:
Involved in transporter activity

# Drug_Target_42_General_References:
12882966	Shouldice SR, Dougan DR, Williams PA, Skene RJ, Snell G, Scheibe D, Kirby S, Hosfield DJ, McRee DE, Schryvers AB, Tari LW: Crystal structure of Pasteurella haemolytica ferric ion-binding protein A reveals a novel class of bacterial iron-binding proteins. J Biol Chem. 2003 Oct 17;278(42):41093-8. Epub 2003 Jul 25.
9884235	Kirby SD, Lainson FA, Donachie W, Okabe A, Tokuda M, Hatase O, Schryvers AB: The Pasteurella haemolytica 35 kDa iron-regulated protein is an FbpA homologue. Microbiology. 1998 Dec;144 ( Pt 12):3425-36.

# Drug_Target_42_HGNC_ID:
Not Available

# Drug_Target_42_HPRD_ID:
Not Available

# Drug_Target_42_ID:
4547

# Drug_Target_42_Locus:
Not Available

# Drug_Target_42_Molecular_Weight:
38024

# Drug_Target_42_Name:
Iron binding protein FbpA

# Drug_Target_42_Number_of_Residues:
342

# Drug_Target_42_PDB_ID:
1SI1

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF01547	SBP_bac_1

# Drug_Target_42_Protein_Sequence:
>Iron binding protein FbpA
MKKTLSALAIAAATFTSTSTLAANEVNVYSYRQPYLIEPMLKNFEKDTGIKVNIIFADKG
LVDRVKQEGELSPADVLLTVDISRVMEIVNADLAQKIDSKVLEKNIPAQFRDSNDQWFGL
TTRARVIYTSKDRVGKLPAGFDYLDLAKPEYKGKVCVRSGKNSYNVSLFAAMIEHYGIEK
TKAFLEGLKANLARKPQGGDRDQVKAIKEGICDYSIGNSYYYGKMLDDEKQKSWAEAAII
NFPSGEHGTHKNISGVVIAKHSPNKANAVKLIEYLSGEKAQGLYAELNHEYPVKEGIEPS
AIVKGWGTFKSDTIKLEDIAKNYEAALKLVDEVKFDDFSEKK

# Drug_Target_42_Reaction:
Not Available

# Drug_Target_42_Signals:
1-22

# Drug_Target_42_Specific_Function:
Not Available

# Drug_Target_42_SwissProt_ID:
Q9Z4N6

# Drug_Target_42_SwissProt_Name:
Q9Z4N6_PASHA

# Drug_Target_42_Synonyms:
Iron binding protein FbpA precursor

# Drug_Target_42_Theoretical_pI:
8.51

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Cytoplasmic

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
Not Available

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
Not Available

# Drug_Target_43_GenBank_ID_Gene:
AF167433

# Drug_Target_43_GenBank_ID_Protein:
Not Available

# Drug_Target_43_GeneCard_ID:
Not Available

# Drug_Target_43_Gene_Name:
gyrB

# Drug_Target_43_Gene_Sequence:
>1905 bp
GTGAGCTACGACGCTTCTGCCATTCGGGTGCTCAAGGGCCTGGAGGGGGTCCGCCACCGC
CCGGCCATGTACATCGGCGGCACGGGGGTGGAAGGGTACCACCACCTCTTCAAGGAGATC
CTGGACAACGCCGTGGACGAGGCCCTGGCGGGCTACGCCACGGAGATCCTGGTGCGCCTC
AACGAGGACGGTTCCCTCACCGTGGAGGACAACGGCCGCGGCATCCCCGTGGACCTCATG
CCCGAGGAGGGAAAGCCCGCCGTGGAGGTCATCTACAACACCCTCCACTCCGGGGGGAAG
TTTGAGCAGGGCGCCTACAAGGTCTCCGGGGGGCTCCACGGGGTGGGGGCGAGCGTGGTG
AACGCCCTTTCGGAGTGGACCGTGGTGGAGGTCTTCCGGGAGGGGAAGCACCACCGGATC
GCCTTCAGCCGGGGCGAGGTCACGGAGCCCCTCCGGGTGGTGGGCGAGGCCCCCAGGGGG
AAGACCGGGACCCGGGTCACCTTCAAGCCCGACCCCGAGATCTTCGGGAACCTCCGCTTT
GACCCGAGCAAGATCCGGGCCCGCCTCCGGGAGGTGGCCTACCTGGTGGCCGGGCTCAAG
CTCGTCTTCCAGGACCGCCAGCACGGAAAGGAGGAGGTCTTCCTGGACAAGGGGGGCGTG
GCCTCCTTCGCCAAGGCCTTGGCCGAGGGGGAGGACCTCCTCTACGAGAAGCCCTTCCTC
ATCCGGGGCACCCACGGGGAGGTGGAGGTGGAGGTGGGCTTCCTCCACACCCAGGGGTAC
AACGCCGAGATCCTCACCTACGCCAACATGATCCCCACCCGGGACGGGGGTACCCACCTC
ACCGCCTTCAAGTCCGCCTACAGCCGCGCCCTGAACCAGTACGCCAAGAAGGCGGGCCTC
AACAAGGAAAAAGGCCCCCAGCCCACGGGGGACGACCTCCTGGAGGGGCTCTACGCCGTG
GTCTCGGTGAAGCTCCCCAACCCCCAGTTTGAGGGGCAGACCAAGGGGAAGCTCCTAAAC
CCCGAGGCCGGGACCGCCGTGGGCCAGGTGGTTTACGAGCGGCTTCTGGAGATCCTGGAG
GAGAACCCCCGCATCGCCAAGGCCGTCTACGAGAAGGCCCTGAGGGCCGCCCAGGCCCGG
GAGGCGGCGAGGAAGGCGAGGGAGCTCGTCCGCAGGCAGAACCCCCTGGAGTCCGACGAG
CTTCCCGGAAAGCTCGCCGACTGCCAGACGGAAAACCCCGAGGAGGCGGAGCTTTTCATC
GTGGAGGGGGACTCGGCAGGGGGGAGCGCCAAGCAGGGCCGGGACCGCCGCTTCCAGGCC
ATCCTGCCCCTCCGGGGGAAGATCCTCAACGTGGAGAAGGCGGGGCTCTCCAAGGCCCTG
AAGAACGCCGAGGTGCGGGCCATGGTCTCGGCCATCGGCGTGGCAGTCGGGGGGGATGGG
GAGGCCCACTTTGACCTCGAGGGCCTCCGCTACCACAAGATCATCATCATGACCGACGCC
GACGTGGACGGAAGCCACATCCGCACCCTCCTCCTCACCTTCTTCTACCGCTACATGCGC
CCCCTCATTGAACGGGGCCACGTCTACATCGCCCAGCCTCCCCTCTACCGCCTCCAGGTG
GGGAAGAAGGTGGAGTACCTCTACTCCGACGAGGAGCTCCAGGCCCGGCTCAAGGAGCTG
GAAGGCAAGCACTACGAGGTCCAGCGCTTCAAGGGCCTGGGGGAGATGAACCCGGAGCAG
CTTTGGGAGACCACCATGAACCCGGAGAAGCGGGTCCTCAAGCGGGTGGAGCTCCAGGAC
GCCCTCGAGGCCAGCGAGCTCTTTGAGAAGCTCATGGGCCAGGAGGTGGCCCCGAGGCGC
GAGTTCATAGAGGAGCACGCCCGCTACGCCGAGCTGGACATCTAA

# Drug_Target_43_General_Function:
Involved in ATP binding

# Drug_Target_43_General_References:
11850422	Lamour V, Hoermann L, Jeltsch JM, Oudet P, Moras D: An open conformation of the Thermus thermophilus gyrase B ATP-binding domain. J Biol Chem. 2002 May 24;277(21):18947-53. Epub 2002 Feb 15.

# Drug_Target_43_HGNC_ID:
Not Available

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
4548

# Drug_Target_43_Locus:
Not Available

# Drug_Target_43_Molecular_Weight:
70538

# Drug_Target_43_Name:
Gyrase B

# Drug_Target_43_Number_of_Residues:
634

# Drug_Target_43_PDB_ID:
1KIJ

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_43_Protein_Sequence:
>Gyrase B
MSYDASAIRVLKGLEGVRHRPAMYIGGTGVEGYHHLFKEILDNAVDEALAGYATEILVRL
NEDGSLTVEDNGRGIPVDLMPEEGKPAVEVIYNTLHSGGKFEQGAYKVSGGLHGVGASVV
NALSEWTVVEVFREGKHHRIAFSRGEVTEPLRVVGEAPRGKTGTRVTFKPDPEIFGNLRF
DPSKIRARLREVAYLVAGLKLVFQDRQHGKEEVFLDKGGVASFAKALAEGEDLLYEKPFL
IRGTHGEVEVEVGFLHTQGYNAEILTYANMIPTRDGGTHLTAFKSAYSRALNQYAKKAGL
NKEKGPQPTGDDLLEGLYAVVSVKLPNPQFEGQTKGKLLNPEAGTAVGQVVYERLLEILE
ENPRIAKAVYEKALRAAQAREAARKARELVRRQNPLESDELPGKLADCQTENPEEAELFI
VEGDSAGGSAKQGRDRRFQAILPLRGKILNVEKAGLSKALKNAEVRAMVSAIGVAVGGDG
EAHFDLEGLRYHKIIIMTDADVDGSHIRTLLLTFFYRYMRPLIERGHVYIAQPPLYRLQV
GKKVEYLYSDEELQARLKELEGKHYEVQRFKGLGEMNPEQLWETTMNPEKRVLKRVELQD
ALEASELFEKLMGQEVAPRREFIEEHARYAELDI

# Drug_Target_43_Reaction:
Not Available

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings (By similarity)

# Drug_Target_43_SwissProt_ID:
Q9LCX5

# Drug_Target_43_SwissProt_Name:
Q9LCX5_THETH

# Drug_Target_43_Synonyms:
Not Available

# Drug_Target_43_Theoretical_pI:
6.30

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Not Available

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
Not Available

# Drug_Target_44_GenBank_ID_Gene:
U29579

# Drug_Target_44_GenBank_ID_Protein:
882632

# Drug_Target_44_GeneCard_ID:
Not Available

# Drug_Target_44_Gene_Name:
ygbM

# Drug_Target_44_Gene_Sequence:
>777 bp
ATGCCTCGTTTTGCAGCTAATTTATCCATGATGTTCACCGAAGTGCCTTTTATTGAACGC
TTCGCCGCAGCGCGAAAAGCCGGGTTCGATGCTGTGGAATTTCTGTTTCCCTATAACTAC
TCCACCCTGCAAATCCAAAAGCAACTGGAGCAAAACCATCTGACACTGGCGCTGTTCAAT
ACCGCTCCCGGAGATATTAATGCGGGGGAATGGGGATTATCCGCCCTTCCCGGACGTGAG
CACGAAGCACACGCAGACATCGACCTGGCACTGGAATATGCATTGGCGCTCAATTGTGAA
CAAGTCCATGTGATGGCAGGCGTCGTGCCCGCTGGCGAAGATGCTGAACGGTACCGGGCA
GTATTTATCGATAATATCCGCTACGCTGCCGACCGCTTTGCGCCACACGGCAAGCGAATA
TTAGTTGAAGCACTCAGCCCCGGCGTTAAGCCTCATTATCTCTTCTCCAGCCAGTATCAG
GCACTGGCTATTGTTGAAGAGGTTGCGCGAGATAACGTGTTTATTCAACTAGATACTTTT
CATGCGCAAAAAGTAGATGGCAACCTGACGCATTTAATCCGCGACTACGCCGGGAAATAT
GCGCACGTACAAATTGCCGGACTACCTGATCGACATGAACCGGACGATGGAGAAATCAAC
TATCCGTGGCTGTTCCGCCTGTTCGATGAGGTGGGATATCAGGGCTGGATCGGTTGTGAA
TATAAACCTCGTGGCCTCACCGAAGAAGGGCTTGGCTGGTTTGACGCCTGGCGCTAA

# Drug_Target_44_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_44_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_44_HGNC_ID:
Not Available

# Drug_Target_44_HPRD_ID:
Not Available

# Drug_Target_44_ID:
2501

# Drug_Target_44_Locus:
Not Available

# Drug_Target_44_Molecular_Weight:
29217

# Drug_Target_44_Name:
Protein ygbM

# Drug_Target_44_Number_of_Residues:
258

# Drug_Target_44_PDB_ID:
1K77

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF01261	AP_endonuc_2

# Drug_Target_44_Protein_Sequence:
>Protein ygbM
MPRFAANLSMMFTEVPFIERFAAARKAGFDAVEFLFPYNYSTLQIQKQLEQNHLTLALFN
TAPGDINAGEWGLSALPGREHEAHADIDLALEYALALNCEQVHVMAGVVPAGEDAERYRA
VFIDNIRYAADRFAPHGKRILVEALSPGVKPHYLFSSQYQALAIVEEVARDNVFIQLDTF
HAQKVDGNLTHLIRDYAGKYAHVQIAGLPDRHEPDDGEINYPWLFRLFDEVGYQGWIGCE
YKPRGLTEEGLGWFDAWR

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Not Available

# Drug_Target_44_SwissProt_ID:
Q46891

# Drug_Target_44_SwissProt_Name:
YGBM_ECOLI

# Drug_Target_44_Synonyms:
Not Available

# Drug_Target_44_Theoretical_pI:
4.90

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
X91820

# Drug_Target_45_GenBank_ID_Protein:
1009431

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
hemB

# Drug_Target_45_Gene_Sequence:
>1014 bp
GTGAGCTTCACTCCCGCCAATCGCGCCTATCCCTACACCCGCCTGCGGCGCAATCGCCGC
GATGACTTCTCCCGCCGCCTGGTCCGCGAGAATGTCCTCACCGTCGACGACCTGATCCTG
CCGGTGTTCGTCCTCGATGGGGTCAACCAGCGTGAAAGCATTCCGTCGATGCCCGGCGTC
GAGCGCCTGTCCATCGACCAGTTGCTGATCGAGGCGGAAGAGTGGGTGGCCCTGGGCATT
CCGGCGCTGGCGCTGTTCCCTGTGACCCCGGTGGAGAAGAAGTCCCTGGACGCCGCCGAG
GCATACAACCCGGAAGGCATCGCCCAGCGCGCCACCCGTGCCCTGCGCGAGCGCTTTCCG
GAGCTGGGCATCATCACCGACGTGGCGCTCGACCCGTTCACCACCCATGGCCAGGACGGC
ATCCTGGATGACGATGGCTACGTCCTCAACGACGTCAGCATCGACGTGCTGGTACGGCAG
GCGCTGTCCCACGCCGAGGCCGGCGCCCAGGTGGTAGCGCCCTCGGACATGATGGACGGT
CGCATCGGTGCGATCCGCGAGGCCCTGGAGTCTGCCGGCCACACCAATGTGCGGATCATG
GCCTACTCGGCCAAGTACGCCAGCGCCTACTACGGTCCGTTCCGCGATGCGGTCGGCTCG
GCTTCGAACCTCGGCAAGGGCAACAAGGCCACCTACCAGATGGATCCGGCGAACAGCGAC
GAGGCACTTCACGAAGTGGCCGCCGACCTGGCCGAAGGCGCCGACATGGTGATGGTCAAG
CCGGGCATGCCCTACCTCGACATCGTGCGTCGGGTGAAGGATGAATTCCGCGCCCCGACC
TTTGTCTACCAGGTCAGCGGCGAGTATGCGATGCACATGGGCGCCATCCAGAACGGCTGG
CTGGCCGAATCGGTGATCCTCGAATCCCTTACCGCCTTCAAACGTGCCGGCGCCGATGGC
ATTCTGACCTACTTCGCCAAGCAGGCCGCAGAACAATTAAGACGGGGGCGTTGA

# Drug_Target_45_General_Function:
Coenzyme transport and metabolism

# Drug_Target_45_General_References:
10356331	Frankenberg N, Erskine PT, Cooper JB, Shoolingin-Jordan PM, Jahn D, Heinz DW: High resolution crystal structure of a Mg2+-dependent porphobilinogen synthase. J Mol Biol. 1999 Jun 11;289(3):591-602.
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
12079382	Frere F, Schubert WD, Stauffer F, Frankenberg N, Neier R, Jahn D, Heinz DW: Structure of porphobilinogen synthase from Pseudomonas aeruginosa in complex with 5-fluorolevulinic acid suggests a double Schiff base mechanism. J Mol Biol. 2002 Jul 5;320(2):237-47.
9529530	Frankenberg N, Kittel T, Hungerer C, Romling U, Jahn D: Cloning, mapping and functional characterization of the hemB gene of Pseudomonas aeruginosa, which encodes a magnesium-dependent 5-aminolevulinic acid dehydratase. Mol Gen Genet. 1998 Feb;257(4):485-9.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
2356

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
37037

# Drug_Target_45_Name:
Delta-aminolevulinic acid dehydratase

# Drug_Target_45_Number_of_Residues:
337

# Drug_Target_45_PDB_ID:
1B4K

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00490	ALAD

# Drug_Target_45_Protein_Sequence:
>Delta-aminolevulinic acid dehydratase
MSFTPANRAYPYTRLRRNRRDDFSRRLVRENVLTVDDLILPVFVLDGVNQRESIPSMPGV
ERLSIDQLLIEAEEWVALGIPALALFPVTPVEKKSLDAAEAYNPEGIAQRATRALRERFP
ELGIITDVALDPFTTHGQDGILDDDGYVLNDVSIDVLVRQALSHAEAGAQVVAPSDMMDG
RIGAIREALESAGHTNVRIMAYSAKYASAYYGPFRDAVGSASNLGKGNKATYQMDPANSD
EALHEVAADLAEGADMVMVKPGMPYLDIVRRVKDEFRAPTFVYQVSGEYAMHMGAIQNGW
LAESVILESLTAFKRAGADGILTYFAKQAAEQLRRGR

# Drug_Target_45_Reaction:
2 5-aminolevulinate = porphobilinogen + 2 H2O

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
2 5-aminolevulinate = porphobilinogen + 2 H(2)O

# Drug_Target_45_SwissProt_ID:
Q59643

# Drug_Target_45_SwissProt_Name:
HEM2_PSEAE

# Drug_Target_45_Synonyms:
ALAD
ALADH
EC 4.2.1.24
Porphobilinogen synthase

# Drug_Target_45_Theoretical_pI:
4.83

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
X00557

# Drug_Target_46_GenBank_ID_Protein:
40966

# Drug_Target_46_GeneCard_ID:
Not Available

# Drug_Target_46_Gene_Name:
aroA

# Drug_Target_46_Gene_Sequence:
>1284 bp
ATGGAATCCCTGACGTTACAACCCATCGCTCGTGTCGATGGCACTATTAATCTGCCCGGT
TCCAAGACCGTTTCTAACCGCGCTTTATTGCTGGCGGCATTAGCACACGGCAAAACAGTA
TTAACCAATCTGCTGGATAGCGATGACGTGCGCCATATGCTGAATGCATTAACAGCGTTA
GGGGTAAGCTATACGCTTTCAGCCGATCGTACGCGTTGCGAAATTATCGGTAACGGCGGT
CCATTACACGCAGAAGGTGCCCTGGAGTTGTTCCTCGGTAACGCCGGAACGGCAATGCGT
CCGCTGGCGGCAGCTCTTTGTCTGGGTAGCAATGATATTGTGCTGACCGGTGAGCCGCGT
ATGAAAGAACGCCCGATTGGTCATCTGGTGGATGCGCTGCGCCTGGGCGGGGCGAAGATC
ACTTACCTGGAACAAGAAAATTATCCGCCGTTGCGTTTACAGGGCGGCTTTACTGGCGGC
AACGTTGACGTTGATGGCTCCGTTTCCAGCCAATTCCTCACCGCACTGTTAATGACTGCG
CCTCTTGCGCCGGAAGATACGGTGATTCGTATTAAAGGCGATCTGGTTTCTAAACCTTAT
ATCGACATCACACTCAATCTGATGAAGACGTTTGGTGTTGAAATTGAAAATCAGCACTAT
CAACAATTTGTCGTAAAAGGCGGGCAGTCTTATCAGTCTCCGGGTACTTATTTGGTCGAA
GGCGATGCATCTTCGGCTTCTTACTTTCTGGCAGCAGCAGCAATCAAAGGCGGCACTGTA
AAAGTGACCGGTATTGGACGTAACAGTATGCAGGGTGATATTCGCTTTGCTGATGTGCTG
GAAAAAATGGGCGCGACCATTTGCTGGGGCGATGATTATATTTCCTGCACGCGTGGTGAA
CTGAACGCTATTGATATGGATATGAACCATATTCCTGATGCGGCGATGACCATTGCCACG
GCGGCGTTATTTGCAAAAGGCACCACCAGGCTGCGCAATATCTATAACTGGCGTGTTAAA
GAGACCGATCGCCTGTTTGCGATGGCAACAGAACTGCGTAAAGTCGGCGCGGAAGTGGAA
GAGGGGCACGATTACATTCGTATCACTCCTCCGGAAAAACTGAACTTTGCCGAGATCGCG
ACATACAATGATCACCGGATGGCGATGTGTTTCTCGCTGGTGGCGTTGTCAGATACACCA
GTGACGATTCTTGATCCCAAATGCACGGCCAAAACATTTCCGGATTATTTCGAGCAGCTG
GCGCGGATTAGCCAGGCAGCCTGA

# Drug_Target_46_General_Function:
Amino acid transport and metabolism

# Drug_Target_46_General_References:
1899181	Huynh QK: 5-Enolpyruvylshikimate-3-phosphate synthase from Escherichia coli--the substrate analogue bromopyruvate inactivates the enzyme by modifying Cys-408 and Lys-411. Arch Biochem Biophys. 1991 Feb 1;284(2):407-12.
8452542	Huynh QK: Photo-oxidation of 5-enolpyruvoylshikimate-3-phosphate synthase from Escherichia coli: evidence for a reactive imidazole group (His385) at the herbicide glyphosate-binding site. Biochem J. 1993 Mar 1;290 ( Pt 2):525-30.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_46_HGNC_ID:
Not Available

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
2525

# Drug_Target_46_Locus:
Not Available

# Drug_Target_46_Molecular_Weight:
46096

# Drug_Target_46_Name:
3-phosphoshikimate 1-carboxyvinyltransferase

# Drug_Target_46_Number_of_Residues:
427

# Drug_Target_46_PDB_ID:
1X8T

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF00275	EPSP_synthase

# Drug_Target_46_Protein_Sequence:
>3-phosphoshikimate 1-carboxyvinyltransferase
MESLTLQPIARVDGTINLPGSKSVSNRALLLAALAHGKTVLTNLLDSDDVRHMLNALTAL
GVSYTLSADRTRCEIIGNGGPLHAEGALELFLGNAGTAMRPLAAALCLGSNDIVLTGEPR
MKERPIGHLVDALRLGGAKITYLEQENYPPLRLQGGFTGGNVDVDGSVSSQFLTALLMTA
PLAPEDTVIRIKGDLVSKPYIDITLNLMKTFGVEIENQHYQQFVVKGGQSYQSPGTYLVE
GDASSASYFLAAAAIKGGTVKVTGIGRNSMQGDIRFADVLEKMGATICWGDDYISCTRGE
LNAIDMDMNHIPDAAMTIATAALFAKGTTTLRNIYNWRVKETDRLFAMATELRKVGAEVE
EGHDYIRITPPEKLNFAEIATYNDHRMAMCFSLVALSDTPVTILDPKCTAKTFPDYFEQL
ARISQAA

# Drug_Target_46_Reaction:
phosphoenolpyruvate + 3-phosphoshikimate = phosphate + 5-O-(1-carboxyvinyl)-3-phosphoshikimate

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
Phosphoenolpyruvate + 3-phosphoshikimate = phosphate + 5-O-(1-carboxyvinyl)-3-phosphoshikimate

# Drug_Target_46_SwissProt_ID:
P0A6D3

# Drug_Target_46_SwissProt_Name:
AROA_ECOLI

# Drug_Target_46_Synonyms:
5- enolpyruvylshikimate-3-phosphate synthase
EC 2.5.1.19
EPSP synthase
EPSPS

# Drug_Target_46_Theoretical_pI:
5.27

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Secreted protein

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
X03341

# Drug_Target_47_GenBank_ID_Protein:
5921206

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
apr

# Drug_Target_47_Gene_Sequence:
>1140 bp
ATGATGAGGAAAAAGAGTTTTTGGCTTGGGATGCTGACGGCCTTCATGCTCGTGTTCACG
ATGGCATTCAGCGATTCCGCTTCTGCTGCTCAACCGGCGAAAAATGTTGAAAAGGATTAT
ATTGTCGGATTTAAGTCAGGAGTGAAAACCGCATCTGTCAAAAAGGACATCATCAAAGAG
AGCGGCGGAAAAGTGGACAAGCAGTTTAGAATCATCAACGCGGCAAAAGCGAAGCTAGAC
AAAGAAGCGCTTAAGGAAGTCAAAAATGATCCGGATGTCGCTTATGTGGAAGAGGATCAT
GTGGCCCATGCCTTGGCGCAAACCGTTCCTTACGGCATTCCTCTCATTAAAGCGGACAAA
GTGCAGGCTCAAGGCTTTAAGGGAGCGAATGTAAAAGTAGCCGTCCTGGATACAGGAATC
CAAGCTTCTCATCCGGACTTGAACGTAGTCGGCGGAGCAAGCTTTGTGGCTGGCGAAGCT
TATAACACCGACGGCAACGGACACGGCACACATGTTGCCGGTACAGTAGCTGCGCTTGAC
AATACAACGGGTGTATTAGGCGTTGCGCCAAGCGTATCCTTGTACGCGGTTAAAGTACTG
AATTCAAGCGGAAGCGGAACTTACAGCGGCATTGTAAGCGGAATCGAGTGGGCGACGACA
AACGGCATGGATGTTATCAACATGAGTCTTGGAGGACCATCAGGCTCAACAGCGATGAAA
CAGGCGGTTGACAATGCATATGCAAGAGGGGTTGTCGTTGTGGCGGCTGCTGGGAACAGC
GGATCTTCAGGAAACACGAATACAATCGGCTATCCTGCGAAATACGACTCTGTCATCGCA
GTTGGCGCGGTAGACTCTAACAGCAACAGAGCTTCATTTTCCAGCGTCGGAGCAGAGCTT
GAAGTCATGGCTCCTGGCGCAGGCGTGTACAGCACTTACCCAACCAGCACTTATGCAACA
TTGAACGGAACGTCAATGGCTTCTCCTCATGTAGCGGGAGCAGCAGCTTTGATCTTGTCA
AAACATCCGAACCTTTCAGCTTCACAAGTCCGCAACCGTCTCTCCAGTACGGCGACTTAT
TTGGGAAGCTCCTTCTACTATGGAAAAGGTCTGATCAATGTCGAAGCTGCCGCTCAATAA

# Drug_Target_47_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_47_General_References:
3001653	Jacobs M, Eliasson M, Uhlen M, Flock JI: Cloning, sequencing and expression of subtilisin Carlsberg from Bacillus licheniformis. Nucleic Acids Res. 1985 Dec 20;13(24):8913-26.
4967581	Smith EL, DeLange RJ, Evans WH, Landon M, Markland FS: Subtilisin Carlsberg. V. The complete sequence; comparison with subtilisin BPN'; evolutionary relationships. J Biol Chem. 1968 May 10;243(9):2184-91.
8512925	Syed R, Wu ZP, Hogle JM, Hilvert D: Crystal structure of selenosubtilisin at 2.0-A resolution. Biochemistry. 1993 Jun 22;32(24):6157-64.
9425066	Stoll VS, Eger BT, Hynes RC, Martichonok V, Jones JB, Pai EF: Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes. Biochemistry. 1998 Jan 13;37(2):451-62.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
2548

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
38908

# Drug_Target_47_Name:
Subtilisin Carlsberg

# Drug_Target_47_Number_of_Residues:
379

# Drug_Target_47_PDB_ID:
1C3L

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF00082	Peptidase_S8
PF05922	Subtilisin_N

# Drug_Target_47_Protein_Sequence:
>Subtilisin Carlsberg precursor
MMRKKSFWLGMLTAFMLVFTMAFSDSASAAQPAKNVEKDYIVGFKSGVKTASVKKDIIKE
SGGKVDKQFRIINAAKAKLDKEALKEVKNDPDVAYVEEDHVAHALAQTVPYGIPLIKADK
VQAQGFKGANVKVAVLDTGIQASHPDLNVVGGASFVAGEAYNTDGNGHGTHVAGTVAALD
NTTGVLGVAPSVSLYAVKVLNSSGSGTYSGIVSGIEWATTNGMDVINMSLGGPSGSTAMK
QAVDNAYARGVVVVAAAGNSGSSGNTNTIGYPAKYDSVIAVGAVDSNSNRASFSSVGAEL
EVMAPGAGVYSTYPTSTYATLNGTSMASPHVAGAAALILSKHPNLSASQVRNRLSSTATY
LGSSFYYGKGLINVEAAAQ

# Drug_Target_47_Reaction:
Hydrolysis of proteins with broad specificity for peptide bonds, and a preference for a large uncharged residue in P1. Hydrolyses peptide amides

# Drug_Target_47_Signals:
1-29

# Drug_Target_47_Specific_Function:
Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides

# Drug_Target_47_SwissProt_ID:
P00780

# Drug_Target_47_SwissProt_Name:
SUBT_BACLI

# Drug_Target_47_Synonyms:
EC 3.4.21.62
Subtilisin Carlsberg precursor

# Drug_Target_47_Theoretical_pI:
9.19

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Not Available

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
FGF1

# Drug_Target_48_GenBank_ID_Gene:
M13361

# Drug_Target_48_GenBank_ID_Protein:
181942

# Drug_Target_48_GeneCard_ID:
FGF1

# Drug_Target_48_Gene_Name:
FGF1

# Drug_Target_48_Gene_Sequence:
>468 bp
ATGGCTGAAGGGGAAATCACCACCTTCACAGCCCTGACCGAGAAGTTTAATCTGCCTCCA
GGGAATTACAAGAAGCCCAAACTCCTCTACTGTAGCAACGGGGGCCACTTCCTGAGGATC
CTTCCGGATGGCACAGTGGATGGGACAAGGGACAGGAGCGACCAGCACATTCAGCTGCAG
CTCAGTGCGGAAAGCGTGGGGGAGGTGTATATAAAGAGTACCGAGACTGGCCAGTACTTG
GCCATGGACACCGACGGGCTTTTATACGGCTCACAGACACCAAATGAGGAATGTTTGTTC
CTGGAAAGGCTGGAGGAGAACCATTACAACACCTATATATCCAAGAAGCATGCAGAGAAG
AATTGGTTTGTTGGCCTCAAGAAGAATGGGAGCTGCAAACGCGGTCCTCGGACTCACTAT
GGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCTTCTGATTAA

# Drug_Target_48_General_Function:
Involved in growth factor activity

# Drug_Target_48_General_References:
10618369	Stauber DJ, DiGabriele AD, Hendrickson WA: Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):49-54.
10830168	Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M: Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 2000 May 12;101(4):413-24.
11069186	Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL: Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000 Oct 26;407(6807):1029-34.
11847269	Kim J, Blaber SI, Blaber M: Alternative type I and I' turn conformations in the beta8/beta9 beta-hairpin of human acidic fibroblast growth factor. Protein Sci. 2002 Mar;11(3):459-66.
1372643	Yu YL, Kha H, Golden JA, Migchielsen AA, Goetzl EJ, Turck CW: An acidic fibroblast growth factor protein generated by alternate splicing acts like an antagonist. J Exp Med. 1992 Apr 1;175(4):1073-80.
1693186	Chiu IM, Wang WP, Lehtoma K: Alternative splicing generates two forms of mRNA coding for human heparin-binding growth factor 1. Oncogene. 1990 May;5(5):755-62.
1702556	Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, Hsu BT, Rees DC: Three-dimensional structures of acidic and basic fibroblast growth factors. Science. 1991 Jan 4;251(4989):90-3.
1717925	Wang WP, Quick D, Balcerzak SP, Needleman SW, Chiu IM: Cloning and sequence analysis of the human acidic fibroblast growth factor gene and its preservation in leukemia patients. Oncogene. 1991 Sep;6(9):1521-9.
1885605	Wu DQ, Kan MK, Sato GH, Okamoto T, Sato JD: Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem. 1991 Sep 5;266(25):16778-85.
2393407	Crumley G, Dionne CA, Jaye M: The gene for human acidic fibroblast growth factor encodes two upstream exons alternatively spliced to the first coding exon. Biochem Biophys Res Commun. 1990 Aug 31;171(1):7-13.
2427112	Harper JW, Strydom DJ, Lobb RR: Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor. Biochemistry. 1986 Jul 15;25(14):4097-103.
2474753	Wang WP, Lehtoma K, Varban ML, Krishnan I, Chiu IM: Cloning of the gene coding for human class 1 heparin-binding growth factor and its expression in fetal tissues. Mol Cell Biol. 1989 Jun;9(6):2387-95.
2590193	Mergia A, Tischer E, Graves D, Tumolo A, Miller J, Gospodarowicz D, Abraham JA, Shipley GD, Fiddes JC: Structural analysis of the gene for human acidic fibroblast growth factor. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1121-9.
3523756	Jaye M, Howk R, Burgess W, Ricca GA, Chiu IM, Ravera MW, O'Brien SJ, Modi WS, Maciag T, Drohan WN: Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. Science. 1986 Aug 1;233(4763):541-5.
3527167	Gimenez-Gallego G, Conn G, Hatcher VB, Thomas KA: The complete amino acid sequence of human brain-derived acidic fibroblast growth factor. Biochem Biophys Res Commun. 1986 Jul 31;138(2):611-7.
3732516	Gautschi P, Frater-Schroder M, Bohlen P: Partial molecular characterization of endothelial cell mitogens from human brain: acidic and basic fibroblast growth factors. FEBS Lett. 1986 Aug 18;204(2):203-7.
3778488	Gautschi-Sova P, Muller T, Bohlen P: Amino acid sequence of human acidic fibroblast growth factor. Biochem Biophys Res Commun. 1986 Nov 14;140(3):874-80.
3964259	Gimenez-Gallego G, Conn G, Hatcher VB, Thomas KA: Human brain-derived acidic and basic fibroblast growth factors: amino terminal sequences and specific mitogenic activities. Biochem Biophys Res Commun. 1986 Mar 13;135(2):541-8.
7504343	Zhao XM, Yeoh TK, Hiebert M, Frist WH, Miller GG: The expression of acidic fibroblast growth factor (heparin-binding growth factor-1) and cytokine genes in human cardiac allografts and T cells. Transplantation. 1993 Nov;56(5):1177-82.
7521397	Pineda-Lucena A, Jimenez MA, Nieto JL, Santoro J, Rico M, Gimenez-Gallego G: 1H-NMR assignment and solution structure of human acidic fibroblast growth factor activated by inositol hexasulfate. J Mol Biol. 1994 Sep 9;242(1):81-98.
8652550	Blaber M, DiSalvo J, Thomas KA: X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry. 1996 Feb 20;35(7):2086-94.
8950275	Pineda-Lucena A, Jimenez MA, Lozano RM, Nieto JL, Santoro J, Rico M, Gimenez-Gallego G: Three-dimensional structure of acidic fibroblast growth factor in solution: effects of binding to a heparin functional analog. J Mol Biol. 1996 Nov 22;264(1):162-78.
9655399	DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA: Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature. 1998 Jun 25;393(6687):812-7.
9719643	Lozano RM, Jimenez M, Santoro J, Rico M, Gimenez-Gallego G: Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas. J Mol Biol. 1998 Sep 4;281(5):899-915.

# Drug_Target_48_HGNC_ID:
HGNC:3665

# Drug_Target_48_HPRD_ID:
00567

# Drug_Target_48_ID:
760

# Drug_Target_48_Locus:
5q31

# Drug_Target_48_Molecular_Weight:
17460

# Drug_Target_48_Name:
Fibroblast growth factor 1

# Drug_Target_48_Number_of_Residues:
155

# Drug_Target_48_PDB_ID:
1RY7

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00167	FGF

# Drug_Target_48_Protein_Sequence:
>Heparin-binding growth factor 1 precursor
MAEGEITTFTALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQ
LSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEK
NWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
The heparin-binding growth factors are angiogenic agents in vivo and are potent mitogens for a variety of cell types in vitro. There are differences in the tissue distribution and concentration of these 2 growth factors

# Drug_Target_48_SwissProt_ID:
P05230

# Drug_Target_48_SwissProt_Name:
FGF1_HUMAN

# Drug_Target_48_Synonyms:
Acidic fibroblast growth factor
Beta-endothelial cell growth factor
ECGF- beta
HBGF-1
Heparin-binding growth factor 1 precursor
aFGF

# Drug_Target_48_Theoretical_pI:
7.04

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Cytoplasmic

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
X77800

# Drug_Target_49_GenBank_ID_Protein:
471304

# Drug_Target_49_GeneCard_ID:
Not Available

# Drug_Target_49_Gene_Name:
def

# Drug_Target_49_Gene_Sequence:
>510 bp
ATGTCAGTTTTGCAAGTGTTACATATTCCGGACGAGCGGCTTCGCAAAGTTGCTAAACCG
GTAGAAGAAGTGAATGCAGAAATTCAGCGTATCGTCGATGATATGTTCGAGACGATGTAC
GCAGAAGAAGGTATTGGCCTGGCGGCAACCCAGGTTGATATCCATCAACGTATCATTGTT
ATTGATGTTTCGGAAAACCGTGACGAACGGCTAGTGTTAATCAATCCAGAGCTTTTAGAA
AAAAGCGGCGAAACAGGCATTGAAGAAGGTTGCCTGTCGATCCCTGAACAACGTGCTTTA
GTGCCGCGCGCAGAGAAAGTTAAAATTCGCGCCCTTGACCGCGACGGTAAACCATTTGAA
CTGGAAGCAGACGGTCTGTTAGCCATCTGTATTCAGCATGAGATGGATCACCTGGTCGGC
AAACTGTTTATGGATTATCTGTCACCGCTGAAACAACAACGTATTCGTCAGAAAGTTGAA
AAACTGGATCGTCTGAAAGCCCGGGCTTAA

# Drug_Target_49_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_49_General_References:
10200158	Hao B, Gong W, Rajagopalan PT, Zhou Y, Pei D, Chan MK: Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry. 1999 Apr 13;38(15):4712-9.
1624424	Guillon JM, Mechulam Y, Schmitter JM, Blanquet S, Fayat G: Disruption of the gene for Met-tRNA(fMet) formyltransferase severely impairs growth of Escherichia coli. J Bacteriol. 1992 Jul;174(13):4294-301.
7896716	Meinnel T, Blanquet S: Enzymatic properties of Escherichia coli peptide deformylase. J Bacteriol. 1995 Apr;177(7):1883-7.
8112305	Mazel D, Pochet S, Marliere P: Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 1994 Feb 15;13(4):914-23.
8432722	Meinnel T, Guillon JM, Mechulam Y, Blanquet S: The Escherichia coli fmt gene, encoding methionyl-tRNA(fMet) formyltransferase, escapes metabolic control. J Bacteriol. 1993 Feb;175(4):993-1000.
8845003	Meinnel T, Blanquet S, Dardel F: A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. J Mol Biol. 1996 Sep 27;262(3):375-86.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9374869	Chan MK, Gong W, Rajagopalan PT, Hao B, Tsai CM, Pei D: Crystal structure of the Escherichia coli peptide deformylase. Biochemistry. 1997 Nov 11;36(45):13904-9.
9565550	Becker A, Schlichting I, Kabsch W, Schultz S, Wagner AF: Structure of peptide deformylase and identification of the substrate binding site. J Biol Chem. 1998 May 8;273(19):11413-6.
9610360	Groche D, Becker A, Schlichting I, Kabsch W, Schultz S, Wagner AF: Isolation and crystallization of functionally competent Escherichia coli peptide deformylase forms containing either iron or nickel in the active site. Biochem Biophys Res Commun. 1998 May 19;246(2):342-6.
9665852	Dardel F, Ragusa S, Lazennec C, Blanquet S, Meinnel T: Solution structure of nickel-peptide deformylase. J Mol Biol. 1998 Jul 17;280(3):501-13.
9846875	Becker A, Schlichting I, Kabsch W, Groche D, Schultz S, Wagner AF: Iron center, substrate recognition and mechanism of peptide deformylase. Nat Struct Biol. 1998 Dec;5(12):1053-8.

# Drug_Target_49_HGNC_ID:
Not Available

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
2688

# Drug_Target_49_Locus:
Not Available

# Drug_Target_49_Molecular_Weight:
19329

# Drug_Target_49_Name:
Peptide deformylase

# Drug_Target_49_Number_of_Residues:
169

# Drug_Target_49_PDB_ID:
1XEO

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF01327	Pep_deformylase

# Drug_Target_49_Protein_Sequence:
>Peptide deformylase
MSVLQVLHIPDERLRKVAKPVEEVNAEIQRIVDDMFETMYAEEGIGLAATQVDIHQRIIV
IDVSENRDERLVLINPELLEKSGETGIEEGCLSIPEQRALVPRAEKVKIRALDRDGKPFE
LEADGLLAICIQHEMDHLVGKLFMDYLSPLKQQRIRQKVEKLDRLKARA

# Drug_Target_49_Reaction:
formyl-L-methionyl peptide + H2O = formate + methionyl peptide

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions

# Drug_Target_49_SwissProt_ID:
P0A6K3

# Drug_Target_49_SwissProt_Name:
DEF_ECOLI

# Drug_Target_49_Synonyms:
EC 3.5.1.88
PDF
Polypeptide deformylase

# Drug_Target_49_Theoretical_pI:
5.00

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M81691

# Drug_Target_4_GenBank_ID_Protein:
155350

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
dhlB

# Drug_Target_4_Gene_Sequence:
>762 bp
ATGATCAAGGCAGTCGTGTTCGACGCTTACGGTACGCTCTTCGACGTCCAGTCGGTGGCC
GACGCCACCGAGCGGGCGTATCCAGGCCGGGGCGAGTACATCACGCAGGTCTGGCGGCAG
AAGCAGCTGGAATACAGCTGGCTCCGCGCGCTGATGGGGCGCTATGCCGACTTTTGGGGC
GTCACGCGGGAAGCGCTGGCCTATACCCTCGGAACGCTGGGGCTGGAGCCGGACGAGTCC
TTCCTCGCCGGGATGGCGCAGGCCTACAACCGCCTCACGCCCTATCCGGACGCCGCGCAA
TGCCTCGCGGAGCTGGCGCCCCTCAAGCGCGCCATCCTCTCCAACGGCGCGCCCGACATG
CTGCAGGCGCTCGTGGCCAATGCGGGCCTGACGGACAGCTTCGATGCCGTCATCAGCGTC
GATGCCAAGCGCGTGTTCAAGCCTCATCCCGACTCCTACGCGCTGGTGGAGGAGGTACTA
GGCGTGACGCCCGCGGAGGTGCTGTTCGTGTCCTCCAACGGCTTCGACGTCGGCGGCGCG
AAGAATTTCGGCTTCAGCGTCGCCCGGGTCGCGCGCCTGTCGCAGGAGGCGCTGGCGCGC
GAACTCGTCTCGGGTACCATCGCGCCCCTGACCATGTTCAAGGCGCTGAGGATGCGGGAA
GAAACCTATGCGGAGGCGCCTGATTTCGTGGTGCCCGCCCTTGGCGACCTGCCGCGGCTG
GTTCGCGGGATGGCCGGCGCTCATCTCGCACCAGCGGTGTGA

# Drug_Target_4_General_Function:
Involved in haloacid dehalogenase activity

# Drug_Target_4_General_References:
1744048	van der Ploeg J, van Hall G, Janssen DB: Characterization of the haloacid dehalogenase from Xanthobacter autotrophicus GJ10 and sequencing of the dhlB gene. J Bacteriol. 1991 Dec;173(24):7925-33.
7580000	van der Ploeg J, Janssen DB: Sequence analysis of the upstream region of dhlB, the gene encoding haloalkanoic acid dehalogenase of Xanthobacter autotrophicus GJ10. Biodegradation. 1995 Sep;6(3):257-63.
9407083	Ridder IS, Rozeboom HJ, Kalk KH, Janssen DB, Dijkstra BW: Three-dimensional structure of L-2-haloacid dehalogenase from Xanthobacter autotrophicus GJ10 complexed with the substrate-analogue formate. J Biol Chem. 1997 Dec 26;272(52):33015-22.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2929

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
27470

# Drug_Target_4_Name:
(S)-2-haloacid dehalogenase

# Drug_Target_4_Number_of_Residues:
253

# Drug_Target_4_PDB_ID:
1AQ6

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00702	Hydrolase

# Drug_Target_4_Protein_Sequence:
>(S)-2-haloacid dehalogenase
MIKAVVFDAYGTLFDVQSVADATERAYPGRGEYITQVWRQKQLEYSWLRALMGRYADFWG
VTREALAYTLGTLGLEPDESFLADMAQAYNRLTPYPDAAQCLAELAPLKRAILSNGAPDM
LQALVANAGLTDSFDAVISVDAKRVFKPHPDSYALVEEVLGVTPAEVLFVSSNGFDVGGA
KNFGFSVARVARLSQEALARELVSGTIAPLTMFKALRMREETYAEAPDFVVPALGDLPRL
VRGMAGAHLAPAV

# Drug_Target_4_Reaction:
(S)-2-haloacid + H2O = (R)-2-hydroxyacid + halide

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Catalyzes the hydrolytic dehalogenation of small L-2- haloalkanoic acids to yield the corresponding D-2-hydroxyalkanoic acids. Active with 2-halogenated carboxylic acids and converts only the L-isomer of 2-chloropropionic acid with inversion of configuration to produce D-lactate

# Drug_Target_4_SwissProt_ID:
Q60099

# Drug_Target_4_SwissProt_Name:
HAD_XANAU

# Drug_Target_4_Synonyms:
2-haloalkanoic acid dehalogenase
EC 3.8.1.2
Halocarboxylic acid halidohydrolase
L-2-haloacid dehalogenase

# Drug_Target_4_Theoretical_pI:
4.71

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Not Available

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
K02673

# Drug_Target_50_GenBank_ID_Protein:
147058

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
pabB

# Drug_Target_50_Gene_Sequence:
>1362 bp
ATGAAGACGTTATCTCCCGCTGTGATTACTTTACTCTGGCGTCAGGACGCCGCTGAATTT
TATTTCTCCCGCTTAAGCCACCTGCCGTGGGCGATGCTTTTACACTCCGGCTATGCCGAT
CATCCGTATAGCCGCTTTGATATTGTGGTCGCCGAGCCGATTTGCACTTTAACCACTTTC
GGTAAAGAAACCGTTGTTAGTGAAAGCGAAAAACGCACAACGACCACTGATGACCCGCTA
CAGGTGCTCCAGCAGGTGCTGGATCGCGCAGACATTCGCCCAACGCATAACGAAGATTTG
CCATTTCAGGGCGGCGCACTGGGGTTGTTTGGCTACGATCTGGGCCGCCGTTTTGAGTCA
CTGCCAGAAATTGCGGAACAAGATATCGTTCTGCCGGATATGGCAGTGGGTATCTACGAT
TGGGCGCTCATTGTCGACCACCAGCGTCATACAGTTTCTTTGCTGAGTCATAATGATGTC
AATGCCCGTCGGGCCTGGCTGGAAAGCCAGCAATTCTCGCCGCAGGAAGATTTCACGCTC
ACTTCCGACTGGCAATCCAATATGACCCGCGAGCAGTACGGCGAAAAATTTCGCCAGGTA
CAGGAATATCTGCACAGCGGTGATTGCTATCAGGTGAATCTCGCCCAACGTTTTCATGCG
ACCTATTCTGGCGATGAATGGCAGGCATTCCTTCAGCTTAATCAGGCCAACCGCGCGCCA
TTTAGCGCTTTTTTACGTCTTGAACAGGGTGCAATTTTAAGCCTTTCGCCAGAGCGGTTT
ATTCTTTGTGATAATAGTGAAATCCAGACCCGCCCGATTAAAGGCACGCTACCACGCCTG
CCCGATCCTCAGGAAGATAGCAAACAAGCAGTAAAACTGGCGAACTCAGCGAAAGATCGT
GCCGAAAATCTGATGATTGTCGATTTAATGCGTAATGATATCGGTCGTGTTGCCGTAGCA
GGTTCGGTAAAAGTACCAGAGCTGTTCGTGGTGGAACCCTTCCCTGCCGTGCATCATCTG
GTCAGCACCATAACGGCGCAACTACCAGAACAGTTACACGCCAGCGATCTGCTGCGCGCA
GCTTTTCCTGGTGGCTCAATAACCGGGGCTCCGAAAGTACGGGCTATGGAAATTATCGAC
GAACTGGAACCGCAGCGACGCAATGCCTGGTGCGGCAGCATTGGCTATTTGAGCTTTTGC
GGCAACATGGATACCAGTATTACTATCCGCACGCTGACTGCCATTAACGGACAAATTTTC
TGCTCTGCGGGCGGTGGAATTGTCGCCGATAGCCAGGAAGAAGCGGAATATCAGGAAACT
TTTGATAAAGTTAATCGTATCCTGAAGCAACTGGAGAAGTAA

# Drug_Target_50_General_Function:
Amino acid transport and metabolism

# Drug_Target_50_General_References:
2251281	Ye QZ, Liu J, Walsh CT: p-Aminobenzoate synthesis in Escherichia coli: purification and characterization of PabB as aminodeoxychorismate synthase and enzyme X as aminodeoxychorismate lyase. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9391-5.
6330050	Goncharoff P, Nichols BP: Nucleotide sequence of Escherichia coli pabB indicates a common evolutionary origin of p-aminobenzoate synthetase and anthranilate synthetase. J Bacteriol. 1984 Jul;159(1):57-62.
7592344	Viswanathan VK, Green JM, Nichols BP: Kinetic characterization of 4-amino 4-deoxychorismate synthase from Escherichia coli. J Bacteriol. 1995 Oct;177(20):5918-23.
7896119	Guttman DS, Dykhuizen DE: Detecting selective sweeps in naturally occurring Escherichia coli. Genetics. 1994 Dec;138(4):993-1003.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
658

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
50970

# Drug_Target_50_Name:
Para-aminobenzoate synthase component 1

# Drug_Target_50_Number_of_Residues:
453

# Drug_Target_50_PDB_ID:
1K0G

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00425	Chorismate_bind
PF04715	Anth_synt_I_N

# Drug_Target_50_Protein_Sequence:
>Para-aminobenzoate synthase component 1
MKTLSPAVITLLWRQDAAEFYFSRLSHLPWAMLLHSGYADHPYSRFDIVVAEPICTLTTF
GKETVVSESEKRTTTTDDPLQVLQQVLDRADIRPTHNEDLPFQGGALGLFGYDLGRRFES
LPEIAEQDIVLPDMAVGIYDWALIVDHQRHTVSLLSHNDVNARRAWLESQQFSPQEDFTL
TSDWQSNMTREQYGEKFRQVQEYLHSGDCYQVNLAQRFHATYSGDEWQAFLQLNQANRAP
FSAFLRLEQGAILSLSPERFILCDNSEIQTRPIKGTLPRLPDPQEDSKQAVKLANSAKDR
AENLMIVDLMRNDIGRVAVAGSVKVPELFVVEPFPAVHHLVSTITAQLPEQLHASDLLRA
AFPGGSITGAPKVRAMEIIDELEPQRRNAWCGSIGYLSFCGNMDTSITIRTLTAINGQIF
CSAGGGIVADSQEEAEYQETFDKVNRILKQLEK

# Drug_Target_50_Reaction:
chorismate + L-glutamine = 4-amino-4-deoxychorismate + L-glutamate

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Catalyzes the biosynthesis of 4-amino-4-deoxychorismate (ADC) from chorismate and glutamine

# Drug_Target_50_SwissProt_ID:
P05041

# Drug_Target_50_SwissProt_Name:
PABB_ECOLI

# Drug_Target_50_Synonyms:
ADC synthase
EC 6.3.5.8
Para- aminobenzoate synthase component I

# Drug_Target_50_Theoretical_pI:
4.88

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Cytoplasm

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
CA2

# Drug_Target_51_GenBank_ID_Gene:
M77181

# Drug_Target_51_GenBank_ID_Protein:
179780

# Drug_Target_51_GeneCard_ID:
CA2

# Drug_Target_51_Gene_Name:
CA2

# Drug_Target_51_Gene_Sequence:
>783 bp
ATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC
CCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT
GACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC
AACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG
GGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT
GATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG
GTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG
GCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT
GATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT
CGTGGCCTCCTTCCTGAATCCTTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT
CCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG
CAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG
GTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA
TAA

# Drug_Target_51_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_51_General_References:
11076507	Cox JD, Hunt JA, Compher KM, Fierke CA, Christianson DW: Structural influence of hydrophobic core residues on metal binding and specificity in carbonic anhydrase II. Biochemistry. 2000 Nov 14;39(45):13687-94.
1542674	Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1804-8.
1928091	Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE: Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene. Am J Hum Genet. 1991 Nov;49(5):1082-90.
3000449	Venta PJ, Montgomery JC, Hewett-Emmett D, Tashian RE: Comparison of the 5' regions of human and mouse carbonic anhydrase II genes and identification of possible regulatory elements. Biochim Biophys Acta. 1985 Dec 18;826(4):195-201.
3108857	Montgomery JC, Venta PJ, Tashian RE, Hewett-Emmett D: Nucleotide sequence of human liver carbonic anhydrase II cDNA. Nucleic Acids Res. 1987 Jun 11;15(11):4687.
3121496	Murakami H, Marelich GP, Grubb JH, Kyle JW, Sly WS: Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II. Genomics. 1987 Oct;1(2):159-66.
3151019	Eriksson AE, Jones TA, Liljas A: Refined structure of human carbonic anhydrase II at 2.0 A resolution. Proteins. 1988;4(4):274-82.
3151020	Eriksson AE, Kylsten PM, Jones TA, Liljas A: Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins. 1988;4(4):283-93.
4207120	Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.
4621826	Liljas A, Kannan KK, Bergsten PC, Waara I, Fridborg K, Strandberg B, Carlbom U, Jarup L, Lovgren S, Petef M: Crystal structure of human carbonic anhydrase C. Nat New Biol. 1972 Feb 2;235(57):131-7.
6407977	Jones GL, Shaw DC: A chemical and enzymological comparison of the common major human erythrocyte carbonic anhydrase II, its minor component, and a new genetic variant, CA II Melbourne (237 Pro leads to His). Hum Genet. 1983;63(4):392-9.
6817747	Jones GL, Sofro AS, Shaw DC: Chemical and enzymological characterization of an Indonesian variant of human erythrocyte carbonic anhydrase II, CAII Jogjakarta (17 Lys leads to Glu). Biochem Genet. 1982 Oct;20(9-10):979-1000.
823150	Henderson LE, Henriksson D, Nyman PO: Primary structure of human carbonic anhydrase C. J Biol Chem. 1976 Sep 25;251(18):5457-63.
8834238	Soda H, Yukizane S, Yoshida I, Koga Y, Aramaki S, Kato H: A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement. Hum Genet. 1996 Apr;97(4):435-7.
9143915	Hu PY, Lim EJ, Ciccolella J, Strisciuglio P, Sly WS: Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum Mutat. 1997;9(5):383-7.
9541386	Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63.

# Drug_Target_51_HGNC_ID:
HGNC:1373

# Drug_Target_51_HPRD_ID:
02023

# Drug_Target_51_ID:
357

# Drug_Target_51_Locus:
8q22

# Drug_Target_51_Molecular_Weight:
29115

# Drug_Target_51_Name:
Carbonic anhydrase 2

# Drug_Target_51_Number_of_Residues:
259

# Drug_Target_51_PDB_ID:
1T9N

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_51_Protein_Sequence:
>Carbonic anhydrase 2
SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILN
NGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLV
HWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPR
GLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMV
DNWRPAQPLKNRQIKASFK

# Drug_Target_51_Reaction:
H2CO3 = CO2 + H2O

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_51_SwissProt_ID:
P00918

# Drug_Target_51_SwissProt_Name:
CAH2_HUMAN

# Drug_Target_51_Synonyms:
CA-II
Carbonate dehydratase II
Carbonic anhydrase C
Carbonic anhydrase II
EC 4.2.1.1

# Drug_Target_51_Theoretical_pI:
7.47

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
M25261

# Drug_Target_5_GenBank_ID_Protein:
154222

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
bla

# Drug_Target_5_Gene_Sequence:
>828 bp
ATGGCAATCCGAATCTTCGCGATACTTTTCTCCATTTTTTCTCTTGCCACTTTCGCGCAT
GCGCAAGAAGGCACGCTAGAACGTTCTGACTGGAGGAAGTTTTTCAGCGAATTTCAAGCC
AAAGGCACGATAGTTGTGGCAGACGAACGCCAAGCGGATCGTGCCATGTTGGTTTTTGAT
CCTGTGCGATCGAAGAAACGCTACTCGCCTGCATCGACATTCAAGATACCTCATACACTT
TTTGCACTTGATGCAGGCGCTGTTCGTGATGAGTTCCAGATTTTTCGATGGGACGGCGTT
AACAGGGGCTTTGCAGGCCACAATCAAGACCAAGATTTGCGATCAGCAATGCGGAATTCT
ACTGTTTGGGTGTATGAGCTATTTGCAAAGGAAATTGGTGATGACAAAGCTCGGCGCTAT
TTGAAGAAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATA
GAAGGCAGCCTTGCAATCTCGGCGCAGGAGCAAATTGCATTTCTCAGGAAGCTCTATCGT
AACGAGCTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGATCTCATGATTGTGGAA
GCCGGTCGCAACTGGATACTGCGTGCAAAGACGGGCTGGGAAGGCCGTATGGGTTGGTGG
GTAGGATGGGTTGAGTGGCCGACTGGCTCCGTATTCTTCGCACTGAATATTGATACGCCA
AACAGAATGGATGATCTTTTCAAGAGGGAGGCAATCGTGCGGGCAATCCTTCGCTCTATT
GAAGCGTTACCGCCCAACCCGGCAGTCAACTCGGACGCTGCGCGATAA

# Drug_Target_5_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_5_General_References:
2538329	Mossakowska D, Ali NA, Dale JW: Oxacillin-hydrolysing beta-lactamases. A comparative analysis at nucleotide and amino acid sequence levels. Eur J Biochem. 1989 Mar 15;180(2):309-18.
2689593	Nucken EJ, Henschke RB, Schmidt FR: Nucleotide sequence of an OXA-2 beta-lactamase gene from the R-plasmid R1767 derived plasmid pBP11 and comparison to closely related resistance determinants found in R46 and Tn2603. J Gen Microbiol. 1989 Apr;135(4):761-5.
3876949	Dale JW, Godwin D, Mossakowska D, Stephenson P, Wall S: Sequence of the OXA2 beta-lactamase: comparison with other penicillin-reactive enzymes. FEBS Lett. 1985 Oct 21;191(1):39-44.
6335398	Holland S, Dale JW: Improved purification and characterization of the OXA-2 beta-lactamase. Biochem J. 1984 Dec 15;224(3):1009-13.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
3237

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
31686

# Drug_Target_5_Name:
Beta-lactamase OXA-2

# Drug_Target_5_Number_of_Residues:
275

# Drug_Target_5_PDB_ID:
1K38

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00905	Transpeptidase

# Drug_Target_5_Protein_Sequence:
>Beta-lactamase OXA-2 precursor
MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFD
PVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNS
TVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSLAISAQEQIAFLRKLYR
NELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTP
NRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR

# Drug_Target_5_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_5_Signals:
1-21

# Drug_Target_5_Specific_Function:
This is an oxacillin-hydrolyzing beta-lactamase

# Drug_Target_5_SwissProt_ID:
P0A1V8

# Drug_Target_5_SwissProt_Name:
BLO2_SALTY

# Drug_Target_5_Synonyms:
Beta-lactamase OXA-2 precursor
EC 3.5.2.6
Penicillinase

# Drug_Target_5_Theoretical_pI:
9.77

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
katA

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_6_General_References:
12486720	Andreoletti P, Sainz G, Jaquinod M, Gagnon J, Jouve HM: High-resolution structure and biochemical properties of a recombinant Proteus mirabilis catalase depleted in iron. Proteins. 2003 Feb 1;50(2):261-71.
7786407	Buzy A, Bracchi V, Sterjiades R, Chroboczek J, Thibault P, Gagnon J, Jouve HM, Hudry-Clergeon G: Complete amino acid sequence of Proteus mirabilis PR catalase. Occurrence of a methionine sulfone in the close proximity of the active site. J Protein Chem. 1995 Feb;14(2):59-72.
7791219	Gouet P, Jouve HM, Dideberg O: Crystal structure of Proteus mirabilis PR catalase with and without bound NADPH. J Mol Biol. 1995 Jun 23;249(5):933-54.
8901874	Gouet P, Jouve HM, Williams PA, Andersson I, Andreoletti P, Nussaume L, Hajdu J: Ferryl intermediates of catalase captured by time-resolved Weissenberg crystallography and UV-VIS spectroscopy. Nat Struct Biol. 1996 Nov;3(11):951-6.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3625

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
55615

# Drug_Target_6_Name:
Catalase

# Drug_Target_6_Number_of_Residues:
484

# Drug_Target_6_PDB_ID:
1MQF

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00199	Catalase

# Drug_Target_6_Protein_Sequence:
>Catalase
MEKKKLTTAAGAPVVDNNNVITAGPRGPMLLQDVWFLEKLAHFDREVIPERRMHAKGSGA
FGTFTVTHDITKYTRAKIFSEVGKKTEMFARFSTVAGERGAADAERDIRGFALKFYTEEG
NWDMVGNNTPVFYLRDPLKFPDLNHIVKRDPRTNMRNMAYKWDFFSHLPESLHQLTIDMS
DRGLPLSYRFVHGFGSHTYSFINKDNERFWVKFHFRCQQGIKNLMDDEAEALVGKDRESS
QRDLFEAIERGDYPRWKLQIQIMPEKEASTVPYNPFDLTKVWPHADYPLMDVGYFELNRN
PDNYFSDVEQAAFSPANIVPGISFSPDKMLQGRLFSYGDAHRYRLGVNHHQIPVNAPKCP
FHNYHRDGAMRVDGNSGNGITYEPNSGGVFQEQPDFKEPPLSIEGAADHWNHREDEDYFS
QPRALYELLSDDEHQRMFARIAGELSQASKETQQRQIDLFTKVHPEYGAGVEKAIKVLEG
KDAK

# Drug_Target_6_Reaction:
2 H2O2 = O2 + 2 H2O

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide

# Drug_Target_6_SwissProt_ID:
P42321

# Drug_Target_6_SwissProt_Name:
CATA_PROMI

# Drug_Target_6_Synonyms:
EC 1.11.1.6

# Drug_Target_6_Theoretical_pI:
6.56

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
U82109

# Drug_Target_7_GenBank_ID_Protein:
2149137

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
ffh

# Drug_Target_7_Gene_Sequence:
>1293 bp
ATGTTCCAACAGCTTTCGGCGCGACTGCAAGAGGCCATCGGCCGCCTTAGGGGGCGGGGC
CGGATCACCGAGGAGGACCTGAAGGCCACCCTCAGGGAGATCCGCCGGGCCCTCATGGAC
GCCGATGTCAACCTGGAGGTGGCCCGGGACTTCGTGGAGCGGGTGCGGGAGGAGGCCTTG
GGGAAGCAGGTCCTGGAGAGCCTCACCCCCGCCGAGGTGATCCTGGCCACCGTCTACGAG
GCCCTCAAGGAGGCCCTGGGGGGCGAGGCCAGGCTCCCTGTCCTCAAGGACAGGAACCTC
TGGTTCCTGGTGGGCCTCCAGGGCTCCGGCAAGACCACCACCGCCGCCAAGCTGGCCCTC
TACTACAAGGGCAAGGGGAGGAGGCCCCTCTTGGTGGCCGCCGACACCCAGAGGCCCGCC
GCCAGGGAGCAACTAAGGCTTCTGGGCGAGAAGGTGGGCGTGCCCGTGCTGGAGGTGATG
GACGGGGAGTCCCCTGAGTCCATCCGCCGCCGGGTGGAGGAGAAGGCCCGCCTCGAGGCC
CGGGACCTGATCCTGGTGGACACCGCCGGCCGCCTGCAGATTGACGAGCCCCTCATGGGG
GAGCTGGCCCGCCTCAAGGAGGTCCTTGGCCCGGACGAGGTTCTCCTGGTCCTGGACGCC
ATGACCGGGCAGGAAGCCCTTTCCGTGGCCAGGGCCTTTGACGAGAAGGTGGGGGTCACG
GGCCTCGTCCTCACCAAGCTGGACGGGGATGCCCGGGGCGGGGCGGCCCTTTCCGCCCGC
CACGTGACGGGCAAGCCCATCTACTTCGCCGGGGTTTCCGAGAAGCCGGAGGGCCTGGAG
CCCTTCTACCCCGAGCGCCTGGCGGGCCGCATCCTGGGCATGGGGGACGTGGCCAGCCTG
GCGGAGAAGGTGCGGGCGGCGGGGCTGGAGGCGGAGGCGCCCAAGTCCGCCAAGGAGCTT
TCCCTGGAGGACTTCCTCAAGCAGATGCAGAACCTCAAGCGCCTGGGCCCCTTCTCCGAG
ATCCTGGGCCTCCTGCCCGGGGTTCCCCAGGGGCTTAAGGTGGACGAGAAGGCCATAAAG
CGCCTGGAGGCCATCGTCCTCTCCATGACCCCCGAGGAGCGCAAAGACCCCCGCATCCTA
AACGGTTCCCGGCGCAAGCGCATCGCCAAGGGAAGCGGGACCTCGGTCCAGGAGGTCAAC
CGCTTCATCAAGGCATTTGAGGAGATGAAGGCCCTAATGAAGTCCCTGGAGAAGAAGAAG
GGCCGGGGACTCATGGGAATGTTCAGGAGGTAA

# Drug_Target_7_General_Function:
Intracellular trafficking, secretion, and vesicular transport

# Drug_Target_7_General_References:
10426959	Freymann DM, Keenan RJ, Stroud RM, Walter P: Functional changes in the structure of the SRP GTPase on binding GDP and Mg2+GDP. Nat Struct Biol. 1999 Aug;6(8):793-801.
9002524	Freymann DM, Keenan RJ, Stroud RM, Walter P: Structure of the conserved GTPase domain of the signal recognition particle. Nature. 1997 Jan 23;385(6614):361-4.
9695947	Keenan RJ, Freymann DM, Walter P, Stroud RM: Crystal structure of the signal sequence binding subunit of the signal recognition particle. Cell. 1998 Jul 24;94(2):181-91.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3261

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
47357

# Drug_Target_7_Name:
Signal recognition particle protein

# Drug_Target_7_Number_of_Residues:
430

# Drug_Target_7_PDB_ID:
2FFH

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00448	SRP54
PF02881	SRP54_N
PF02978	SRP_SPB

# Drug_Target_7_Protein_Sequence:
>Signal recognition particle protein
MFQQLSARLQEAIGRLRGRGRITEEDLKATLREIRRALMDADVNLEVARDFVERVREEAL
GKQVLESLTPAEVILATVYEALKEALGGEARLPVLKDRNLWFLVGLQGSGKTTTAAKLAL
YYKGKGRRPLLVAADTQRPAAREQLRLLGEKVGVPVLEVMDGESPESIRRRVEEKARLEA
RDLILVDTAGRLQIDEPLMGELARLKEVLGPDEVLLVLDAMTGQEALSVARAFDEKVGVT
GLVLTKLDGDARGGAALSARHVTGKPIYFAGVSEKPEGLEPFYPERLAGRILGMGDVASL
AEKVRAAGLEAEAPKSAKELSLEDFLKQMQNLKRLGPFSEILGLLPGVPQGLKVDEKAIK
RLEAIVLSMTPEERKDPRILNGSRRKRIAKGSGTSVQEVNRFIKAFEEMKALMKSLEKKK
GRGLMGMFRR

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Necessary for efficient export of extracytoplasmic proteins. Binds to the signal sequence when it emerges from the ribosomes

# Drug_Target_7_SwissProt_ID:
O07347

# Drug_Target_7_SwissProt_Name:
SRP54_THEAQ

# Drug_Target_7_Synonyms:
Fifty-four homolog

# Drug_Target_7_Theoretical_pI:
10.17

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Secreted protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X03591

# Drug_Target_8_GenBank_ID_Protein:
46741

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
Not Available

# Drug_Target_8_Gene_Sequence:
>552 bp
ATGCGCAAGATCGTCGTTGCAGCCATCGCCGTTTCCCTGACCACGGTCTCGATTACGGCC
AGCGCTTCGGCAGACCCCTCCAAGGACTCGAAGGCCCAGGTCTCGGCCGCCGAGGCCGGC
ATCACCGGCACCTGGTACAACCAGCTCGGCTCGACCTTCATCGTGACCGCGGGCGCCGAC
GGCGCCCTGACCGGAACCTACGAGTCGGCCGTCGGCAACGCCGAGAGCCGCTACGTCCTG
ACCGGTCGTTACGACAGCGCCCCGGCCACCGACGGCAGCGGCACCGCCCTCGGTTGGACG
GTGGCCTGGAAGAATAACTACCGCAACGCCCACTCCGCGACCACGTGGAGCGGCCAGTAC
GTCGGCGGCGCCGAGGCGAGGATCAACACCCAGTGGCTGCTGACCTCCGGCACCACCGAG
GCCAACGCCTGGAAGTCCACGCTGGTCGGCCACGACACCTTCACCAAGGTGAAGCCGTCC
GCCGCCTCCATCGACGCGGCGAAGAAGGCCGGCGTCAACAACGGCAACCCGCTCGACGCC
GTTCAGCAGTAG

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
2386489	Gitlin G, Bayer EA, Wilchek M: Studies on the biotin-binding sites of avidin and streptavidin. Tyrosine residues are involved in the binding site. Biochem J. 1990 Jul 15;269(2):527-30.
2390089	Alon R, Bayer EA, Wilchek M: Streptavidin contains an RYD sequence which mimics the RGD receptor domain of fibronectin. Biochem Biophys Res Commun. 1990 Aug 16;170(3):1236-41.
2911722	Weber PC, Ohlendorf DH, Wendoloski JJ, Salemme FR: Structural origins of high-affinity biotin binding to streptavidin. Science. 1989 Jan 6;243(4887):85-8.
3223904	Gitlin G, Bayer EA, Wilchek M: Studies on the biotin-binding site of streptavidin. Tryptophan residues involved in the active site. Biochem J. 1988 Nov 15;256(1):279-82.
3951999	Argarana CE, Kuntz ID, Birken S, Axel R, Cantor CR: Molecular cloning and nucleotide sequence of the streptavidin gene. Nucleic Acids Res. 1986 Feb 25;14(4):1871-82.
9148939	Katz BA, Cass RT: In crystals of complexes of streptavidin with peptide ligands containing the HPQ sequence the pKa of the peptide histidine is less than 3.0. J Biol Chem. 1997 May 16;272(20):13220-8.
9194176	Freitag S, Le Trong I, Klumb L, Stayton PS, Stenkamp RE: Structural studies of the streptavidin binding loop. Protein Sci. 1997 Jun;6(6):1157-66.
9405158	Katz BA: Binding of biotin to streptavidin stabilizes intersubunit salt bridges between Asp61 and His87 at low pH. J Mol Biol. 1997 Dec 19;274(5):776-800.
9636711	Freitag S, Le Trong I, Chilkoti A, Klumb LA, Stayton PS, Stenkamp RE: Structural studies of binding site tryptophan mutants in the high-affinity streptavidin-biotin complex. J Mol Biol. 1998 May 29;279(1):211-21.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
3027

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
18834

# Drug_Target_8_Name:
Streptavidin

# Drug_Target_8_Number_of_Residues:
183

# Drug_Target_8_PDB_ID:
1STP

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01382	Avidin

# Drug_Target_8_Protein_Sequence:
>Streptavidin precursor
MRKIVVAAIAVSLTTVSITASASADPSKDSKAQVSAAEAGITGTWYNQLGSTFIVTAGAD
GALTGTYESAVGNAESRYVLTGRYDSAPATDGSGTALGWTVAWKNNYRNAHSATTWSGQY
VGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAASIDAAKKAGVNNGNPLDA
VQQ

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-24

# Drug_Target_8_Specific_Function:
The biological function of streptavidin is not known. Forms a strong non-covalent specific complex with biotin (one molecule of biotin per subunit of streptavidin)

# Drug_Target_8_SwissProt_ID:
P22629

# Drug_Target_8_SwissProt_Name:
SAV_STRAV

# Drug_Target_8_Synonyms:
Streptavidin precursor

# Drug_Target_8_Theoretical_pI:
8.81

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasm

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
AE005674

# Drug_Target_9_GenBank_ID_Protein:
24051245

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
mgsA

# Drug_Target_9_Gene_Sequence:
>468 bp
TTACTTCAGACGGTCAGCGAGATAACGCTGATAATCGGGGATAAGAATATCGACCGCGTC
GTTGAAATGCGGCGACTGGATAATGAAGTCTGCCGTTGCCACGTTGGTGGCGACCGGAAT
GTTCCATACCGTCGCCAGACGCAGCAAGGCTTTCACGTCAGGATCGTGCGGCACGGCATT
TAGTGGATCCCAGAAGAATATCAATACATCAATTTTCCCTTCTGAGATCAATGCGCCAAC
CTGCTGGTCACCCCCCATTGGGCCACTCAACATCGCGTTGACGTTCATGCCGGTCGCGCG
GGAAATCAAGTTACCGGTAGTGCCTGTTGCATACAGTACGTGTTGTTCCAGTAACGGTTG
ATGCCGTTCCACCCAGCTCATCAGCATTTGTTTGCAGTGATCGTGTGCCACCAGCGCAAT
ATGTTTCCGCGCAGGTAAAGTGCGAGTCGTCAGTTCCATAATGTACAT

# Drug_Target_9_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_9_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3467

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
16919

# Drug_Target_9_Name:
Methylglyoxal synthase

# Drug_Target_9_Number_of_Residues:
152

# Drug_Target_9_PDB_ID:
1IK4

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF02142	MGS

# Drug_Target_9_Protein_Sequence:
>Methylglyoxal synthase
MELTTRTLPARKHIALVAHDHCKQMLMSWVERHQPLLEQHVLYATGTTGNLISRATGMNV
NAMLSGPMGGDQQVGALISEGKIDVLIFFWDPLNAVPHDPDVKALLRLATVWNIPVATNV
ATADFIIQSPHFNDAVDILIPDYQRYLADRLK

# Drug_Target_9_Reaction:
glycerone phosphate = methylglyoxal + phosphate

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Glycerone phosphate = methylglyoxal + phosphate

# Drug_Target_9_SwissProt_ID:
P0A733

# Drug_Target_9_SwissProt_Name:
MGSA_SHIFL

# Drug_Target_9_Synonyms:
EC 4.2.3.3
MGS

# Drug_Target_9_Theoretical_pI:
6.63

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB01942
